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Abstract 
 
Platelets are small, anucleated cellular fragments derived from the megakaryocytes of the bone 
marrow. These small cellular fragments have a specialized role in maintaining hemostasis, a 
process that prevents blood loss, through the initiation of blood coagulation. However, excessive 
platelet reactivity can lead to a pathophysiological condition known as thrombosis. Platelet-
mediated thrombosis is the primary underlying mechanism leading to cardiovascular life-
threatening clinical events, such as myocardial infarction and stroke. Regulating excessive 
platelet reactivity is an essential aspect of antithrombotic therapy. A number of anti-platelet 
drugs have been developed to target specific signaling pathways or endpoints involved in platelet 
activation. Despite the effectiveness of current anti-platelet therapies, uncontrolled thrombosis or 
bleeding complications still persist. Therefore, elucidating the mechanisms involved in platelet 
activation is crucial for identifying the development of novel or alternative anti-thrombotic 
strategies. 
Platelet 12-lipoxygenase (12-LOX), an oxygenase principally found to convert freed 
polyunsaturated fatty acids (PUFA) substrates from the membrane phospholipids following 
cellular stimulation, was identified to be a potential target for regulating platelet reactivity. Thus, 
the studies described in this thesis seek to assess whether 12-LOX activity modulated platelet 
responses or reactivity by using newly developed selective 12-LOX inhibitors, NCTT-956 and 
ML355. Although both NCTT-956 and ML355 blocked 12-LOX activity in platelets, ML355 
was shown to be much more potent in inhibiting platelet activation. In support of the 
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pharmacological ex vivo studies, mice lacking 12-LOX (12-LOX-/-) in platelets were protected 
from platelet-induced activation as well as thrombosis in vivo.  
Additionally, the role of 12-LOX in immune-mediated platelet activation was also 
investigated in this thesis work. One form of immune-mediated platelet activation or thrombosis 
is heparin-induced thrombocytopenia and thrombosis (HITT), a life-threatening cardiovascular 
disorder. A key component of this disorder is the activation of FcγRIIa, a transmembrane 
receptor, by immune-complexes. I had shown that 12-LOX potentiated immune-mediated 
platelet activation and 12-LOX activity regulated early signaling effectors in the immune 
signaling pathways of platelet activation.  
12-LOX predominantly generates 12(S)-HETE, an oxylipin or metabolite, from 
arachidonic acid (AA), since this is the most abundant ω-6 PUFA found in the lipid bilayer of 
cells. Dietary supplementation of plant- or fish-based oils can alter and enrich the contents of the 
lipid bilayer by which they shift 12-LOX substrate from AA to other PUFAs. Consumption of 
borage or primrose oil, which is enriched in ω-6 PUFA dihomo-γ-linolenic acid (DGLA), has 
been shown to be cardioprotective; however, its mechanism of action was unclear. In this thesis, 
I had also sought to elucidate the underlying mechanism by which DGLA could provide 
cardioprotection via the prevention of thrombosis. I had demonstrated that the oxylipin of DGLA 
generated by 12-LOX, 12(S)-HETrE, inhibited platelet activation and thrombosis in vivo in a 
Gα-signaling dependent manner. Altogether, my thesis work highlighted the importance of 
targeting 12-LOX in platelets or using its endogenous mechanism to generate oxylipins that have 
anti-platelet effects as potential therapeutic avenues for preventing unwanted platelet activation.  
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CHAPTER 1  
 
Platelet Biology 
Hemostasis is an intrinsic property of the vascular system that involves the interplay of platelets 
and the endothelial lining to 1) maintain blood in a fluid state, 2) close off damaged blood 
vessels, and 3) remove clots after restoration of vascular integrity. Extending beyond the 
classical roles of hemostasis and thrombosis, platelets are increasingly being recognized for other 
pathological disorders such as, inflammation, tumor metastasis, atherosclerosis, and non- or pro-
infectious immunological functions.    
1.1 Platelet structure 
In 1882, Giulio Bizzozzero had established the phenomena of platelet morphology and their 
major contribution to thrombosis and hemostasis1. Bizzozzero had also demonstrated the 
difficulty in isolating platelets in blood removed from the vessel. Subsequently, he developed 
methods to isolate and preserve platelets as separate and intact structures, which led him to 
describe platelet morphology. To date, platelets are described as small, anucleated cytoplasmic 
fragments (approximately 2-5 µm in diameter and .5 µm thickness) derived from the 
megakaryocytes in the bone marrow.  
Structurally, platelets can be conceptually divided into peripheral, sol-gel, and organelle zones2.  
The peripheral zone refers to the platelet plasma membrane that is coated with glycocalyx 
(glycoprotein-polysaccharide covering) that enables platelets to adhere to and aggregate with 
subendothelial matrix proteins and other platelets. Beneath the glycocalyx is the rigid lipid 
bilayer; however, additional membrane structure which aids in platelet spreading is provided by 
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the tiny folds of the platelet surface and the internalized membrane parts of the open canicular 
system3. The sol-gel zone contains organized microtubules, microfilaments, open canalicular, 
and the dense tubular systems. The cytoskeletal arrangement in this zone helps support platelet 
membrane contraction, as well as constriction to move secretory organelles (granules and dense 
bodies) to the platelet center prior to secretion of their vesicle contents through the open 
canalicular system4-6.  
The organelle zone contains three major types of secretory contents, α-, δ- granules, and 
lysosomes. While the α- and δ- granule contents do play important roles in hemostasis, 
thrombosis, and inflammation, the role of lysosomal contents in hemostasis and thrombosis is 
still unclear. The α-granules are the largest secretory organelles, ranging from 50 to 80 vesicles 
per platelet, and each is 200-500 nm in diameter. Contents of α-granules include cell adhesion 
molecules (integrin αIIbβ3, glycoprotein (GP)Ib-IX-V complex, GPVI, and P-selectin), 
chemokines (platelet factor 4 (PF4)/(CXCL4), growth or angiogenic factors (insulin-like growth 
factor 1, platelet-derived growth factor (PDGF), transforming growth factor β1 (TGF-β1)), and 
clotting factors (fibronectin, thrombospondin, factor V, von Willebrand (vWF)). In humans, 
approximately 3 to 8 δ- granules per platelet with a diameter of 150 nm have been observed. 
Each δ-granule is filled with adenosine nucleotides (ADP, ATP), serotonin, ionized calcium, 
pyrophosphate, magnesium, and CD63. There are less than 3 lysosomes observed in each human 
platelet, and each lysosome ranges from 200-250 nm in diameter. Each lysosome is comprised of 
acid hydrolases, cathepsin D and E, lysosomal-associated membrane protein (LAMP)-2, and 
CD63.  
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1.2 Overview of platelets in hemostasis and thrombosis 
Under steady state conditions, platelets circulate freely in a quiescent state in the blood without 
interacting with each other or the vascular endothelium. However, in the presence of endothelial 
damage whether from vascular injury or rupture of an atherosclerotic plaque, a chain of events is 
triggered, ultimately leading to platelet-rich clot formation. Depending on the initiating event, 
platelets may participate in normal hemostasis or pathologic intravascular thrombosis.  
The molecular mechanisms underlying platelet function in hemostasis and thrombosis are well 
defined. Under high arterial shear rates (1000 – 10,000 s-1), circulating platelets are rapidly 
decelerated and transiently interact with the damaged and exposed subendothelial connective 
tissue containing immobilized glycoprotein vWF bound to collagen (type I, III, and VI). vWF-
collagen interacts with the platelet glycoprotein receptor (GP) Ib-V-IX complex, allowing 
platelets to translocate along the vessel wall and engage their receptors, glycoprotein VI (GPVI) 
and integrin α2β1, with the subendothelial fibrillar collagen. This firm interaction also facilitates 
platelets to associate with fibronectin through its engagement with integrin α5β1.  
The engagement of platelet receptors with collagen also induces an “inside-out” cellular 
signaling cascade that leads to integrin αIIbβ3 activation7,8. This process involves intermediary 
proteins, talin and kindlin, which bind to the cytoplasmic domain of β3 integrin to shift αIIbβ3 
from an inactive to active state9,10. Active αIIbβ3 conformation increases its affinity for adhesive 
proteins, vWF, fibrinogen, fibrin, and fibronectin. These interactions are essential for the 
platelets to form stable aggregates with other activated platelets to promote thrombus growth 
(Figure 1.1).  
Following firm adhesion and aggregate formation, platelets also release or locally generate 
soluble agonists, such as ADP, thromboxane A2 (TxA2), and thrombin, to mediate feedforward 
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autocrine and paracrine platelet activation via their respective G protein-coupled receptors 
(GPCRs). The activation of GPCRs initiates a series of intracellular signaling events, including 
generation of second messengers (DAG and IP3). Eventually, the cascade of downstream 
signaling events culminates in the secretion of soluble factors, platelet spreading, and integrin 
activation. The secreted soluble agonists act on circulating platelets to be recruited and 
incorporated into a growing thrombus (Figure 1.1).  
 
 
Figure 1.1 Processes of platelet adhesion and activation to form a hemostatic plug or thrombus formation. 
Following vessel injury, platelets adhere to the vessel by “tethering” to the exposed collagen bound to von Willebrand factor 
(vWF) on the underlying subendothelial extracellular matrix (ECM) via glycoprotein receptor, GPIb-V-IX complex. Platelets are 
transiently immobilized at the injured site enabling platelets to engage their GPVI receptors with nearby fibrillar collagen, 
resulting in platelet activation, firm adhesion, and spreading mediated by their integrins. Platelet activation and firm adhesion are 
achieved by the synchrony of multiple surface receptors activation (i.e., thrombin, purinergic, and thromboxane receptors). 
Activated platelets also release granules to support a growing thrombus facilitated by platelet recruitment and aggregation11. 
Illustration is taken from (Tourdot et al, 2017). 
 
1.3 The role of collagen in hemostasis and thrombosis 
Collagen, a triple helical structure comprised of α-chains, is the most abundant structural protein 
in the extracellular matrix (ECM) to provide mechanical strength to the connective tissues. To 
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date, there are 42 different collagen genes that encode 28 different types of collagen α-chains. 
Collagen types I, III, IV, and VI have been observed to play a direct role in hemostasis through 
their interactions with platelet receptors. This section focuses on the signaling pathways of three 
main platelet adhesion receptors (GPIb, GPVI, and α2β1) that indirectly or directly bind to 
subendothelial collagen. 
GPIb-V-IX receptor complex-mediated platelet activation 
vWF is a large multimeric glycoprotein that is found in circulation in its inactive conformation, 
platelet α-granules, subendothelial cell matrix, and the endothelial Weibel-Palade bodies. 
Damage to the vessel enables the A3 domain of vWF to bind to the exposed collagens from the 
subendothelial matrix 12,13. As a consequence of this binding and under high arterial shear stress, 
vWF undergoes conformational change to expose the A1 cryptic binding site of vWF for the 
GPIb-V-IX complex (4 covalently linked type I transmembrane proteins: GPIbα disulfide-linked 
to two GPIbβ subunits to form GPIb, GPIX, and GPV)14. The interaction of GPIb-V-IX complex 
with vWF-collagen initiates platelet “tethering,” which defines transient platelet adhesion. 
vWF/GPIb-V-IX complex interaction also induces intracellular platelet activation signaling 
events, leading to granule secretion, integrin activation and integrin-dependent stable platelet 
adhesion and aggregation15.  
Some studies have demonstrated that the initial vWF-induced activation of the GPIb-V-IX 
complex relies on the association of Src family kinases (SFKs) (Lyn and Fyn)16 14-3-3ξ, 
calmodulin, and phosphoinositide 3-kinases (PI3Ks) with the cytoplasmic tail of the GPIbα. 
These early complex interactions are deemed important for recruiting and activating spleen 
tyrosine kinase (Syk) and subsequent phospholipase Cγ2 (PLCγ2) phosphorylation17, leading to 
enhanced intracellular calcium flux, as well as Akt activation leading to integrin αIIbβ3 
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activation18,19. In contrast, Syk has also been observed not to be required for GPIb-V-IX- and 
integrin-dependent stable platelet adhesion to vWF under high stress.  
Studies have also reported that GPIbα can form a non-covalent complex with GPVI20, which 
could possibly explain the observation of tyrosine phosphorylation of the immunoglobulin (Ig) 
receptors, FcRγ and FcγRIIa, following ligand binding to GPIb-V-IX complex. These 
observations suggest GPIb-V-IX may utilize the same signaling pathway as GPVI and FcγRIIa 
16. In contrast, the loss of FcRγ and linker for activation of T cells (LAT) has also been shown to 
not affect GPIb-V-IX-mediated integrin activation and TxA2 production 21,22.  
Interestingly, vWF induction of platelet GPIb-V-IX complex has been shown to enhance 
intracellular cGMP levels, and subsequent cGMP-dependent protein kinase (PKG), MAPK, p38, 
and extracellular signal-regulated kinase (ERK) activation23. The cGMP signaling cascade is 
reported to be activated downstream of the Lyn/PI3K/Akt pathway, which leads to nitric oxide 
(NO) synthase production of NO. Low concentrations of NO/cGMP synthesis is demonstrated to 
stimulate platelet activation; whereas, high concentrations of NO and cGMP inhibit platelet 
reactivity24.   
There is no doubt that the main function of GPIb-V-IX is to bind to vWF and then mediate 
platelet adhesion at high shear rates. However, the induced signaling pathway of platelet 
activation remains unclear. Different aspects of receptor-induced signaling and complex 
interactions have been proposed and tested, but to date, the lack of consensus on the GPIb-V-IX 
signaling pathway still remains.  
GPVI-mediated platelet activation 
GPVI is a platelet-specific transmembrane type I receptor belonging to the immunoglobulin (Ig) 
superfamily, and estimated to express between 4000 and 6000 copies per cell. GPVI consists of 
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two extracellular Ig C2 loops or domains (D1 and D2) linked together by disulfide bonds, a 
mucin-like stalk, a transmembrane region, and a short cytoplasmic domain 25. GPVI non-
covalently associates with the Fc receptor (FcR) γ-chain, a promiscuous protein expressed on 
other hematopoietic cells. The FcRγ-chain is a covalently linked homodimer, whereby each 
chain possesses a copy of an immunoreceptor tyrosine-based activation motif (ITAM) in the 
intracellular domain 25,26, defined by two Yxx(L/I) sequences separated by seven amino acids. 
Loss of FcRγ-chain in platelets has been demonstrated to prevent GPVI from reaching to the 
platelet surface, resulting in abrogated collagen-induced platelet activation as well as mild 
bleeding diathesis. Thus, GPVI surface expression and function requires its association with the 
FcRγ-chain27. 
The identification of GPVI ligands (collagen type I and III, collagen-related peptides (CRPs), 
convulxin (snake toxin), and JAQ1 (monoclonal antibodies)) aided in elucidating the underlying 
mechanisms of GPVI signaling in platelet activation. It is thought that GPVI associates with its 
ligands, containing repeated amino acid motif sequence, glycine-proline-hydroxyproline (GPO), 
which induce receptor activation via clustering28. In resting or inactive state, GPVI is either 
completely or partially excluded from lipid rafts; however, upon ligand stimulation, GPVI/FcRγ 
complex is found to be enriched with lipid rafts29 and some membrane-associated proteins, 
including Src family kinases, Lyn and Fyn, and palmitoylated adaptor protein, LAT. Lipid rafts 
have been reported to facilitate proximal Src kinase interaction with GPVI by which Src kinase 
docks on the conserved proline-rich region (PxxP) of GPVI via their Src homology 3 (SH3) 
domains. On the one hand, previous studies had shown that there is already a pool of active Fyn 
and Lyn constitutively associated with the PxxP motif of GPVI, and this interaction increases the 
intrinsic activity of GPVI, which places the receptor in a “ready-to-go” state30. Due to the 
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crosslinking of  GPVI, Src kinases are induced to come in close proximity and engage with their 
substrates, the FcRγ-chain ITAM. 
Following Src kinases phosphorylation of the FcRγ-chain ITAM, the tandem SH2 domain-
containing tyrosine kinase, Syk, is recruited to the dually phosphorylated ITAM, undergoes 
autophosphorylation and phosphorylation by Src kinases, and initiates a downstream signaling 
cascade 31. The initiation of the downstream signaling cascade involves the phosphorylation of 
LAT and concurrent assembly of a signalosome. The core of the signalosome consists of 
phosphorylated transmembrane adaptor LAT32 and cytosolic adaptors, Src homology 2 domain-
containing leukocyte phosphoprotein of 76 kDa (SLP-76) bound to Gads or Grb233,34. These 
three proteins associate with a number of signaling molecules, including Bruton tyrosine kinase 
(Btk)35, GTP exchange factors (Vav1 and Vav3)36,37, small GTPase Rac, and the α and β 
isoforms of PI3K, which are critical for the recruitment and activation of phospholipase C 
(PLCγ2). For instance, the pleckstrin homology (PH) domain of PLCγ2 facilitates its recruitment 
to the plasma membrane through its binding of the PI3K product, phosphatidylinositol (3,4,5)-
triphosphate (PIP3). This binding plays an important role in the maximal activation of PLCγ2, 
which liberates second messengers 1,2-diacylglycerol (DAG) and inositol-1,4,5-triphosphate 
(IP3) from phosphatidylinositol-4,5-bisphosphate (PIP2). 
IP3 binds to the inositol triphosphate receptor (InsP3R) to transiently release Ca2+ from 
intracellular stores, elevating cytosolic Ca2+ concentration from approximately .1 µM (resting) to 
1-10 µM. DAG and cytosolic Ca2+ concurrently activate downstream effectors, which includes 
actin-myosin interaction, calmodulin, protein kinase C (PKC), Ca2+-dependent exchange factor 
(CalDAG-GEF) activation, and small GTPase, Ras-related protein 1 (Rap1b) activation. 
Subsequently, a Rap1-GTP-interacting adaptor molecule (RIAM) enables talin to induce the 
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cytoplasmic tail of β3 to undergo conformational change of the αIIbβ3 integrin, increasing the 
αIIbβ3 integrin affinity for fibrinogen, vWF, or fibronectin, in order to form platelet-platelet 
aggregates (Figure 1.2).  
α2β1-mediated platelet activation 
The importance of the α2β1 integrin in platelet function was first implicated in 1986 when a 
patient showed no platelet response to collagen due to the fact the individual had 15-20% of the 
normal level of glycoprotein Ia (GPIa) 38. Interestingly, integrin α2β1 had been also identified in 
other cells (endothelial and epithelial), serving as a receptor for both collagen and laminin. 
Platelet α2β1 integrin is a receptor for collagen type I and IV, but the ligand binding is 
accommodated by the α2 subunit that has a 200-amino acid inserted domain, the I domain, that is 
homologous to the vWF A domains39. Collagen interacts with the α2-I domain via conserved 
sequences containing the GFOGER motif40.  The α2-I domain has been shown to bind to 
collagen in a cation-dependent manner, more specifically Mg2+ and Mn2+, but not by Ca2+ 41,42. 
Platelet α2β1 integrin has primarily been recognized in providing platelets firm adhesion to the 
subendothelial wall following platelet translocation along the vessel wall (see section 1.2).  
The role played by α2β1 in the collagen-induced platelet activation still remains unclear. Many of 
the contradicting results on whether collagen binding to α2β1 is critical for platelet activation 
were due to differing experimental conditions. On the one hand, one general consensus was that 
genetic ablation or pharmacological inhibition of α2β1 integrin in platelets delayed platelets 
response to collagen without affecting the final extent of activation compared to controls. It has 
been demonstrated that, analogous to αIIbβ3 binding to fibrinogen, α2β1 integrin undergoes a shift 
from low to high affinity state for collagen following stimulation43, supporting an “inside-out” 
signaling mechanism. In contrast, an “outside-in” model has also been demonstrated by which 
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platelets spread on GFOGER motifs. Platelet spreading on α2β1 recognition motif, GFOGER, 
induced activation of the Src kinases and subsequent Syk recruitment and PLCγ2 activation44. 
This observation was also supported by PLCγ2-deficient mouse platelets, which exhibited 
limited spreading on GFOGER coated surface. Interestingly, this study also provided insights to 
the underlying intracellular signaling events involved in α2β1-mediated platelet adhesion and 
spreading. α2β1-mediated spreading was demonstrated to share similar signaling pathways as the 
“outside-in” models of αIIbβ3 and FcγRIIa. 
1.4 Immune receptor mediated activation of platelet 
Platelets are increasingly being recognized for their functions in immunological pathological 
conditions due to drug exposure, bacterial and viral infections45-49, as well as immunological host 
defense involving IgG-dependent platelet opsonization-destruction, activation/thrombosis, or 
even recruitment or modulation of leukocyte responses. One of the major mediators of immune 
functions is the activation of Fcγ receptors. Fcγ receptors are widely expressed throughout the 
human hematopoietic system, including FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa, and FcγRIIIb. These 
receptors are distinguished by their affinity for the Fc-fragment of antibody and the inhibitory or 
activating signaling pathways they induce. This section will focus on the role of FcγRIIa in 
platelet function, since it is the only Fcγ receptor expressed by human platelets.  
FcγRIIa-mediated platelet activation 
The human FcγRIIa (CD32) is a 40 kDa type I transmembrane glycoprotein belonging to a 
subclass of FcγRs in the Ig superfamily50. Structurally, FcγRIIa is a single-chain receptor 
composed of two extracellular Ig-like domains with the second domain mediating binding to the 
Fc region of IgG51 and a cytoplasmic tail containing the ITAM (see section 1.3).  Although 
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FcγRIIa is expressed by many cell types (monocytes, neutrophils, and dendritic cells), it is the 
only FcγR on human platelets, ranging from 900-5000 copies 52,53, but absent in mice. FcγRIIa 
exhibits low affinity for single monomeric IgG molecules; however, has high avidity and affinity 
for multimeric IgG immune complexes54. In addition, a polymorphism of FcγRIIa, determined by 
a single-nucleotide change (G to A) resulting in the replacement of arginine with histidine at 
position 131, also dictates its binding efficacy to IgGs 55.  
The most commonly used agonists (heat aggregated IgGs, IgG-coated beads, and anti-FγRIIa 
mAb IV.3 with F(ab’)2 fragments of a secondary antibody) cluster FcγRIIa to activate the same 
ITAM signaling pathway shared by GPVI (see section 1.3.2). Upon clustering or activation, the 
cytoplasmic ITAM of FγRIIa is phosphorylated followed by recruitment of the proximal effector, 
Syk. Docked Syk is phosphorylated at tyrosine residues and subsequently activates nearby 
effectors in order to trigger downstream signaling transduction. A key component that is 
activated in this pathway is PLCγ2, which hydrolyzes PIP2 into IP3 and DAG, leading to calcium 
mobilization and PKC activation (see section 1.3). These intracellular events culminate in 
integrin activation as well as granule secretion (Figure 1.2). 
FcγRIIa has also been demonstrated to participate in the “outside-in” signaling process by which 
ligand binding (fibrinogen, fibronectin, and vWF) to integrin αIIbβ3 triggers intracellular 
signaling events, resulting in platelet adhesion, spreading, granule secretion, stabilization of 
platelet aggregations, and clot retraction. A key component in the “outside-in” signaling pathway 
is Src family kinases activation, which has been shown to directly interact with the cytoplasmic 
tails of β3 of the αIIbβ3 integrin and phosphorylated FcγRIIa and Syk44,56. For this case, FcγRIIa 
was demonstrated to serve as a “functional conduit” or adaptor for αIIbβ3-mediated outside-in 
signaling57. Platelets from FcγRIIa-positive mice showed enhanced platelet spreading, clot 
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retraction compared to platelets from FcγRIIa-negative mice. FcγRIIa-positive platelets also 
exhibited enhanced tyrosine phosphorylation of Syk and PLCγ2 upon interaction with 
immobilized fibrinogen.  
 
Figure 1.2 Immunoreceptor tyrosine-based activation motif (ITAM) receptors in platelets.  
FcγRIIa and GPVI are immune receptors that either bears cytoplasmic ITAM or constitutively associates with the FcγR-chain 
that contains the ITAM, respectively. Receptor clustering initiates phosphorylation of the ITAM motif by Src family kinases 
(SFK), recruits spleen tyrosine kinase (Syk) and induce subsequent activation of kinases, adaptors, and effector molecules to 
form the signalosome. The signalosome consists of linker for activation of T cells (LAT), SH2 domain-containing leukocyte 
protein of 76 kDa (SLP-76), growth factor receptor-bound protein 2 (Grb2), and Grb2-related protein 2 (Gads), phosphoinositide 
3-kinase (PI3K), bruton’s tyrosine kinase (BTK), Vav proteins, and phospholipase C γ2 (PLCγ2). The assembly of the 
signalosome is critical for PLCγ2 activation, which generates second messenger signaling lipids, diacylglycerol (DAG) and 
inositol triphosphate (IP3), from phosphatidylinositol 4,5-bisphosphate (PIP2). Eventually, these intracellular signaling events 
culminate in the activation of platelets.   
1.5 Platelet activation and signaling mediated by G-protein-coupled receptors.   
A variety of soluble of platelet agonists (adenosine nucleosides, ATP and ADP, TxA2) are 
released from damaged endothelial cells as well as activated platelets to enhance aggregation. 
Activated platelets also develop procoagulant surfaces to aid in thrombin generation in order to 
promote thrombus growth and fibrin formation.  Unlike collagen and vWF-mediated platelet 
activation, this section details the mechanisms of the major agonists that exert their function 
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through the GPCRs. Depending on the GPCRs, agonists can induce more than one signaling 
mechanism. For instance, each GPCR can be associated with more than one G protein (Gs, Gi, 
Gq, and G12/13) in the platelets to elicit multiple signaling cascades.  
Thrombin receptors 
Thrombin, a serine protease produced from coagulation factor II (FII) of the clotting cascade, not 
only converts soluble fibrinogen into insoluble fibrin, but also cleaves protease activated 
receptors (PARs) on the surface of platelets. Depending on the type of species, specific PARs are 
expressed. PAR1 and PAR4 are expressed on human platelets; whereas mouse platelets express 
PAR3 and PAR4. Thrombin cleaves the extended N-terminus of the PARs, unmasking a new N-
terminus (SFLLRN) that serves as a tethered ligand58 by binding intramolecularly to the receptor. 
Following ligand binding, Gαq and Gα12/13 undergo conformational change, switching from GDP 
(inactive) to GTP-bound state (active), and dissociation from their Gβγ subunits and respective 
receptors. Immediately, Gαq and Gα12/13 interact with specific effectors to activate downstream  
signaling cascades.  
Gαq mainly amplifies its signal through phospholipase C (PLC) β, which hydrolyzes PIP2 into 
IP3 and DAG. These second messengers propagate downstream signaling effectors (see section 
1.3.2) leading to platelet aggregation.  On the other hand, the GTP-bound form of Gα12/13 
interacts with and activates guanine nucleotide exchange factors (GEFs), such as p115RhoGEF, 
which converts RhoA into active GTP-bound form, followed by its activation of Rho kinase, 
p160ROCK. RhoA kinase phosphorylates LIM kinase to induce cofilin activity as well as 
myosin light chain (MLC) phosphatase in order to induce MLC-dependent contraction. In 
general, Gα12/13 plays a major role in mediating platelet shape change and granule secretion.  
P2Y12 and P2Y1 receptors 
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Platelet activation stimulated by several agonists (ie thrombin, TxA2, collagen) results in 
secretion of granule contents, such as ADP, which serves as a prominent autocrine and paracrine 
mediator of platelet function through the purinergic receptors, P2Y1 and P2Y12. Optimal platelet 
activation by ADP requires both receptors, by which each receptor contributes uniquely through 
its associated G proteins. P2Y1 is a GPCR coupled to Gαq that mediates activation of PLCβ and 
subsequent production of IP3 and DAG, causing Ca2+ release and PKC activation (see section 
1.5.1). In addition, P2Y1 activation has been reported to contribute to morphological changes in 
platelets 59, most likely due to calcium or calmodulin-, or Rac-dependent contractile signaling60.  
On the other hand, P2Y12 is found to be directly coupled to Gαi2. Gαi2 activation inhibits the 
ability of adenylyl cyclase to convert ATP to 3’,5’-cyclic AMP (cAMP). This relieves the 
inhibitory effect of cAMP-dependent protein kinase on platelet activation. In parallel, the βγ 
subunit dissociated from the P2Y12 coupled Gαi also activates a host of cellular effectors, 
including PI3Kγ/β, Akt/protein kinase B (PKB), Rap1b, and Src family tyrosine kinases, leading 
to partial platelet aggregation61.   
TPα receptor 
As a consequence of agonists-mediated platelet activation, thromboxane A2 (TxA2) is generated 
from COX-1 oxidation of cytoplasmic phospholipase A2 (cPLA2) freed arachidonic acid (AA) 
from the lipid bilayer. Similar to the ADP released from the granules in platelets, TxA2 behaves 
as a secondary mediator or potentiator of platelet activation. TxA2 acts on the thromboxane A2 
receptor, TPα receptor, which is coupled to both Gαq and Gα12/13 (see figure 1.3).  Both Gαq and 
Gα12/13 elicit unique signaling pathways, which eventually culminates or converges in integrin 
activation to facilitate platelet aggregation (see thrombin receptors section). 
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Figure 1.3 Overview of G-protein coupled receptors and signaling in platelet activation 
 
1.6 Central hypothesis aims 
The elucidation of the major signaling pathways or endpoints involved in platelet activation 
(described in this chapter) has facilitated in the development of a number of anti-platelet drugs to 
regulate platelet reactivity. While several of the current anti-platelet agents (chapter 2) had 
effectively reduced mortality due to thrombotic-associated cardiovascular events, morbidity and 
mortality still remain. However, as platelets are also essential for hemostasis, there is also the 
risk for bleeding as a consequence for inhibiting a number of targets in the signaling pathway 
involved in platelet activation. This warrants the need to identify novel or alternative targets in 
platelets that will effectively inhibit thrombosis, but with minimal impact on hemostasis or risk 
of bleeding.  
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  Two potential therapeutic avenues for regulating platelet reactivity to prevent thrombosis 
were proposed in this thesis. One potential anti-platelet therapeutic avenue is targeting 12-
lipoxygenase (12-LOX), a non-heme oxygenase, with the first in class selective platelet 12-LOX 
inhibitors, NCTT-956 and ML355. Thus, I hypothesized that selectively targeting 12-LOX with 
NCTT-956 or ML355, would modulate platelet reactivity through the inhibition of the 
predominant oxylipin, 12(S)-HETE, derived from arachidonic acid (AA). In addition, these 
selective inhibitors also aided in characterizing the importance of 12-LOX’s role in platelet 
function described in chapters 5-6. The utility of targeting 12-LOX as a potential anti-platelet 
therapy was demonstrated in an immune-mediated thrombotic disease model, heparin-induced 
thrombocytopenia (HIT), described in chapter 7.  
 The second aim of my thesis work investigated the role of utilizing 12-LOX as an 
endogenous anti-platelet therapeutic approach through the modification of eicosanoid or oxylipin 
production. While 12-LOX predominantly generates 12(S)-HETE from AA, since it is the most 
abundant ω-6 polyunsaturated fatty acid (PUFA) found in the lipid bilayer of cells, 12-LOX can 
also oxidize a number of PUFAs to generate an assortment of other oxylipins or lipid mediators 
(chapter 8). Dietary supplementation or exogenous addition of plant- or fish-based oils can alter 
and enrich the contents of the lipid bilayer by which they shift 12-LOX substrate from AA to 
other PUFAs. For instance, consumption of borage or primrose oil, which is enriched in ω-6 
PUFA dihomo-γ-linolenic acid (DGLA), has been shown to be cardioprotective; however. its 
mechanism of action had been unclear.  I hypothesized that DGLA regulates platelet reactivity 
through its oxylipin, 12(S)-HETrE, derived from 12-LOX oxidation. The 12-LOX derived 
oxylipin of DGLA, 12(S)-HETrE was found to inhibit platelet activation through a Gαs-
dependent manner (chapter 9). 
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CHAPTER 2  
 
Anti-platelet Therapy1 
2.1 Summary 
Anti-platelet therapy remains the mainstay in preventing aberrant platelet activation in 
pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although 
there has been significant advancement in anti-platelet therapeutic approaches, aspirin still 
remain the gold standard treatment in the clinical setting. Limitations in safety, efficacy, and 
tolerability, have precluded many of the anti-platelet inhibitors from use in patients. Unforeseen 
incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have 
hampered the development of superior next generation anti-platelet therapies. The 
pharmacokinetic and pharmacodynamic profiles have also limited the effectiveness of a number 
of anti-platelet inhibitors currently in use due to variability in metabolism, time to onset, and 
reversibility. A focused effort in the development of newer anti-platelet therapies to address 
some of these shortcomings has resulted in a significant number of potential anti-platelet drugs 
which target enzymes (phosphodiesterase, cyclooxygenase), receptors (purinergic, 
prostaglandins, protease-activated receptors, thromboxane), and glycoproteins (αIIbβ3, GPVI, 
vWF, GPIb) in the platelet. The validation and search for newer anti-platelet therapeutic 
approaches proven to be superior to aspirin is still ongoing and should yield a better 
pharmacodynamic profile with fewer untoward side-effects to what is currently in use today. 
                                                
1 This section has been published in Journal of Blood Medicine. Yeung J, Holinstat, M. Newer agents in antiplatelet therapy: a 
review. J. Blood Med. 2012; 3:33-42.  
2 This section has been published in Cardiovascular & Hematological Agents in Medicinal Chemistry. Yeung J and Holinstat, M. 
12-Lipoxygenase: A potential Target Novel Anti-Platelet Therapeutics.  CHAMC  2011; 9(3):154-164. 
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2.2 Introduction 
Anti-platelet drugs are the cornerstone in treatment of cardiovascular diseases. Despite the 
significant decrease in morbidity and mortality due to the currently approved anti-platelet drugs, 
recurrent ischemia, myocardial infarction, and unwanted bleeding still occur. The majority of 
drugs in development have focused on targeting either surface receptors or enzymes in the 
platelet in order to protect against unwanted clot formation following initial platelet activation. 
The first target for anti-platelet therapy was cyclooxygenase-1 (COX-1) by aspirin. While newer 
approaches for containing platelet activity have been developed, the pharmacodynamics and 
pharmacoeconomics suggest that aspirin will continue to be a mainstay for platelet therapy in the 
years to come. Currently, a combination regimen of aspirin and clopidogrel are the standard of 
care for prevention of platelet activation, thrombosis, and stroke. Unfortunately, many of the 
current anti-platelet drugs face limitations in their utility due to genetic differences in the ability 
to metabolize pro-drugs such as is the case with clopidogrel, acquired allergic responses such as 
is seen with heparin and aspirin, and resistance as has been reported with aspirin (see Table 2.1). 
Additional limitations observed in the application of currently approved anti-platelet drugs 
include a narrow therapeutic window and limited efficacy. An overview of the current federal 
drug administration (FDA) approved anti-platelet therapies as well as those in development will 
be discussed in this chapter. 
2.3 P2Y Receptor Antagonists 
The P2Y receptors are G-protein coupled (GPCR) purinergic receptors belonging to the P2 
family. Two receptors, P2Y1 and P2Y12, are present in the platelet. P2Y1 is a Gq coupled GPCR 
while P2Y12 is coupled to Gαi2. Activation of P2Y1 signals phospholipase β, leading to DAG 
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formation, calcium mobilization, and eventually PKC and CalDAG-GEF activation 62. In 
contrast, P2Y12 activation inhibits adenylyl cyclase, activates phosphoinositide 3-kinase 63, the 
small GTPase Rap164, and the activation of αIIbβ3 65. 
 
Table 2.1 Approved antiplatelet drugs. 
Ticlopidine (Ticlid; Roche) is a first generation thienopyridine that requires cytochrome P450 
(CYP) 1A metabolism prior to exerting its irreversible antagonistic effects on platelet reactivity 
via the P2Y12 receptor 66. Early experimental observations showed agonist-induced platelet 
aggregation was intermittently inhibited by ticlopidine 67,68. Studies with ticlopidine however, 
exhibit off-target effects mediated by the inhibition of intracellular calcium mobilization 69. 
Maximal inhibition of platelet aggregation is observed 3 to 5 days post administration of 
ticlopidine 70. The delayed onset of anti-platelet effects is a consequence of metabolism of the 
pro-drug 67. Clinical trials (CATS and TASS studies) have shown ticlopidine to be more 
effective than aspirin alone 71,72, but exhibiting significant off-target effects including minor 
bleeding with hemorrhagic events observed in less than 1% of subjects studied. Additionally, 
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ticlopidine-treated patients typically discontinue treatment due to a variety of secondary adverse 
events including diarrhea, skin rash, and neutropenia 71,73. 
Clopidogrel (Plavix; Bristol-Myers Squibb), a second generation oral thienopyridine, also 
requires metabolism of a pro-drug by the CYP2C19. The active metabolite, which is a highly 
labile compound, irreversibly binds to and inhibits the P2Y12 receptor through a disulfide bridge. 
The CURE trial has shown the clinical benefit of the dual clopidogrel-aspirin therapy compared 
with aspirin alone by significantly reducing mortality and nonfatal MI or stroke in patients with 
unstable angina; however, the dual regimen was associated with an increase in bleeding 
compared with placebo 74,75. The CAPRIE trial, which evaluated the efficacy of clopidogrel 
monotherapy compared with dual therapy of clopidogrel plus aspirin, showed clopidogrel 
treatment results in a reduction of primary end points 76. Evidence of poor metabolizers for 
clopidogrel has helped to explain the reduced function in patients with an altered CYP2C19 
allele.77 Poor metabolizers of clopidogrel have diminished platelet inhibition resulting in a higher 
rate of adverse cardiovascular events than non-carriers 78.  
Prasugrel (Effient, Eli Lilly) is a third generation thienopyridine, chemically distinct from 
clopidogrel. In vivo and in vitro pharmacological studies have demonstrated that this ATP analog 
selectively and irreversibly inhibits ADP-induced aggregation to a greater degree than 
clopidogrel 79. The irreversible binding is thought to be due to the disulfide binding between the 
reactive thiol group of the active metabolite and the cysteine residue of the P2Y12 receptor 80-82.  
Prasugrel is an orally available pro-drug that requires active transformation by CYP450 and 
esterases 83. Activation of the pro-drug requires CYP3A4 and CYP2B6 84. Clinical studies have 
verified that inhibition of platelet aggregation is more effective with prasugrel compared to 
clopidogrel after a single dose in healthy subjects 84. Furthermore, subjects who responded 
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poorly to clopidogrel showed greater platelet-induced inhibition in response to prasugrel 84,85. In 
addition, assessment of secondary endpoints favors prasugrel due to lower incidences of 
cardiovascular death, nonfatal MI, and re-hospitalization due to recurrent ischemia.  
Ticagrelor (Brillinta; AstraZeneca), an oral cyclopentyl-triazolo-pyrimidine (CTP) analog, 
unlike thienopyridines, is a direct and reversible inhibitor of the P2Y12 receptor that is activated 
from its pro-drug by CYP3A 86. Ticagrelor exerts its action via binding to the P2Y12 receptor at a 
site distinct from the ADP binding site, thus making it an allosteric inhibitor 86. As a 
consequence of P2Y12 inhibition, ATP is converted to cyclic monophosphate, vasodilator-
stimulated phospoprotein (VASP) is dephosphorylated, and activation of PI3-K is inhibited 87. 
The PLATO trial compared ticagrelor with clopidogrel in which the primary composite 
endpoints, stroke, MI, cardiovascular death, and stent thrombosis, were reduced in patients with 
acute coronary syndromes (ACS) (with or without ST-elevation myocardial infarction (STEMI)) 
88. The benefit of ticagrelor appears to be attenuated in patients with lower body weight and 
those not taking lipid-lowering drugs in North American groups relative to comparative studies 
elsewhere 89. There is no significant difference in major bleeding between the two agents; 
however, spontaneous (non-coronary artery bypass grafts) or non-procedural related bleeding is 
increased with ticagrelor. Additionally, off-target effects of dyspnea and asymptomatic 
ventricular pauses are associated with ticagrelor use 89,90. In general, ticagrelor has so far proven 
superior to current treatment regimens, including a rapid onset of action, acceptable safety 
profile, and effectiveness in reducing the primary end points in ACS patients.  
Elinogrel (PRT060128,Novartis/ Portola Pharmaceuticals) is a direct-acting reversible P2Y12 
receptor inhibitor that is currently undergoing clinical investigation (INNOVATE-PCI) for 
efficacy and safety in patients undergoing percutaneous coronary intervention (PCI) (see Table 
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2.2) 91. Preclinical data show that intravenous or orally administered elinogrel is superior to 
clopidogrel and had minimal effect on bleeding times 92. In addition, a single dose of elinogrel 
has been shown to overcome high platelet reactivity in patients undergoing PCI who were non-
responsive to clopidogrel 92. Elinogrel, while still in clinical development for safety and efficacy 
assessment in patients, shows promise as a next generation P2Y12 antagonist. 
 
Table 2.2 Antiplatelet drugs under development 
Cangrelor (ARC-69931MX; Medicines Company) is an intravenous non-theinopyridine and 
reversible P2Y12 inhibitor. Like prasugrel and ticagrelor, cangrelor showed a more rapid onset of 
action and greater degree of platelet inhibition than clopidogrel. Recent evaluations of the 
inhibitor in the CHAMPION-PCI and CHAMPION-PLATFORM trials were stopped early due 
to its lack of apparent differences in the primary end point of death, myocardial infarction or 
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ischemia-driven revascularization 48 hours after PCI 93. Also, the rate of major bleeding in 
patients undergoing PCI was higher with cangrelor compared to clopidogrel in both studies 94.  
BX 667 is an orally active reversible P2Y12 receptor antagonist that is metabolized by esterases to 
form the carboxylic active form, BX 048 95. In vitro, ADP-induced aggregation was potently 
inhibited by BX 667. Additionally, administration of BX 667 resulted in a rapid and sustained 
inhibition aggregation 96. This observation is also supported by the intravenous BX 048 and oral 
BX 667 administration in rat arteriovenous-shunt model, which showed a similar 
pharmacodynamic relationship between the plasma concentration of BX 048 and thrombus 
inhibition 95. This antagonist has yet to be evaluated in healthy human subjects. 
2.4 Glycoprotein (GP) Antagonists 
αIIbβ3 Antagonists 
Glycoprotein GPIIbIIIa (αIIbβ3) is the most abundant integrin on the platelet surface 97. αIIbβ3 is 
known to be involved in both inside-out or outside-in platelet signaling. The inside-out signaling 
in platelet activation involves the various signaling pathways that converge into a common 
signaling endpoint that leads to the activation of integrin αIIbβ3. Ligand binding of fibrinogen or 
von Willebrand factor (vWF) to αIIbβ3 mediates platelet adhesion and aggregation, triggers 
outside-in integrin activation and results in additional granule secretion, stabilization of platelet 
adhesion, aggregation, and clot retraction 98.  
Abciximab (ReoPro; Eli Lilly) is an antibody developed from the murine human chimera c7E3 
Fab which targets the integrin αIIbβ3 99, preventing integrin binding to fibrinogen and vWF. 
Abciximab rapidly binds with high affinity and has a slow rate of dissociation from its target 100. 
In addition, abciximab binds with high affinity to αvβ3 (vitronectin receptor) 101 and low affinity 
to the leukocyte MAC-1 receptor 102.  Initial intravenous administration enables rapid onset of 
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platelet inhibition 103. As abciximab has an extremely short half-life 104, platelet aggregation 
returns to baseline levels within 12-24 hours following discontinuation of therapy 105,106. 
Interestingly, the ISAR-REACT trial demonstrated no additional benefit of abciximab over 
placebo in the reduction of ischemic complications or mortality 104,107. Similarly, among diabetic 
patients without elevated troponin levels undergoing elective PCI, no difference was observed in 
primary end point events between abciximab and placebo/clopidogrel groups 108. Conversely, in 
patients with elevated troponin levels, the incidence of mortality and recurrent ischemic 
complications was significantly reduced with abciximab 109. Careful monitoring must be 
accompanied with the administration of abciximab as bleeding and thrombocytopenia have been 
observed 110-112.  
Eptifibatide (Integrilin; Millenium Pharmaceuticals/Shering-Plough) is a cyclic heptapeptide 
derived from snake venom that contains a KGD (lysine-glycine-aspartic acid) sequence which 
selectively recognizes αIIβ3 113. The IMPACT-II study showed that a single loading dose 
followed by continuous infusion for 20 to 24 hours only resulted in 50% αIIbβ3 receptor 
blockade; thus limited benefits and efficacy through eptifibatide were observed 114. The ESPRIT 
trial however, which utilized intravenous administration of a double bolus 115 followed by 
maintenance infusion, significantly reduced the 30 days incidence of death, myocardial 
infarction, and target vessel revascularization 116 establishing the clinical efficacy for this drug. 
These observations were confirmed in the PURSUIT trial, which showed an absolute reduction 
in the 30 day incidence of death and myocardial infarction on eptifibatide 117. Despite the 
reduction in mortality, the ACUITY trial also showed an increase incidence of major bleeding in 
patients with ACS undergoing PCI 118,119.  
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Tirofiban (Aggrastat; Merck) is a tyrosine-derivative nonpeptide mimetic reversible inhibitor of 
αIIbβ3 that specifically and competitively binds to the receptor. Treatment with tirofiban in 
combination with aspirin and heparin in patients with ACS significantly reduced the 30-day post-
treatment incidence of death, myocardial infarction or recurrent ischemia 120. Further, tirofiban 
was superior for ACS patients recovering from invasive coronary angiography 120. As for the use 
of tirofiban as an adjunct to PCI, tirofiban was shown to be inferior to abciximab in the 
RESTORE and TARGET trials where the incidence of composite death, non-fatal myocardial 
infarction, and urgent target vessel revascularization were higher with tirofiban or abciximab at 
30 days 121.  
Z4A5 is a novel αIIbβ3 peptide antagonist that is currently in development. This antagonist has 
been shown to inhibit platelet-induced aggregation and thrombi formation. Additionally, when 
Z4A5 was examined along with heparin and /or aspirin in the rabbit arteriovenous shunt 
thrombosis model, it was shown to be an effective antithrombotic agent when administered with 
aspirin 122. The pharmacodynamics and pharmacokinetics in humans are currently under 
investigation 122. 
Additional Glycoprotein Antagonists 
Additional glycoprotein targets have received a fair amount of attention in the drive to develop 
novel approaches for anti-platelet intervention. Von Willebrand factor (vWF), a multimeric 
glycoprotein that acts as a bridging element between damaged endothelial sites and the 
glycoprotein receptors on platelets, is one such target. The A1 and A3 domains of vWF bind to 
collagen, while the A1 domain is bound to the GPIb-IX-V platelet receptor complex 123,124. vWF 
also binds to active αIIbβ3 on the platelet surface. Interactions between αIIbβ3 and vWF 
contribute to the final, irreversible binding of platelets to the sub-endothelium and play a leading 
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role in platelet aggregation 125. A second target receiving attention as a potential site for anti-
platelet therapy is the collagen receptor glycoprotein VI (GPVI). The collagen-GPVI interaction 
triggers subsequent tyrosine phosphorylation of the ITAM motif of the Fc receptor γ chain, 
activating the Syk kinases pathway, LAT, SLP-76, and phospholipase Cγ2 126, resulting in 
platelet activation or aggregation. 
vWF Antagonists 
AJW200 is an IgG4 humanized monoclonal antibody to vWF which has been shown to 
specifically inhibit high-shear-stress-induced platelet aggregation in a concentration dependent 
manner in vitro in blood from human volunteers 127.  
ARC1779 (Archemix Corp) is an aptamer based antagonist. This second generation nuclease-
resistant aptamer is conjugated to a 20-kDA polyethylene glycol and binds with high affinity to 
the active vWF A1-domain and inhibits vWF-dependent platelet aggregation 128. A phase II trial 
demonstrated that continuous infusion of ARC1779 effectively increased platelet counts in 
critically ill thrombotic thrombocytopenic purpura patients by preventing platelet aggregation 
and loss of platelets. Cessation of ARC1779 infusion resulted in platelet count reduction and 
progression of thrombotic thrombocytopenic purpura-related organ damage 129. This drug is 
currently clinical investigation. 
Other vWF antagonists in clinical development or investigations include ARC15105, ALX-0081 
(Ablynx), ALX-0681, and 82D6A3. ARC15105 is a chemically advanced aptamer with assumed 
higher affinity to vWF, but less specific inhibitor of vWF-dependent platelet aggregation than 
ARC1779 based on ex vivo trials 130. The preclinical and clinical trials have shown that ALX-
0081, a bivalent humanized nanobody that recognizes the Glycoprotein Ib (GPIb) binding site of 
vWF, is a potent and safe inhibitor of vWF-mediate platelet aggregation over a wide range of 
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doses when administered in combination with aspirin, heparin, and clopidogrel. ALX-0081 is 
currently under investigation in PCI patients in a phase II trial. 82D6A3, a monoclonal antibody 
directed against amino acids Arg-963, Pro-981, Asp-1009, Arg-1016, Ser-1020, Met-1022 and 
His-1023 of the vWF A3 domain 131, was shown to result in complete inhibition of vWF binding 
to collagen during the first 3 days after stent implantation in baboons 132. Further trials will need 
to follow to verify 82D6A3 efficacy, safety, and tolerability.  
GPVI Receptor Antagonists 
PR-15 (Revacept; ABX-CRO/Medifacts GmbH) is a soluble, dimeric glycoprotein (GPVI)-Fc that 
has been shown to adhere to exposed collagen in endothelial lesions preventing the binding to 
platelet GPVI receptors. Collagen-induced human platelet adhesion or plaque formation were 
significantly reduced with pre-treatment of soluble GPVI-Fc 133,134. Similarly, infusion of GPVI-
Fc was shown to virtually abolish stable arrest and aggregation of platelets following vascular 
injury in mice 126. Subsequently, a phase I clinical trial demonstrated that intravenous 
administrated of PR-15 is safe and well tolerated by healthy volunteers 135. 
DZ-697b is an orally active collagen and ristocetin inhibitor. Safety and efficacy have been 
assessed in a phase I trial which showed potential benefits such that bleeding time was 
substantially shortened compared to clopidogrel treatment 136.  DZ-697b is currently under 
clinical investigation.  
GPIb Receptor Antagonists 
Novel targets still under investigation include h6B4-Fab, GPGP-290, and SZ2. h6B4-Fab is a 
murine monoclonal antibody, derived from the humanized Fab fragment of 6B4 targeting GPIbα 
and neutralizes the binding site of the vWF A1 domain137,138. 6B4 had been shown to inhibit 
platelet adhesion by competing with vWF for binding to GPIbα under high-shear conditions. 
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Moreover, preliminary data show 6B4 had no effect on platelet count or bleeding times in vivo in 
baboons, but dose-and time-dependently inhibited ristocetin-induced platelet aggregation 139. 
GPG-290 is a recombinant, chimeric antibody purified from chinese hamster ovary cell culture 
that contains the amino-terminal 290 amino acids of GPIbα linked to the human IgG1.  GPG-290 
treated dogs were shown to exhibit prolong bleeding compared to the clopidogrel-treated control, 
despite the prevention of coronary artery thrombosis 140. SZ2, a monoclonal antibody developed 
against GPIbα, has also been shown to inhibit both ristocetin- and botrocetin-induced platelet 
aggregation in vitro 141. Preclinical investigations are still underway to determine the in vivo 
efficacy of SZ2.  
2.5 Phosphodiesterase Antagonists 
Platelets express three phosphodiesterase (PDE) isoenzymes, PDE 2, 3 and 5. 
Phosphodiesterases regulate the levels of 3’,5’-cyclic adenosine monophosphate (cAMP) and 
3’,5’-cyclic guanosine monophosphate (cGMP) by catalyzing the hydrolysis of cAMP and 
cGMP to inactive 5’-AMP and 5’-GMP, respectively.142 Platelet activation relies on degradation 
of cAMP and cGMP; hence regulating these secondary messengers are fundamental in regulating 
platelet activation and thrombosis.  
Cilostazol (Pletal, Otzuka Pharmaceutical Co.) is a type III-phosphodiesterase (PDE3) selective 
oral inhibitor 143. Liu and colleagues have shown that cilostazol enhances the interstitial 
concentration of adenosine in several in vitro and in vivo models 144 by inhibiting adenosine 
uptake. This in turn stimulates A2 receptors, which further increases cAMP levels. As a result, 
platelet-induced aggregation is reversibly inhibited by cilostazol 145. Cilostazol is extensively 
metabolized by CYP3A4; while CYP2C19 is also shown to have a minor role in cilostazol 
metabolism 146. Cilostazol is safe and effective in reducing the incidence of repeated 
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revascularization after PCI and risk of restenosis; however, this drug does not show superiority 
in reducing the primary composite end points of adverse cardiovascular events after drug-elution 
stent (DES) implantation 147. Despite the functional implications of adjunctive treatment with 
cilostazol compared with standard aspirin and clopidogrel treatment, as shown in the OPTIMUS-
2 study, the accompanied side effects (headaches, gastrointestinal symptoms, and skin rash) 
often lead to the discontinuation of the drug 148. 
Dipyridamole (Aggrenox; Boehringer Ingelheim) is a pryimidopyrimidine derivative with both 
anti-platelet and vasodilator properties 149. Similar to cilostazol, dipyridamole inhibits cyclic 
nucleotide phosphodiesterase and blocks adenosine uptake, which results in increased cAMP 150. 
The ESPS-2 and ESPRIT trials showed that dual treatment of dipyridamole and aspirin reduced 
risk of stroke or death by 37% compared with aspirin alone 151,152. Based on the ESPRIT and 
ESPS-2 trials, dipyridamole has been FDA approved for stroke prevention 152.  
2.6 Thromboxane A2 Receptor Antagonists 
Platelets express the thromboxane receptor α (TP α), a GPCR that is coupled to Gq and G12/13 and 
signals platelet activation through a number of intracellular pathways which converge to 
reinforce primary platelet activation through thrombin or collagen 153.  
S18886 (Terutroban) is an oral reversible inhibitor of TPα. In preclinical studies, S18886 dose-
dependently prolonged occlusive thrombus formation in animal models, but did not alter the size 
of the myocardial infarct size in the ischemia-perfusion model. S18886 and clopidogrel were 
effective in preventing occlusive thrombus formation with a moderate increase in bleeding time 
154.  Subsequently however, in the phase III clinical trial (PERFORM), S18886 did not meeting 
the pre-defined criteria for non-inferiority since S18886 and aspirin had similar rates of 
protection without safety advantages for S18886 155. 
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Z-335 ((+/-)-sodium[2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate monohydrate) is 
an oral TPα antagonist that has previously been shown to dose-dependently inhibit the specific 
binding of [3H]SQ-29548 (TPα inhibitor) to human and guinea pig platelet membranes 156. In 
healthy male Japanese volunteers, Z-335 inhibited U46619-induced platelet aggregation within 2 
hours of administration 157.  
BM-573, another investigational inhibitor that targets TPα, has been shown to halt the 
progression of atherosclerosis in LDL receptor deficient mice 158. Pre-clinical models have 
shown that arachidonic acid-induced aggregation is completely inhibited in the presence of BM-
573 159 and clinical studies on this compound are currently ongoing. 
2.7 Thrombin Receptor Antagonists 
Thrombin activates human platelets via two protease activated receptors (PARs), PAR1 and 
PAR4. PAR activation leads to a diverse range of pro-thrombotic signaling events mediated 
through Gq, G12/13, and possibly Gi, resulting in phospholipase (PLC) β activation, Rho 
activation, and adenylyl cyclase inhibition, respectively. PAR activation requires thrombin 
cleavage of the amino terminus of the receptor revealing a tethered ligand. While it has been 
challenging to develop an inhibitor that can directly compete with the endogenous tethered 
ligand, development of PAR1 inhibitors as a therapeutic target to minimize uncontrolled platelet 
activation have recently been investigated.  
SCH 530348 (Vorapaxar; Merk & Co.) is an orally active synthetic analog of himbacine 160 that 
competitively binds with high affinity to the PAR1.  Previous in vitro assays show SCH 530348 
inhibited thrombin- and thrombin receptor activating peptide (TRAP) – induced platelet 
aggregation, without affecting the aggregation induced by adenosine diphosphate (ADP), 
U46619, or collagen. In addition, SCH 530348 did not affect the prothrombin and activated 
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partial thromboplastin time, suggesting that bleeding time may not be increased.  Pre-clinically, 
cynomolgus monkeys treated with SCH 530348 alone or in addition with aspirin and clopidogrel, 
showed no increase in bleeding times 161. The TRA-PCI study verified that addition of SCH 
530348 to standard anti-platelet therapy (aspirin and clopidogrel) was not associated with 
increases in thrombolysis in myocardial infarction (TIMI) or bleeding compared with the control 
group 162. The phase III clinical trials TRA-CER and TRA 2ºP-TIMI, which sought to assess the 
impact of vorapaxar on cardiovascular death, MI, stroke, and recurrent vascular events in 
patients with established coronary, cerebral, or peripheral atherosclerosis 163 failed due to 
unforeseen intracranial bleeding 163. 
E5555 (Atopaxar; Eisai Limited) Pre-clinical trials showed that oral administration of the PAR1 
antagonist, E5555, significantly prolonged bleeding times in guinea pigs 164. Further, PECAM-1, 
active αIIbβ3, GPIb, thrombospondin, and vitronectin expression, were significantly reduced by 
E5555 in whole blood flow cytometry. Clinical studies have shown that E5555 attenuated 
thrombin-induced but not ADP-induced platelet aggregation 165,166.  
Additional PAR-1 antagonists: SCH 205831 and SCH 602539 are still under investigation. 
Preliminary data show SCH 205831 derived from himbacine, inhibited platelet deposition in 
baboons with arteriovenous-shunt thrombosis. Similarly, SCH 602539 inhibited thrombosis in a 
dose-dependent manner in the Folts model of thrombosis in anesthetized cynomolgus monkeys 
167. These compounds continue to be developed in pre-clinical models. 
2.8 Conclusion  
Significant progress has been made in advancing our understanding of how platelet activation 
directly regulates thrombus formation in the vessel leading to occlusive thrombi and stroke. 
However, a continued need for the development of new anti-platelet therapies exists as the risk 
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for myocardial infarction, stroke, and death, remain a persistent problem for individuals suffering 
from cardiovascular disease. Further, while aspirin continues to be the first line of 
pharmacological intervention in anti-platelet therapy, the risk of bleeding is significantly 
exacerbated by its irreversible action coupled to the additional regimen of dual therapy often 
employed to minimize thrombotic events.  In hopes of reducing prolonged bleeding or 
myocardial infarct events, newer compounds continue to be developed to target alternative sites 
in the platelet. The successful implementation of these strategies may significantly reduce the 
morbidity and mortality in cardiovascular disease due to unwanted platelet activation as well as 
excessive bleeding due to traditional approaches. Even with the newer anti-platelet drugs 
entering the market in the near future, we are faced with the realization that activation of the 
platelet involves an increasingly complex signaling network. Hence, new frontiers will need to 
be explored which will take advantage of this signaling to reveal novel therapeutic targets with 
diminished off-target effects. 
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CHAPTER 3  
 
12-Lipoxygenase: A Novel Target for Anti-Platelet Therapeutics2 
 
3.1 Summary 
Platelets play an essential role in the regulation of hemostasis and thrombosis and controlling 
their level of activation is central to prevention of occlusive clot formation and stroke. Although 
a number of anti-platelet targets have been identified to address this issue including COX-1, the 
P2Y12 receptor, the integrin αIIbβ3, and more recently the protease-activated receptor-1, each of 
these targets has resulted in a significant increase in bleeding which in many cases may be more 
deleterious than the clot itself. Therefore, alternative approaches to treat uncontrolled platelet 
activation are warranted. Platelet-type 12-lipoxygenase is an enzyme which oxidizes the free 
fatty acid in the platelet resulting in the production of the stable metabolite 12-
hydroxyeicosatetraenoic acid (12-HETE). The role of 12-HETE in the platelet has been 
controversial with reports associating its function as being both anti- and pro-thrombotic. In this 
review, the role of 12-lipoxygenase and its bioactive metabolites in regulation of platelet 
reactivity, clot formation, and hemostasis is described. Understanding the mechanisms by which 
12-lipoxygenase and its metabolites modulate platelet function may lead to the development of a 
novel class of anti-platelet therapies targeting the enzyme in order to attenuate injury-induced 
clot formation, vessel occlusion and pathophysiological shifts in hemostasis. 
 
                                                
2 This section has been published in Cardiovascular & Hematological Agents in Medicinal Chemistry. Yeung J and Holinstat, M. 
12-Lipoxygenase: A potential Target Novel Anti-Platelet Therapeutics.  CHAMC  2011; 9(3):154-164. 
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3.2 Platelet Therapy in Cardiovascular Disease 
Incidence of CVD. Recently, the American Heart Association reported that cardiovascular 
diseases (CVD) accounted for 33.6% of all deaths in the United States based on the 2007 data 
168, and is the single leading cause of death in the nation and worldwide 169 occurring before age 
65. Furthermore, more than 67.3% of adults over the age of 20 are reported to be obese, which is 
one of the major contributing factors to developing CVD along with smoking. Surgical 
procedures for cardiovascular complications have also increased by 27% from 1997 to 2007 168. 
Despite these alarming statistics, the mortality rate resulting from CVD complications has 
slightly decreased, although the burden of the disease still remains high. This is due, in part, to 
the successful development and widespread use in the clinic of a number of anti-platelet drugs.  
Current anti-platelet drugs. One of the earliest targets for anti-platelet therapy was 
cyclooxygenase-1 (COX-1), responsible for the formation of prostanoids, which are involved in 
inflammation 170. A number of pharmacological approaches have been developed over the years 
to inhibit COX activation in platelets including aspirin, indomethacin, and nonsteroidal anti-
inflammatory drugs (NSAIDS) 171 The efficacy in treating and preventing vascular-occulsive 
events with COX-1 inhibitors has been limiting in a significant proportion of the population 
172,173. One study for example, reported that greater than 33% of the patients with cardiovascular 
diseases (CVD) exhibited aspirin resistance 170,174. Another target on the platelet which has 
successfully been inhibited in order to limit platelet activation is the ADP receptor, P2Y12. 
Targeting P2Y12 with clopidogrel, a pro-drug that binds to and inhibits receptor activation, has 
been shown to be effective in further reducing platelet activation when given as dual anti-platelet 
therapy with aspirin 175. However, due to the nature of this pro-drug and the genetic variability of 
the P450 enzyme required to convert clopidogrel to its active form its utility is limited as is 
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evident from the development of next generation P2Y12 inhibitors ticangralor and presagrel 
176,177. Integrin IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban), although a breakthrough in 
antibody-based anti-platelet therapy 177-179, have resulted in an increase in hemorrhagic 
complications following PCI. Furthermore, some patients developed frequent myocardial 
infarction and refractory ischemia post-tibrofiban administration 180.  
Adverse side effects such as bleeding are of primary concern for current treatment against 
platelet activation in CVD therapy, especially prior to and during surgical procedures 181. Thus, 
alternative strategies which would inhibit platelet activation while minimizing the bleeding side 
effect are warranted. A novel target for anti-platelet therapy in the treatment of patients with 
cardiovascular related diseases may be human 12-lipoxygenase (12-LOX). In order to develop 
potential 12-LOX inhibitors however, we must have a comprehensive understanding of its 
pathophysiological and biochemical implications and the role 12-LOX metabolites play in the 
vascular system. Our current knowledge of this enzyme and its oxidized products in platelets and 
other tissues is still limited, but the preliminary evidence shows the potential advantages of 
inhibiting 12-LOX on the platelet to treat human diseases. 
History of lipoxygenases. Lipoxygenases (LOXs) are a family of nonheme iron dioxygenases, 
originally known as lipoxidases that catalyzes the oxidation of polyunsaturated fatty-acids such 
as linoleic acid or arachidonic acid (AA), containing the cis-methylene interrupted diene 
structure and esters yielding conjugated hydroperoxides 182. The earliest lipoxygenase studies 
showed 15-lipoxygenase purified from soybean oxidized unsaturated moieties of fatty acids 183 at 
a specific carbon site of the acyl chain; that eventually allowed lipoxygenase isoforms to be 
identified according to their site of carbon oxidation and stereochemistry. The transformation of 
AA to 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12(S)-HETE) was first demonstrated in 
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human and bovine platelets in the mid-1970s 184. These metabolites, produced by  5-, 8 -, 12-, 
and 15- LO, have been reported to potentially form signaling lipid mediators that exert their 
effects through the G protein –coupled receptor (GPCR) 185. Lipoxygenases and their metabolites 
have been demonstrated experimentally and clinically to be restricted to specific cells or tissues 
and show significant species specificity. To date, three isoforms of 12(S)-lipoxygenases have 
been identified accordingly to their cell type: epidermis, leukocyte, and platelet 186. 12-LOX 
activation has been reported to play a role in a number of diseases including psoriasis187 and 
ulcerative colitis 188,189. Despite intensive research in this field, the majority of the discoveries of 
12-lipoxygenase functions and their implications have been established using animal models. 
Thus, our current understanding of the biological significance of these enzymes and products in 
humans is still limited. 12-LOX isoforms and their products will be the focus of this review 
showing their involvement in platelet reactivity contributing to hemostasis and thrombosis and 
the overall scheme in developing alternative targets to prevent vascular occlusion, myocardial 
infarction, and stroke.  
3.3 12-LOX in the Human Platelet 
Activation of platelets through a number of receptors is known to result in activation of cytosolic 
phospholipase A2 (cPLA2), a lipid lipase that generates free fatty acid such as AA from the 
phospholipid membrane by cleaving the sn-2 position 184. Once AA is formed, it is available for 
oxidation by either COX-1 or 12-LOX and can produce a number of bioactive lipid metabolites 
184. In leukocytes, oxidized AA will result in the production of PGE2 and LTB4 190,191 as pro-
inflammatory effectors or thromboxane (TxA2) and 12-HETE in platelets. Recently, we have 
shown that COX-1 and 12-LOX-mediated signaling may rely on different pools of AA based on 
the kinetics of TxA2 and 12-HETE formation and their differential reliance on cPLA2 at the 
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surface of the platelet 192. Unpublished data further indicates that 12-LOX activation is required 
for dense granule secretion in platelets as well as normal platelet aggregation and adhesion. This 
is not surprising considering blocking 12-LOX attenuates aggregation and integrin activation in 
the presence of thromboxane, collagen, thrombin, and protease-activated receptors (PARs) 193-195. 
Additionally, 12-LOX has also been implicated to play a role in regulating calcium mobilization. 
A role for 12-LOX in the platelet using one of the classical 12-LOX inhibitors, baicalein, was 
first described in the mid-1990s, where stimulation with AA in the absence of 12-LOX resulted 
in a significant attenuation of thrombin-induced calcium [Ca2+]i transients and aggregation 196. In 
addition to oxidation, 12-LOX in platelets has also been reported to have lipoxin synthase 
activity. Lipoxins, such as LXA4 and LXB4, are tetraene-containing eicosanoids generated from 
exogeneous leukotriene A4 (LTA4) that induces vasoconstriction of the smooth muscles and 
regulates neutrophil function via binding at specific recognition sites 197-200.The molecular 
observations above confirm an important role for 12-LOX in human platelet reactivity and a 
renewed interest in this field attests to the therapeutic potential inherent with regulation of 12-
LOX. Finally, although human studies to date are limited to platelet reactivity and thrombosis, a 
number of animal models have added crucial information as to the potential role of 12-LOX in 
hemostasis including studies with 12/15-LO knockout mice, canines, porcine, and rabbits, show 
varying and sometimes unrelated physiological effects compared with humans 201 (Table 3.1). 
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Table 3.1 12-LOX expression and function different species 
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3.4 12-LOX Substrates 
Polyunsaturated fatty acids (PUFA) as regulators of 12-LOX-mediated platelet activity. A 
possible alternative approach to anti-platelet therapy may lie in the dietary intake of certain 
essential fatty acids (EFA). Large prospective studies have shown that there is a positive 
relationship between increased dietary intake of ω-3 fatty acids and reduced CVD. For instance, 
Eskimos from the West Coast of Greenland with greater whale, fish, and seal intake correlated 
with lower incidence of myocardial infarction, stroke, and mild tendency to bruise 202.  Another 
study showed rats receiving Thomas-Hartroft thrombogenic diet were subsequently fed with 
unsaturated fatty acid supplements, which comparatively showed reduced thromboplastin 
generation and mortality 203. In addition, the epidemiological studies of high eicosapentaenoic 
acid (EPA) to AA consumption in Japan had shown that the incidence of mortality due to 
ischemic heart disease and cerebrovascular disease between 1950 and 1982 tended to be lower in 
the fishing residents than the farming villages 204-206. Hence 12-LOX may be the key to 
regulating platelet function through oxidation of various free fatty acid substrates. While the 
addition of polyunsaturated fatty acids as dietary supplement may be beneficial, the amount of 
fatty acids added to the diet needs to be carefully monitored in patients with existing 
cardiovascular risk. Previous studies for example, have suggested that docosahexaenoic acid 
(DHA) has an adverse effect on diabetics and elderly who are already suffering from a lower 
antioxidant potential. In one study, platelets from an elderly subject with low DHA were given 
low DHA supplements and exhibited lower lipid peroxidation activity, whereas incubated with 
high DHA concentration induced higher 12-HETE formation 207,208.  As for EPA, 30mg and 
200mg/kg/day of the fatty acid supplement given to patients resulted in attenuated platelet 
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aggregation. TxB2 production had also been observed to be blocked in platelets pre-treated with 
EPA207. 
12-LOX substrate availability. Dietary intake of certain essential fatty acids (EFAs), ω-3 or ω-6, 
have been shown to impact the type of metabolic products generated by 12-LOX. For instance, 
AA, a ω-6 series fatty acid derived from cis-linoleic acid (LA), can be found mostly in peanut 
oil. As for ω-3, fish oil, flaxeed, and algal oil, are the common sources for α-linolenic acid 
(ALA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) 209. Platelet membranes 
containing DHA have been reported to be catalyzed by 12-LOX to various hydroxyl 
docosahexaenoic acid (HDoHE) isoforms, but largely forming 14-HDoHE in an agonist and 
calcium-dependent manner 184. A number of metabolic products are formed following 12-LOX 
oxidation of another fatty acid, EPA, which include AA, TxB3, 12(S)-hydroxyeicosapentanoic 
acid (12-HEPE), and hydroxy-5,8,10-14-heptadecatetraenoic acid (HhTE) 210,211. One study 
showed that EPA conversion to TxB3 depended on the presence of hydroxy-5,8,10, 14-
eicosatetraenoic acid (12-HpETE), whereas, pre-incubation with 12-HETE did not induce EPA 
metabolism. In another case, pre-incubation with 12(S)-HpETE has been shown to increase the 
amount of nonesterified AA in collagen stimulated platelets, significantly enhancing platelet 
aggregation and the formation of TXB2212.. The eicosanoid metabolites, once formed, can have a 
number of regulatory functions in the platelet probably through both autocrine as well as 
paracrine signaling schemes. The physiological and cellular effects due to oxidized products are 
further discussed in detail below. 
Direct 12-LOX regulation of eicosanoid metabolites. Eicosanoid metabolites are able to be 
further oxidized by 12-LOX. 12-LOX can catalyze 5-HETE to generate 5(S), 12-
dihydroxyeicosatetraenoic acid (12(S)-DHETE) and 15-HETE to 14,15-DHETE in platelets 
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under conditions of prolonged exposure to the enzyme 213.  Similarly, exogenous AA and 5-
HETE showed reduced production of 5(S), 12(S)-DHETE. 11,12-DHETE had also been reported 
to be generated from 12-LOX214. 
3.5 The Biological Role of Metabolites 
Metabolite profiling in the blood. Profiling of lipid metabolites and mediators in whole blood in 
the presence of the calcium ionophore A23187, demonstrated that 12-LOX contributes a large 
proportion of the total products formed 215 compared with the other lipoxygenases. The 
predominant products were 12-HETE, 12-HEPE, and 12- hydroxydocosahexaenoic acid (12-
HDHA). A significant number of 5-LOX products, including leukotriene B4 (LTB4), LTB5, and 
prostaglandin E2 (PGE2), were also found in circulation under these conditions. Shifting ω-3 or 
ω-6 content in the lipid bilayer of the cells has been shown to contribute to differences in their 
respective lipid mediators and metabolites and thus regulate biochemical and physiological 
events in the cells of the individuals 210,216.  
12-LOX metabolite regulation of various tissues. 12-LOX oxidation of various fatty acids in the 
platelet can result in the formation of a number of unique eicosanoid metabolites.  Many, if not 
all, of these eicosanoids can play a regulatory role both within the platelet itself as well as at 
distal tissues and organ systems. Previous studies support a pro-inflammatory role for eicosanoid 
formed through 12-LOX oxidation of ω-3 fatty acids and AA in a number of animal models 
including the mouse and rabbit 217 Further, work in cell lines confirms a role for these 
eicosanoids in a number of distant tissue beds as well. For example, mouse pre-adipocytes 3T3-
L1 cells pre-treated with 12(S)-HETE and 12(S)-HpETE induce upregulation of 
proinflammatory cytokine genes, such as tumor necrosis factor-alpha (TNF-α), interleukin 6(IL-
6), IL-12p40, and monocyte chemoattractant protein (MCP-1) 201.  In the human epidermis, 
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12(R)-HETE, which is sterochemically different from platelet-derived 12(S)-HETE, has been 
reported to increase DNA synthesis and plays a significant role in psoriasis 218,219.  
12-LOX metabolite regulation of platelets. As for platelets, the role of the AA oxidized 
metabolite, 12-HETE, is not well understood. Furthermore, work in the field is controversial as 
to whether 12-HETE is pro-thrombotic, anti-thrombotic, or inert towards platelet activity. One 
study indicated that 12-HETE had no effect on either basal or thrombin-induced [Ca2+]i levels or 
aggregation220 Conversely, other reports showed a clear potentiation of thrombin-induced 
aggregation in platelets in the presence of 12-HETE 221.. 12-HpETE has also been shown to 
stimulate 12-LOX but inhibit COX-1 in lysed platelets222 and one report indicated that 12(S)-
HETE acts as an inhibitor of platelet and neutrophil PLA2 223. Additionally, the eicosanoid, 15-
HETE, which is primarily produced in leukocytes, has been reported to act as an inhibitor of 12-
LOX224. Other eicosanoid products, such as 12-HPEPE and 12-HEPE originating from 12-LOX 
oxidation of EPA, are thought to elicit an inhibitory effect on platelet aggregation 204,205. In 
addition to their effects on aggregation, 12-HPEPE and 12-HEPE have been shown to attenuate  
serotonin (5-HT) release mediated by AA and collagen in a dose dependent manner225. The level 
of fatty acid substrate available to 12-LOX may also play a role in its physiological regulation of 
platelet function. On the one hand, incorporation of DHA into one’s diet lowers lipid 
peroxidation, which lends to attenuating platelet reactivity at high concentrations by inhibiting 
TXA2 induced aggregation226, whereas higher DHA concentrations result in potentiation of 
platelet reactivity. This paradoxical phenomenon has also been observed for the 12-LOX 
metabolite, 12-HEPE. 
12-LOX metabolite regulation of CVD. Patients with essential hypertension, a significant risk 
factor for vascular occlusion 227, have shown an increase in the basal level of 12(S)-HETE in the 
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platelets and in urinary excretion of 12(S)-HETE compared to healthy subjects 228. Further, the 
protein levels of 12-LOX in the cytosolic fraction from hypertensive patients was much higher 
than in normotensive subjects. Thrombin-mediated 12(S)-HETE generation however, did not 
differ between the groups implying a potential role for genetic variation in the levels of 12-
HETE formed 228. SNP analysis has uncovered an association in the coding polymorphism of the 
12-LOX gene with essential hypertension and urinary production of 12(S)-HETE 229.  
Age is known to be directly correlated to an increased risk for cardiovascular disease230,231. 
Similarly, platelet reactivity is also increased in older patients due, in part, to increasing levels of 
AA and TxA2 formation [85-87] Although 12-LOX product formation has not been studied in 
young versus older subjects, it is likely that 12-HETE is also increased in this segment of the 
population. Additionally, diabetics have been shown to exhibit an increase in PLA2 activity 
linked to an increase in TxA2 formation232. 12-LOX has been reported to have a link to platelet 
function in diabetes as well. 12-HETE levels in platelets from a group of Japanese with type 2 
diabetes were observed to be decreased compared with healthy subjects 233, whereas noninsulin 
dependent patients in the US showed an increase in 12-HETE formation in the urine samples 
compared to healthy subjects 234. These controversial observations, although perplexing, support 
a link between the levels of 12-LOX activity in the platelet and diabetes. 
3.6 12-LOX Inhibitors 
The studies described above show that regulating amount of essential fatty acids and their 
metabolites via 12-LOX is essential in understanding both the pathophysiological processes of 
the platelets and CVD. Various groups have screened for potential natural and small molecule 
drugs targeting 12-LOX, however, many of these screens have failed due to problems with 
efficacy, off-target effects, and adverse events, both in animals and human platelets (Table 3.2). 
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One of the earliest drugs tested on arachidonate 12-LOX was an acetylenic acid, 4,6-10-13-
eicosatetrayonic acid (4,7,10,13-ETYA) 235. This approach however, also targeted human 
peripheral neutrophil 5-LOX with an ID50 of 2-3uM and other lipoxygenases from different 
sources and was therefore not developed further. Esculetin, also known as curcumin, was shown 
to inhibit 12-HETE production in both human and rat platelets 236, but did not inhibit formations 
of TxB2 and HHT 237. Besides curcumin, baicalein (5,6,7-tihydroxyflavone), a compound 
extracted from Scutellariae roots 238, was first reported to selectively inhibit 12-LOX in human 
platelets in the 1980s 239 without affecting cyclooxygenase activity 240. In addition, platelet 
activation and ATP secretion stimulated by Chlyamydia pnemoniae was markedly reduced by 
this inhibitor 241. More recent data suggests that baicalein inhibits cPLA2 in human platelets and 
that some of its effects may be due to a lower level of AA formation following initial platelet 
activation. Baicalein has also been reported to be an inhibitor of CYP2C9, an enzyme involved 
in drug metabolism 242 as well as other human LOs and COXs 243. In addition to its off target 
effects, baicalein in rats showed that the amount of 12-HETE produced in the presence of the 
inhibitor and thrombin stimulation did not correlate with the potentiation of contractile responses 
in the artery 244.  
Other potential inhibitors which have shown little efficacy toward 12-LOX include 1) 
Dicranin (acetylenic fatty acid: 9,12,15-octadecatrien-6-ynoic), extracted from Dicranum 
Scoparium, which weakly inhibited COX-1, but resulted in an increase in 12-HETE 245, 2) 
Knipholone, which is isolated from the roots of Kniphofa foliosa and shown to inhibit 
leukotriene synthesis, but only weakly inhibit 12-HETE production 246, and 3) OPC-29030 which 
inhibits thrombin-mediated 12(S)-HETE production 247. Additionally, Hinokitiol, extracted from 
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Japanese wood, was shown to be a selective 12-LOX inhibitor. Unfortunately, Hinokitiol has 
also been reported to be cytotoxic and teratogeneic on living tissues 248,249.   
Recently, there has been an increased interest in developing a highly selective small molecule 
inhibitor targeting 12-LOX. These compounds structurally exhibit greater selectivity than the 
previous natural inhibitors described above due to their selectivity in distinguishing and LO 
paralogs in species specific tissues/cells 250.These small molecule inhibitors may possibly reduce 
off-target effects in the system due to their greater selectivity and aid in clarifying the role of 12-
LOX in the pathophysiology of thrombosis in the human.  
3.7 Conclusions 
Cardiovascular disease remains the leading cause of death in the world and is a growing problem 
both globally as well as within the United States. Research spanning over three decades has 
convincingly established a central role for platelet activation in the pathophysiology of 
cardiovascular disorders and acute coronary syndrome. Current pharmacological therapy for 
treatment of diseases caused by blood clots, such as heart disease and stroke, often involves the 
use of drugs that do not reflect current scientific understanding of these pathologies. Although 
targeting of enzymes such as COX-1 or surface receptors including P2Y12, PAR1, and integrin 
receptor αIIbβ3, has been extremely useful in decreasing morbidity due to MI, these therapies 
have failed to shift the incidence of mortality in these patients. This may be due, in part, to the 
fact that these anti-platelet drugs do not fully attenuate platelet activation, can have delayed onset 
and long durations of action, and may result in significant morbidity due to bleeding 
complications 76,251. New therapeutic approaches targeting the level of platelet activation 
necessary to inhibit vessel occlusion and stroke without significantly increasing bleeding are 
needed. 12-LOX may be a viable target for anti-platelet therapy. Studies have shown that a link 
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exists between the level of 12-LOX and cardiovascular risks such as type 2 diabetes and 
hypertension. Furthermore, 12-LOX metabolites such as 12-HETE, have been shown to 
potentiate platelet activation, thrombin generation, and calcium mobilization. Recent 
unpublished work using small molecule inhibitors now supports a pro-thrombotic role for 12-
LOX in the human platelet. Thus, ,targeting this enzyme may allow for attenuation of the platelet 
clotting cycle without a significant increased risk of bleeding. 
 Although 12-LOX was identified in the early 1970s by Hamberg and Samuelsson 252, 
identifying the regulatory role of 12-LOX and its metabolites in platelet function has been 
difficult, in no small part due the poor selectivity of naturally occurring lipoxygenase inhibitors 
(see table 3.2). Recently however, several research groups have revisited this enzyme and are 
developing a number of natural and synthetic molecule approaches in order to identify highly 
selective inhibitors against platelet-type 12-lipoxygenase in the human. The first generation of 
these inhibitors is now being tested in human platelets and early results support targeting this 
enzyme for future use as an anti-platelet therapy. Platelet-type 12-LOX is not the only potential 
target in development, however, its relatively selective expression in megakaryocytes and 
platelets, and its pro-thrombotic activity in human platelets supports further development of this 
target for anti-platelet therapeutics.  
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Table 3.2 12-LOX inhibitors and targets 
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CHAPTER 4  
 
Oxygenases and Their Derived Oxylipins Regulation of Platelet Function3 
 
4.1 Summary 
In mammals, three major oxygenases, cyclooxygenases (COXs), lipoxygenases (LOXs), and 
cytochrome P450 (CYP450), generate an assortment of unique lipid mediators (oxylipins) from 
polyunsaturated fatty acids (PUFAs) which exhibit pro- or anti-thrombotic activity. Over the 
years, novel oxylipins generated from the interplay of the oxygenase activity in various cells, 
such as the specialized pro-resolving mediators (SPMs), have been identified and investigated in 
inflammatory disease models. Although platelets have been implicated in inflammation, the role 
and mechanism of these SPMs produced from immune cells on platelet function are still unclear. 
This review highlights the burgeoning classes of oxylipins that have been found to regulate 
platelet function; however, their mechanism of action still remains to be elucidated.  
4.2 Introduction 
Cardiovascular disease remains the leading the cause of mortality globally accounting for nearly 
1 in 3 deaths annually253. Platelet activation leading to clot formation and thrombosis is an 
essential component of both the hemostatic and thrombotic responses in the blood following 
physiological and pathophysiological disturbance of the endothelium lining the vessel wall 254. 
The inability to properly regulate platelet reactivity often leads to atherothrombotic events, 
including myocardial infarction and stroke. Recent work in the field has uncovered a number of 
                                                
3 This section has been published in Journal of Molecular Medicine. Yeung J, Hawley, M, and Holinstat, M. The expansive role 
of oxylipins on platelet biology.  J. Mol. Med. 2017; 95(6):575-588. 
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lipid products, eicosanoids, derived from ω-3 or -6 polyunsaturated fatty acids (PUFAs) that 
significantly regulate and alter platelet function. The PUFAs include: arachidonic acid (AA), 
linoleic acid (LA), eicospentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic 
acid (DHA), and dihomo-γ-linolenic acid (DGLA). Understanding how these newly identified 
lipids fit into the overall regulation of platelets in the vessel will aid in our understanding of 
lipid-platelet interactions, often resulting from altered diet or fatty acid supplementation, that 
play key roles in the ability of the platelet to form a hemostatic “plug” following vascular injury 
or alternatively form an occlusive thrombus following pathophysiologic insult to the vessel. 
Finally, understanding how these lipids and lipid products are generated and regulate platelet 
reactivity should reveal novel targets for therapeutic intervention to prevent thrombosis while 
limiting the risk for bleeding following vessel injury. Thus, this chapter will be limited to 
describing the various lipids and bioactive lipid products shown to regulate platelet function and 
modulate hemostasis and thrombosis in the vessel. 
PUFAs are generally inert and depend on oxygenase activity to generate a wide array of 
structurally distinct bioactive fatty acids metabolites. The formation of lipid products is typically 
initiated by stimulation of the cell that results in an increase in intracellular calcium. This 
calcium flux results in translocation of cytosolic phospholipase A2 (cPLA2) to the lipid 
membrane where it cleaves the fatty acid from the sn-2 position of the phospholipids to release 
free fatty acids for oxidation in the cell. Once cleaved from the lipid membrane, the freed fatty 
acids can be metabolized by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 
(CYP450) to form oxidized lipids (oxylipins). Oxylipins have been thought to predominantly 
function by regulating cellular properties and signaling through one of three pathways.  The first 
involves binding to G protein-coupled receptors (GPCRs) to further propagate intercellular 
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signaling.  Secondly, fatty acids or their oxylipins can directly interact with peroxisome 
proliferator-activated receptors (PPARs) within the cell. While fatty acids are thought to be weak 
activators of PPARs, when they accumulate in the vicinity of the PPAR, reports have shown 
their affinity for activating PPAR signaling is significantly increased 255. The third regulatory 
mechanism utilized by fatty acids and oxylipins in the platelet is direct inhibition of oxylipin-
producing enzymatic pathways or further metabolic transformation of lipids within the cell 
(Figure 4.1). The chapter will cover the oxygenase pathways, classes of structurally distinct 
oxylipins, and their biological effects on the platelets. 
 
Figure 4.1 Mechanisms of oxylipin regulation of platelet function.  
Polyunsaturated fatty acids (PUFAs) are released from the embedded phospholipid bilayer membrane, which are then converted 
by intracellular oxygenases (COX, LOX, or CYP450) to generate wide array of oxylipins that can diffuse across the cellular 
membrane to be further converted by oxygenases, act on intracellular signaling component, PPAR, or act on receptor to regulate 
platelet function. This illustration was generated by Jennifer Yeung and Megan Hawley 
4.3 Cyclooxygenase  
Cyclooxygenase (COX) exists in two isoforms, COX-1 and COX-2 in the body; however, the 
platelet expresses primarily COX-1, and its inhibition is thought to be a primary target for 
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reduction of platelet reactivity in the patients with cardiovascular risk. COX activation primarily 
results in the generation of prostanoids (prostaglandins (PGs) and thromboxanes (TXs)) derived 
from PUFAs that are responsible for maintaining either physiological or pathophysiologic states, 
such as inflammation and tumorigenesis 256. This section describes the select prostanoid lipids 
generated from the PUFAs through the COX pathway that regulate platelet function. 
COX derived metabolites and their regulatory roles on platelet function  
COX transforms AA to series 2 PGs (PGE2, PGD2, PGI2) and thromboxanes (TX) A2 that can 
exhibit either pro-thrombotic or anti-thrombotic modulation of platelet function (Table 4.1) 
257,258. In terms of thrombosis, TXA2, when formed, is released and acts through the thromboxane 
receptor (TPα), which is coupled to G αq and G α13 and functions to amplify platelet activation 
leading to enhanced aggregation and thrombosis 259.  In contrast, PGD2 derived mainly from 
mast cells, leukocytes and some platelets260, had been shown to dampen platelet activation 261-263 
through its binding to the DP1 receptor and subsequent elevation of cAMP 264-266; however, there 
are evidence that PGD2 can also directly activate PPARs 267. PGD2 can be further dehydrated to 
PGJ2, Δ12-PGJ2, and 15-deoxy-Δ12,14-PGJ2, and inhibit platelet activation through a number of 
signaling pathways including activation of PPARs 268,269. While PGD2 derivatives are known 
PPAR ligands, the role of PPARs in platelet activation has not been fully elucidated. Similar to 
PGD2, PGI2 (prostacyclin), a well-characterized vasodilator 270, has been shown to activate 
adenylate cyclase in the platelet via the prostacyclin (IP) receptor and in turn antagonizes platelet 
aggregation at sites of injury 258,271. Although PGI2 has been shown to exert antiplatelet effects in 
vivo and is also clinically available to treat cardiovascular related diseases, a major concern of 
the use is the increased occurrence of hypotension. Moreover, PGE2 exhibits pleiotropic effects 
by which it can induce both pro- and anti-platelet responses depending on the concentration 
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272,273 through the binding of one of more of its prostaglandin receptors: EP1, EP2, EP3 and EP4 
274.  
DGLA is an omega-6 (ω-6) PUFA that can be acquired through supplementation of γ-
linolenic acid (GLA) in the diet. COX converts DGLA to series 1 prostaglandins (PGD1, PGE1) 
and TXA1 275,276, which inhibit platelet function in vitro and in vivo 277. These DGLA-derived 
COX prostanoids exerted their antiplatelet action by activating the Gαs-coupled GPCRs, 
prostaglandin receptors (EP2 and EP4) or IP receptor.  
Similar to DGLA, COX acts on EPA, an ω-3 PUFA, to generate anti-inflammatory 278 
lipid mediators, known as series 3 PGs and TXs 279,280. EPA-derived metabolites of COX (PGE3, 
PGD3, PGI3) inhibit platelet aggregation 281-284 and P-Selectin expression induced by platelet 
activating factor (PAF) as well as inhibiting platelet-rich plasma (PRP) 259. Evidence for the 
series 3 PGs receptors is scant. PGE3 had been suggested to be a partial agonist of the EP 
receptors in human kidney cells with varying degree of affinity potencies281 and secondary 
messenger actions. PGE3 mediated Gαq activation and intracellular calcium release through the 
EP1 receptor. While Gαs and enhanced cAMP formation were observed in EP2 and EP4 
overexpressed cells treated with PGE3, EP3 ligand binding resulted in reduced cAMP generation 
and augmented IP formation coupled to Gαi activation281. Platelets treated with EP3, EP4, IP and 
receptor antagonists (DG-41, ONO-AE3-208, and CAY10441 respectively) demonstrated that 
PGE3 acted as an antagonist to the EP3 to further inhibit platelet function, but with no effect 
mediated by the IP receptor on platelet reactivity. In contrast, CAY10441 reversed the ability of 
PGE3 to inhibit platelet function 282. These studies indicate that PGE3 is also capable of 
producing multiple and simultaneous effects, resulting in either pro- or anti-thrombotic outcome.  
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Table 4.1 Oxylipin regulation of platelets 
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Both PGD3 and PGI3 are deemed to behave similarly to PGD2 and PGI2 agonists as well 
as exerting through the same cognate receptors to increase cAMP. PGD3 is also shown to be 
further dehydrated PGJ3, Δ12-PGJ3, and 15-deoxy-Δ12,14-PGJ3 285 and act on DP receptor or 
possibly function through PPARs 286. PGI3 is an unstable analog of PGI2 that exerts its action on 
the IP receptor, but has been observed to activate PPAR 287. TXA3 is presumed to act on EP2 and 
EP4 receptors to to enhance cAMP 283 to inhibit platelet function similar to TXA1, but further cell 
line and pharmacological models are required to verify this assumption. 
4.3 Lipoxygenases 
Mammalian lipoxygenases (LOXs) constitute the following heterogeneous group of lipid-
peroxidizing enzymes that are categorized accordingly to their positional specificity of AA 
oxygenation: 5-LOX, 12-LOX, and 15-LOX. While these enzymes are expressed in a number of 
cells, they each produce oxylipins that function in part to regulate platelet activity, hemostasis, 
and thrombosis.  
5-Lipoxygenase (5-LOX) 
5-LOX is best known for its ability to produce leukotrienes (LTs) 280. LTs are synthesized in 
myeloid cells (eosinophils, neutrophils, mast cells, macrophages, monocytes, dendritic cells, 
basophils, and B-lymphocytes) that are involved in inflammatory, immune, and allergy 
responses.  5-LOX also produces non-LT products (5-hydroxyeicosatetraenoic acid (5-HETE)) 
and two structural forms of LTs, which consist of cysteinyl-free (LTA, LTB) and cysteinyl-LTs 
(LTC, LTD, LTE, LTF)288 (Figure 4.2, Table 4.1).   The type of PUFA substrate being oxidized 
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dictates the class of LTs formed to modulate inflammatory response and vascular tone. While 
platelets lack 5-LOX, there are numerous studies suggesting the interplay between leukocytes 
and platelets through their eicosanoid production 289 by which platelets can modulate 
immunological response or vice versa 290,291. 
 
Figure 4.2 Oxidation of arachidonic acid into their respective products by oxygenases.  
Arachidonic acid (AA) is oxidized by 5-LOX, 12-LOX, 15-LOX, COX, and CYP450 into their respective classes of oxylipins: 1) 
non-leukotrienes (LTs) (5-HETE, 5-oxo-ETE) or cysteinyl-free LTs (LTA4, LTB4) and cysteinyl-LTs (LTC4, LTD4, LTE4); 2) 
12-HETE; 3) series 2 prostaglandins (PGD2, PGE2, PGI2, and TXA2); 4) epoxyeicosatrienoic acids (EETs) (5,6-EET, 8,9-EET, 
11,12-EET, 14,15-EET) and hydroxylates (19-HETE, 20-HETE). This illustration was generated by Jennifer Yeung and Megan 
Hawley 
5-LOX derived metabolites and their regulation of platelet function 
Cellular induction by various stimuli (chemotactic agents, immune complexes, bacterial 
peptides) leads to translocation of 5-LOX to the membrane 292-294 to convert AA to 5-HETE. 5-
HETE can further be converted by 5-hydroxyeicosanoid dehydrogenase to form 5-oxo-6,8,11,14-
eicatetraenoic acid (5-oxo-ETE) (Figure 4.2), or dehydrated to a member of series 4 epoxide 
intermediate leukotriene, LTA4 295.  
 
 
57 
Previous studies have demonstrated a platelet role in the transcellular metabolism of LTs 
released by neutrophils, enhancing platelet-neutrophil interactions. The interplay between 
platelet-adherent leukocyte interactions has been implicated in chronic inflammatory diseases in 
patients, including aspirin-exacerbated respiratory disease (AERD). While neutrophils lack LTC4 
synthase to convert LTs, platelets have been shown to possess abundant LTC4 synthase 296-299 to 
convert unmetabolitzed LTA4 secreted from neutrophils or monocytes to LTC4 requiring P-
selectin-dependent interaction 300-302. Through this interaction, transcellular metabolism of LTC4 
is increased, resulting in exacerbated inflammatory response 303-305.  
Although the secreted LTs function principally to activate and recruit additional 
neutrophils to propagate inflammatory responses in allergy or asthma, platelets have also been 
shown to respond to LTs. Human PRP pretreated with exogenous LTs (LTE4, LTD4, LTC4) for 
example, showed potentiation in aggregation and TXB2 production following sub-threshold 
stimulation with thrombin and epinephrine 306. The effects of LTs potentiation of human PRP 
aggregation and TXB2 generation are presumed to be mediated through the platelet cys-LT 
receptors, type 1 and type 2 (CysLT1R and CysLT2R) 307, which are involved in chemokine, 
RANTES, release in inflammation 307-311. The functional importance of CysLT2R in platelet 
function was demonstrated in transgenic mice deficient in CysLT2R (Cysltr2-/-) where it was 
shown in Cysltr2-/- that CysLT2R expression was required for low nanomolar LTC4 induction of 
P-selectin, ADP, and TXB2 release from platelets 312. On the other hand, LTE4 and LTD4 did not 
augment P-selectin expression from wild-type, Cysltr1-/- or Cysltr2-/- platelets suggesting 
metabolite specificity for these biochemical regulatory steps. Interestingly, LTC4 induction of P-
selectin expression was also observed to be markedly impaired in purinergic receptor P2Y12 
knockout mouse platelets. Together, these studies suggest that P2Y12-targed thienopyridine drugs 
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used for the management of cardiovascular ischemic events may also interfere with the LTC4/ 
CysLT2R-dependent pathway of platelet activation.   
The biological activity of 5-HETE on platelet function has been controversial. In vitro 
studies showed 5-HETE inhibits the binding of the radiolabeled thromboxane mimetic, [125I]BOP 
to the PGH2/TXA2 receptor in washed human platelets with IC50 values greater than 25 µM. This 
observation suggests that 5-HETE directly inhibits platelet activation through direct competition 
with PGH2/TXA2 313.  Conversely, thrombin-induced platelet aggregation and ADP release was 
shown to be potentiated with 30 µM of 5-HETE 221. In light of clinical studies being conducted 
with the use of 5-HETE inhibitors, it will be of high importance to delineate the potential effect 
of these inhibitory strategies targeting 5-HETE production on platelet reactivity and hemostasis.     
12-Lipoxygenase (12-LOX) 
Both 12S-LOX and 12R-LOX isoenzymes, which generate distinct chiral metabolites from 
PUFAs, are expressed in selective mammalian tissues and cells. 12-LOX is further classified as 
platelet, leukocyte, or epithelial-type. Platelet-type 12-LOX is expressed in all mammalian 
species, whereas the leukocyte-type 12-LOX is found in murine, porcine, and bovine, but not in 
humans or rabbits 314-316. Conventionally, 12-LOX is characterized for its ability to convert AA 
to 12-hyderoperoxyeicosatetraenoic acid (12-HpETE), which is rapidly reduced to 12-
hydroxyeicosatetraenic acid (12-HETE) (Figure 4.2). To date, majority of the platelet related 
studies have focused on 12S-LOX products, since no 12R-LOX products have been found to 
regulate platelet function. Thus, for the purpose of this review only the S configuration 
metabolites of 12-LOX will be discussed.   
Regulation of platelet function by 12-LOX derived metabolites 
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The major metabolite of 12-LOX, 12-HETE, has been described to have both anti-thrombotic 
and pro-thrombotic effects. The anti-thrombotic effect of 12-HETE was first implicated by its 
direct inhibition of neutrophil PLA2 activity by which the availability of AA was reduced in vitro 
317. In support, exogenous 12-HETE suppressed collagen-induced liberation of AA in bovine 
platelets 318. Platelets from 12-LOX deficient mice were hyper-responsive to aggregation induced 
by ADP, and this phenomenon was reversed by 12-HETE treatment 319. 12-HETE and 12-
HpETE were also reported to inhibit PGH2- and collagen- induced platelet aggregation 320-322 as 
well as to prevent binding of PGH2 and TxA2 to their cognate receptors 319. 
In stark contrast, 12-HpETE and 12-HETE have been demonstrated to potentiate platelet 
activation and aggregation. Exogenous 12-HpETE, at nanomolar concentrations, activated 
platelet p38 mitogen-activate protein kinase involved in platelet activation, as well as 
phosphorylation of cytosolic PLA2, increased TxB2 and dense granule secretion 322-325.  12-HETE 
was also shown to potentiate bovine platelet aggregation induced by thrombin as well as 
inhibiting PGE1-induced elevation of cAMP. Pharmacological inhibition and genetic ablation of 
12-LOX have demonstrated the importance of 12-HETE in potentiation of platelet activation 325-
327. 
The pro-thrombotic effect of 12-HETE is thought to be mediated through its esterification 
into the lipid membrane following formation in the platelet, which results in enhanced tissue 
factor-dependent thrombin generation in the vessel 328. It is also possible that 12-HETE could be 
mediating its effect on platelet function through high affinity binding to an orphan GPCR, 
GPR31 (12-HETER) 329, which was originally discovered in cancer cells to promote survival and 
metastasis as well as neuronal cells that modulate voltage-sensitive calcium channels 330. 
Alternatively, 12(S)-HETE had also been shown to enhance and activate peroxisome 
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proliferator-activated receptor γ (PPARγ), a member of the nuclear hormone receptor family of 
ligand-dependent transcription factors 331.  To date, the expression of 12-HETER in platelets has 
not been confirmed.  
 
Figure 4.3 PUFA oxidation by oxygenase.  
a) Dihomo-γ-linolenic acid (DGLA) is oxidized by 12-LOX, 15-LOX, and COX into the corresponding metabolites: 12-HETrE, 
15-HETrE, and series 1 prostaglandins (PGD1, PGE1, TXA2). b Docosahexaenoic acid (DHA) is also metabolized by the 
oxygenases into the following: 11- or 14-HDHA by 12-LOX, 17-HDHA by 15-LOX, and epoxydocosapentaenoic acids (EDPs) 
(7,8-EDP, 10,11-EDP, 13,14-EDP, 16,17-EDP, 19,20-EDP) by CYP 450 isoforms. This illustration was generated by Jennifer 
Yeung and Megan Hawley. 
While the predominant metabolite, 12-HETE, has been shown to have contradicting 
roles, other 12-LOX derived metabolites from EPA, DHA, DPA, and DGLA (12-HEPE, 11/14-
hydroxydocosahexaenoic acid (11/14-HDHA), 11/14-hydroxydocosapentaenoic acid (11/14-
HDPA), and 12-hydroxyeicosatrienoic acid (12-HETrE)) 321,327,332 have been shown to exert anti-
platelet or anti-thrombotic in vivo effects. These metabolites vary in potency and ability to be 
synthesized. For instance, only trace amounts of 11/14-HDHA (Figure 4.3) were detected in EPA 
or DHA pretreatment compared to 12-HEPE and 12-HETE following thrombin-stimulation in 
platelets, suggesting that higher concentrations of DHA are needed for platelet inhibition 333. 
Additionally, DPA is observed to exert its anti-platelet effect 334 through inhibition of COX-1 
activity by 11/14-HDPA335 (Figure 4.4).  
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Though previous studies have implicated the 12-LOX-derived metabolites in 
cardioprotection through the dampening of platelet activation, there was no direct in vivo 
evidence to support those claims. More recently, the role of platelet 12-HETrE on thrombosis 
and underlying mechanisms were investigated in vivo and ex vivo.  Mice intravenously 
administered 6 mg/kg of 12-HETrE or 50 mg/kg DGLA were protected from thrombus 
accumulation at the site of arteriole vessel injury 336. The antiplatelet effects of DGLA in vivo 
were also shown to be dependent on the presence of functional platelet 12-LOX in mouse 
platelets. For instance, even though mice lacking 12-LOX (ALOX12-/-) had attenuated thrombus 
formation within the vessel following laser injury, DGLA treatment did not further prevent 
thrombus growth in the ALOX12-/- mice compared to the wild-type. This demonstrated that 12-
LOX was required for DGLA-mediated inhibition of platelet activation and thrombus formation. 
Finally, the anti-platelet effect of 12-HETrE was shown to be mediated through a Gαs-linked 
GPCR, which activates adenylyl cyclase and subsequent downstream effectors to inhibit platelet 
activation.  
15-Lipoxygenase (15-LOX) 
Two forms of 15-LOX isoforms exist in mammalian tissues, leukocyte-type 15S-LOX (15-LOX-
1) and epidermis-type 15-LOX type B (15-LOX-2) 337-339.  Tissue distribution of 15-LOX-2 is 
limited when compared to that of 15-LOX-1. 15-LOX-1 is expressed in eosinophils, leukocytes, 
reticulocytes, macrophages, dendritic, epithelial cells (bronchial, corneal, and mammary)340,341, 
whereas, 15-LOX-2 is predominantly found in skin, prostate, lung, and cornea 342.   
15-LOX derived metabolites and regulation of platelet function 
While the existence of 15-LOX-1 and -2 in platelets is questionable, platelets have demonstrated 
the ability to generate the 15-LOX oxylipin products, 15-hydroxyeicosatetraenoic acid (15-
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HETE), 8,15-dihydroxyeicosatetraenoic acid (8,15-diHETE), and 14,15-
dihydroxyeicosatetraenoic acid (14,15-diHETE) from AA (Figure 4.2), 338 and 17-
hydroxydocosahexaenoic acid (17-HDHA) 343 from DHA (Figure 4.3, Table 4.1). Both 15-HETE 
and 8,15-diHETE were shown to inhibit platelet aggregation induced by collagen, ADP, 
epinephrine, AA, or prostaglandin H2 analog 344-346.  Conversely, 15-HETE and 15-HpETE were 
also demonstrated to enhance whole blood aggregation and thrombin generation in the presence 
of macrophages 347.  15-HETE (between 1 and 100 nM) enhanced thrombin-stimulated platelet 
aggregation, ADP release, and secondary messengers (inositol-1,4,5-triphosphate, 
diacylglycerol, and intracellular calcium) production221. Similarly, 17-HDHA was shown to 
potentiate ADP-induced platelet aggregation and spreading, but inhibited alpha granule secretion 
348. The latter data suggests that 15-LOX products can function as pro-coagulant mediators. 
Both 13-hydoxyoctadecadienoic acid (13-HODE) and 15-hydroxyeicosatrienoic acid (15-
HETrE), major metabolites of 15-LOX derived from linolenic acid (LA) (Figure  4.4) and DGLA 
(Figure 4.3), respectively, were shown to inhibit rabbit 349 and human platelet aggregation 350. 
Additionally, 13-HODE was demonstrated to inhibit thrombin-induced TxB2 and 12-HETE 
production in platelets as well as platelet adherence to endothelial cells in vitro 350,351. 
Interestingly, 15-HETrE exhibited biphasic effects on platelet aggregation in which low 
concentrations potentiated and higher concentrations inhibited platelet aggregation 352.  
4.4 Cytochrome P450  
Cytochrome P450 enzymes (CYP450s) belong to a large group of oxygenases, with at least 57 
putatively functional subfamilies in humans and upwards of 102 in mice 353,354.  CYP450s are 
expressed primarily in the liver, with some detection in the heart, lung, vasculature, kidney and 
gastrointestinal tract.  Traditionally, these membrane-bound and heme-containing oxygenases are 
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recognized for their xenobiotic metabolism and detoxification of drugs, however multifaceted 
functions have been investigated. These enzymes are also involved in the metabolism of 
eicosanoids from fatty acids, vitamin D3 synthesis, biosynthesis of cholesterol and bile acids, 
and synthesis and metabolism of steroids 355.  
 
 
Figure 4.4 PUFA oxidation by oxygenases.  
a 12-LOX acts on docosapentaenoic acid (DPA) to convert to 11- or 14-HDPA. b Linoleic acid (LA) is metabolitzed by 15-LOX 
to generate 13-HODE. c Eicosapentaenoic acid (EPA) is oxidized by 12-LOX, COX, CYP 450 to 12-HEPE, series 3 
prostaglandins (PGD3, PGE3, PGI3, and TXA3), and  epoxyeicosatetraenoic acids (EEQs) (8,9-EEQ, 11,12-EEQ, 14,15-EEQ, and 
17,18-EEQ). This illustration was generated by Jennifer Yeung and Megan Hawley. 
 
Regulation of platelet function by CYP450  epoxygenase and hydroxylase derived metabolites 
AA can be synthesized by endothelial epoxygenase into a number of epoxyeicosatrienoic acids 
(5,6-epoxyeicosatrienoic acid (5,6-EET), 8,9-epoxyeicosatrienoic acid (8,9-EET), 11,12-
epoxyeicosatrienoic acid (11,12-EET), and 14,15-epoxyeicosatrienoic acid (14,15-EET), which 
are further catalyzed to dihydroxyeicosatrienoic acids (5,6-diHETrE, 8,9-diHETrE, 11,12-
diHETrE, 14,15-diHETrE) by soluble expoxide hydrolase (sEH), and the CYP450 ω-
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hydroxylase to generate 19-hydroxyeicosatetraenoic acid (19-HETE) and 20-
hydroxyeicosatetraenoic acid (20-HETE) that had been demonstrated to maintain vascular tone 
and hemostasis (Figure 4.2). Early studies demonstrated that many epoxygenase isomers ranging 
from 1 to 10 µM, regardless of their regiochemical, geometric, and steriochemical structures, 
were effective at inhibiting human platelet 356-358 or PRP 359 aggregation independent of TxB2 
and cAMP formation 358. However, in contrast to earlier reports, more recent reports suggest that 
11,12-EET (ranging from 1 to 10 µM) do not inhibit platelet aggregation stimulated with 
collagen, ADP or a thrombin-receptor activating peptide 360. The conflicting observations from 
several research groups will require further study to determine if this class of EETs is pro-
thrombotic, anti-thrombotic, or is bi-functional depending on platelet conditions (PRP or isolated 
platelets) and agonist stimulation used. 
EETs (5,6-EET, 11,12-EET, 8,9-EET, and 14,15-EET) have additionally been 
demonstrated to hyperpolarize platelets through the activation of calcium potassium channels 
resulting in decreased ADP-induced P-selectin expression on platelet surface as well as platelet 
adhesion to cultured endothelial cells under physiological shear stress 361. To further support 
CYP450-derived products from endothelial cells regulate platelet function, supernatant releasate 
from bradykinin-stimulated cultured endothelial cells overexpressing CYP2C9 were shown to 
inhibit platelet adhesion. Finally, in vivo anti-thrombotic effects of CYP2C9 derived metabolites 
were demonstrated in the arteriolar wall of hamster. Hamsters administered with CYP2CP 
inhibitor, sulfaphenazole, at doses known to block endothelium-derived hyperpolarizing factor-
dependent dilations, significantly enhanced platelet-vessel wall interactions. The firm adhesion 
of platelets to vessel wall was reversed when superfused with 10 µM of 11,12-EET 362. 
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 The CYP450 ω-hydroxylase product of AA, 19-HETE, was found to be an orthosteric 
prostacyclin receptor agonist that inhibited mouse platelet aggregation. To verify that 19(S)-
HETE, and not its regioisomer 19(R)-HETE, was responsible for binding to the prostacyclin 
receptor and inhibiting platelet activity, a megakaryocyte cell line, MEG-01 363, with intact Gαs 
expression was shown to enhance cAMP formation following dose-dependent 19(S)-HETE 
treatment. Additionally, COX-1/2 inhibition of COS-1 human IP receptor expressing cells did 
not interfere with the ability of 19(S)-HETE to directly induce cAMP formation in MEG-01. 
Blocking the IP receptor with the selective prostacyclin receptor inhibitor Cay104401 prevented 
19(S)-HETE stimulation of cAMP generation in MEG-01 cells. Similarly, 19(S)-HETE was able 
to displace 3H-iloprost in COS-1 cells expressing IP receptor demonstrated that 19(S)-HETE 
behaved as a competitive agonist binding to the same domain of the IP receptor as Iliprost (and 
likely PGI2). These observations were Confirmed when Pretreatment of IP deficient mouse 
(Ptgir-/-)_platelets with 3 µM 19(S)-HETE failed to block thrombin-induced platelet aggregation.  
Another eicosanoid found to have potent inhibitory properties against the platelet is 20-
HETE. This eicosanoid was found to have a potent effect on inhibiting human platelet 
aggregation and TxB2 formation induced by AA, calcium ionohophore, A23187, and the TxB2 
mimetic without affecting thrombin-induced aggregation 364. The proposed inhibitory effect of 
20-HETE on platelet activation was also presumed to be its antagonism of the PGH2/TxA2 
receptors 364,365. However, aside from receptors antagonism, 20-HETE was also demonstrated to 
be further metabolized by COX-1 and 12-LOX to the inactive 11,12-dihydroxyeicosatetraenoic 
acid (11,12-diHETE) and 12,20-dihydroxyeicosatetraenic acid (12,20-diHETE), respectively, in 
human platelets 364. Thus, it is possible that at least some of the observed anti-platelet effect 
could be attributed to its metabolic transformation to the diHETEs. 
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Upon dietary supplementation of ω-3 or -6 PUFAs, AA-derived products of CYP450 
epoxygenase are partially replaced by EPA and DHA-derived epoxyeicosatetraenoic acids 
(EEQs) and (epoxydocosapentaenoic acids (EDPs), respectively 366. In the case of CYP450 
epoxygenase derived metabolites of EPA (8,9-EEQ, 11,12-EEQ, 14,15-EEQ, 17,18-EEQ) 
(Figure 4.4) and DHA (7,8-EDP, 10,11-EDP, 13,14-EDP, 16,17-EDP, and 19,20-EDP) (Figure 
4.3), all metabolites were shown to inhibit AA-induced platelet aggregation 367 (Table 4.1).  Even 
though all the diols produced by sEH conversion of the EEQs (8,9-DiHETE, 11,12- DiHETE, 
14,15- DiHETE, 17,18- DiHETE) and EDPs (7,8-DiHDPA, 10,11-DiHDPA, 13,14-DiHDPA, 
16,17-DiHDPA, 19,20-HiDPA) inhibited platelet aggregation; they were less potent at inhibiting 
platelet aggregation than the parent epoxides.  
Although several of these studies have demonstrated EET and hydroxylate metabolites 
are derived from cells with intact CYP450, preformed expoxides and 20-HETE of AA have been 
found as integral components of human platelet membrane 357. Thus, it is possible that 
circulating EETs and their diol products, DHETs, and hydroxylates are avidly taken up by 
platelets and endothelial cells 368,369. These products can be released during receptor-mediated 
hydrolysis of platelet phospholipids 357 or further metabolized by COX 370 and LOX 364. For 
instance, once stimulated, EETs are de-esterified in platelets and released to influence the 
migration pattern of nearby neutrophils 357,371.  In contrast, CYP450 ω-hydroxylase inhibitor, 
HET0016, blocked angiotensin and endothelin-stimulation of 20-HETE secretion from platelets, 
suggesting that CYP450 isoforms exist in the platelet 366.  Based on study discrepancy, the 
endogenous expression of CYP450 in the platelet has not been confirmed and will need to be 
definitively determined before platelet generation of expoxide or hydroxylate products can be 
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assigned to the platelet itself or alternatively if these products are presented to the platelet from 
other blood cells including the endothelium and neutrophils.  
4.5 The interplay of oxygenases and generation of specialized pro-resolving lipid mediators 
(SPMs) 
Over the past decade, studies have focused on the role of specialized pro-resolving lipid 
mediators (SPMs) on preventing excessive inflammation, infection, and wound repair, through 
their ability to attenuate or dissipate chemotactic and pro-inflammatory signals. SPMs, which 
include lipoxins (LX), D and E series resolvins (Rv), (neuro)protectins (PD), and maresins 
(MaR), are synthesized by the sequential action of LOXs on PUFAs to resolve and restrain 
inflammation 351 (Figure 4.5). Despite the prevalence of platelet involvement in the inflammatory 
process, little is known on how and whether SPMs play a direct role on regulation of platelet 
function.  
 
Figure 4.5 Specialized pro-resolving lipid mediators (SPMs) constitute a wide array of lipids classes derived from the 
interplay of oxygenase activity on AA, EPA, and DHA.  
Lipoxins, (LXA4, LXB4) and E series resolvin (RvE1) are derived from AA and EPA, respectively. DHA can be indirectly 
converted by the interaction of the oxygenases into MaR1, PDX, or D series resolvin, RvD1. ). This illustration was generated by 
Jennifer Yeung and Megan Hawley. 
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Lipoxins A (LXA4) and B (LXB4) were one of the first SPMs to be identified from the 
combination of 5- and 15-LOX in human leukocytes [43] as well as neutrophil-derived 5-LOX 
and platelet 12-LOX 372-375 from AA. Although platelets express LXA4 receptor (ALX) 376, 
LXA4 does not directly inhibit platelet aggregation induced by ADP 349 and bacterial infection 
349. Alternatively, aspirin-triggered lipoxin (ATL), 15(R)-epi-lipoxin A4 (15(R)-epi-LXA4)) 377, 
is indirectly derived from the acetylated COX-2 metabolism of AA. Both LXA4 and 15(R)-epi-
LXA4 had been demonstrated to modulate neutrophil-platelet aggregation through ALX; 
however, it remains unclear whether these lipoxins can directly regulate platelet function based 
on limited studies.  
Resolvin E1 (RvE1), synthesized by acetylated COX-2 or sequential CYP450 and 5-LOX 
activity of EPA, was demonstrated to inhibit human PRP aggregation stimulated by ADP and 
TxB2, but not collagen 378. RvE1 was also shown to inhibit P-selectin expression on activated 
platelets and platelet actin polymerization, without affecting calcium mobilization. The observed 
anti-platelet effects of RvE1 were shown to act through the ChemR23 receptor on the surface of 
platelets 379. In contrast, resolvin D1 (RvD1) and its intermediary precursor 17-HDHA, derived 
from 15-LOX and 5-LOX synthesis of DHA, potentiated ADP-mediated platelet aggregation and 
platelet spreading on fibrinogen.  ADP-mediated release of alpha granules in platelets were not 
affected by RvD1 and 17-HDHA; however, thrombin stimulation of alpha granules was 
significantly attenuated by these SPMs 380. RvD1 is presumed to exert its effect on its cognate 
receptor, GPR32, on the platelet surface. Thus far, while data support a role for platelets in the 
generation of inflammatory markers, the mechanism by which resolvins regulate platelets 
remains unclear.  
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Maresin 1 (MaR1) is derived from the biosynthesis of DHA by both neutrophil 15-LOX 
and platelet 12-LOX 349. Early studies demonstrated MaR1 anti-inflammatory and pro-resolving 
properties in lung catabasis.  While MaR1 was shown to potentiate platelet aggregation and 
spreading, it also dampened pro-inflammatory and pro-thrombotic granules, suggesting MaR1 
differentially regulates platelet function through a mechanism that has not been fully elucidated 
to date. 
Protectin DX (PDX) belongs to a group of di-oxygenated derivatives of PUFAs, called 
poxytrins 381. PDX is an isomer of neuroprotein D1 (PD1) 382, which was originally discovered to 
attenuate brain ischemia-reperfusion 383,384. The PDX isomer was demonstrated to be biologically 
less potent than PD1 in the resolution of inflammation; however, effective in inhibiting collagen-
, AA-, and thromboxane -induced platelet aggregation through inhibition of COX-1, at 
nanomolar concentrations 385.  
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Figure 4.6 LOX, COX, CYP 450 derived lipid mediators and SPMs can be divided into either pro- or anti-thrombotic 
classes based on their effects on platelet function. ). This illustration was generated by Megan Hawley. 
4.6 Discussion and Future Implications 
 Regulation of platelet function is a key step in both physiological and pathological 
hemostatic processes. While inhibition of platelet activation remains a first line approach for 
prevention of myocardial infarction and stroke, morbidity and mortality due to cardiovascular 
diseases and stroke remain the top causes of death globally. Hence a greater understanding of the 
regulators of platelet function in vivo will significantly aid in the development of novel 
treatments to prevent unwanted clotting and occlusive thrombosis. Lipids and their oxylipins 
have long been known to regulate platelet function; however, until recently, the breadth of 
regulators and functions they control in the platelet have not been fully appreciated.  
In this chapter, we have highlighted some of the major breakthroughs in identifying oxylipins we 
now know have direct effects on the platelet. The use of genetic manipulation and 
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pharmacological tools in both mouse and cellular models to determine the oxygenases and their 
lipid contributions to vascular and platelet functions has progressed considerably over the last 
two decades. These tools have greatly enhanced our understanding of the varying roles of 
oxylipins in platelet biology; however, these studies are still limited to another layer of 
complexity. The difficulty in targeting the precise pathway or oxylipins associated with 
pathophysiological disease states stems from the source of oxylipins generated by the 
involvement of multiple oxygenase enzymes localized in different organs and cell types. Even 
with the use of pharmacological tools to determine the contributions for each oxygenase 
metabolites to platelet function, selectivity of drug target still remains a major setback. For 
instance, chemical compounds designed to inhibit CYP epoxygenase enzymes also antagonized 
CYP hydroxylase enzymes activity. Therefore, interpretation of results with pharmacological 
inhibitors should be taken with caution. Future work will thus focus on further delineating the 
full breadth and diversity of oxylipins regulating platelet function ex vivo and in vivo and 
determining the mechanism(s) by which they exert their regulatory function on the human 
platelet to develop newer pharmacological approaches for targeting pathways involved in the 
regulation of platelet to address pathological conditions whereby normal regulation of 
hemostasis and thrombosis has become dysfunctional. 
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CHAPTER 5  
 
Protein Kinase Regulation of 12-Lipoxygenase-Mediated Human Platelet Activation4* 
5.1 Summary 
Platelet activation is important in the regulation of hemostasis and thrombosis. Uncontrolled 
activation of platelets may lead to arterial thrombosis which is a major cause of myocardial 
infarction and stroke. Following activation, metabolism of arachidonic acid (AA) by 12-
lipoxygenase (12-LOX) may play a significant role in regulating the degree and stability of 
platelet activation as inhibition of 12-LOX significantly attenuates platelet aggregation in 
response to various agonists. Protein kinase C (PKC) activation is also known to be an important 
regulator of platelet activity. Using a newly developed selective inhibitor for 12-LOX and a pan–
PKC inhibitor, we investigated the role of PKC in 12-LOX-mediated regulation of agonist 
signaling in the platelet. To determine the role of PKC within the 12-LOX pathway, a number of 
biochemical endpoints were measured including platelet aggregation, calcium mobilization, and 
integrin activation. Inhibition of 12-LOX or PKC resulted in inhibition of dense granule 
secretion and attenuation of both aggregation and αIIbβ3 activation. However, activation of PKC 
downstream of 12-LOX inhibition rescued agonist-induced aggregation and integrin activation. 
Furthermore, inhibition of 12-LOX had no effect on PKC-mediated aggregation indicating that 
12-LOX is upstream of PKC. These studies support an essential role for PKC downstream of 12-
                                                
 
4This section has been published in Molecular Pharmacology. Yeung J, Apopa PL, Vesci J, Kenyon V, Rai G, Jadhav A, 
Simeonov A, Holman TR, Maloney DJ, Boutaud O, Holinstat M. Protein kinase C regulation of 12-lipoxygenase-mediated 
human platelet activation. Molecular pharmacology. 2012 Mar 1;81(3):420-30. 
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LOX activation in human platelets and suggest 12-LOX as a possible target for anti-platelet 
therapy. 
5.2 Introduction 
Platelet activation plays a significant role in hemostasis and thrombosis and a central role 
in the pathophysiology of cardiovascular disease. Platelet activation can be initiated through a 
number of different receptor pathways including thrombin and collagen. Reinforcement of the 
initial activation signal is known to be regulated in part by secondary signaling events mediated 
by arachidonic acid (AA) released from the phospholipid membrane. Although active 
metabolites formed by the oxidation of AA by cyclooxygenase-1 (COX-1) are known to regulate 
platelet reactivity 386, the role of metabolites produced by the oxidation of AA by platelet-type 
12-lipoxygenase (12-LOX) is controversial. Some reports have shown that metabolic products of 
12-LOX  attenuate AA-induced aggregation 387 and also inhibit AA release from membrane 
phospholipids by blocking PLA2 318, while other studies suggest 12-LOX activation is pro-
thrombotic and is linked to calcium mobilization 196, regulation of tissue factor activation, and 
thrombin generation in the platelet 329. The mechanistic basis for these physiological changes in 
platelet activity through the 12-LOX pathway is not clear. In particular, the events that occur 
both upstream and downstream of 12-LOX upon agonist stimulation have not been well 
characterized. 
Protein kinase C (PKC), which is known to play an important role in a number of biochemical 
activation steps in the platelet 388,389, has also been suggested to play a role in 12-HETE 
regulation in tumor cells (Szekeres et al., 2000). In platelets, similarly to 12-LOX, PKC has been 
shown to regulate aggregation and play an important role in granule secretion and integrin 
activation 390. Further, protease-activated receptor-1 (PAR1) and PAR4 signaling in the platelet 
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have been shown to result in Ca2+ mobilization and PKC-mediated aggregation and secretion 391. 
However, the underlying mechanism by which PKC regulates platelet activity is controversial. 
Kim et al 392 reported that PKC inhibition by the pan-PKC inhibitor, Ro 31-8220, potentiated 
epinephrine induced platelet aggregation and Unsworth et al 393 showed that PKC inhibition 
potentiates platelets secretion in the presence of Ca2+. Other reports have shown that PKC 
inhibition attenuates platelet aggregation 394.  
In this study, we investigated the coupling between the activation of 12-LOX and PKC in 
regulating platelet aggregation and integrin activation. We sought to determine if PKC acted 
downstream of 12-LOX upon agonist stimulation. Agonist-mediated platelet aggregation was 
significantly decreased in the presence of either a 12-LOX or PKC inhibitor. Inhibition of 12-
LOX activity by selective small molecule inhibitors 395 which leads to attenuation of aggregation 
was overcome when the PKC activator, PMA, was added together with agonist to the platelets. 
Furthermore, inhibition of 12-LOX had no effect on PMA-mediated platelet aggregation. Finally, 
αIIbβ3 attenuation in the absence of 12-LOX was rescued by addition of PMA. Hence, this is the 
first report to show that PKC activity occurs downstream of 12-LOX in human platelets and 
begins to elucidate how this essential pathway mediates normal platelet activation through a 
number of GPCR and non-GPCR receptors. 
  
 
 
75 
5.3 Materials and Methods 
Materials: 12-LOX inhibitor (NCTT-956) was synthesized at the NIH Chemical Genomics 
Center (Rockville, MD) and provided by David Maloney. Baicalein was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Phospho-ERK and total-ERK antibodies were purchased 
from Cell Signaling Technology (Boston, MA), PAR1-AP (SFLLRN) and PAR4-AP (AYPGKF) 
were purchased from GL Biochem (Shanghai, China). Fluo-4 AM was from Invitrogen (Eugene, 
OR). Human α-thrombin was purchased from Enzyme Research Labs (South Bend, IN). 
Convulxin was purchased from Center Chem (Norwalk, CT). Fluorescein isothiocyanate (FITC)-
conjugated PAC1 antibody was purchased from BD Biosciences (San Jose, CA). C6 flow 
cytometer was from Accuri (Ann Arbor, MI). Aggregometer, collagen, chronolume reagent, and 
other aggregation supplies were purchased from Chrono-Log Corp. (Havertown, PA). 
Human Platelets: Human platelets were obtained from healthy volunteers within the Thomas 
Jefferson University community and the Philadelphia area. These studies were approved by the 
Thomas Jefferson University Institutional Review Board and informed consent was obtained 
from all donors before blood draw. Blood was centrifuged at 200 g for 13 minutes at room 
temperature. Platelet-rich plasma was transferred into a conical tube containing a 10% acid 
citrate dextrose solution (39 mM citric acid, 75 mM sodium citrate, and 135 mM glucose, pH 
7.4) and centrifuged at 2000 g for 15 minutes at room temperature. Platelets were resuspended in 
Tyrode’s buffer (12 mM NaHCO3, 127 mM NaCl, 5 mM KCl, 0.5 mM NaH2PO4, 1 mM MgCl2, 
5 mM glucose, and 10 mM HEPES), and the final platelet concentration was adjusted to 3 X 108 
platelets/ml after counting with a ZI Coulter particle counter (Beckman Coulter, Fullerton, CA). 
Reported results are the data obtained using platelets from at least three different subjects. 
Agonists and inhibitors were used at concentrations indicated in the figures and figure legends. 
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GC/MS analysis of [2H8] Thromboxane synthesis in platelets: 2 ng of [2H4] TxB2 was added to 
the samples as internal standards. Briefly, the sample prepurified with a C18 SepPak column. 
[2H8] TxB2 was eluted with 10 ml heptane/ethyl acetate (1:1), dried, dissolved in acetonitrile and 
TxB2 was converted to pentafluorobenzyl esters. TxB2 was then purified and the sample was 
converted to O-trimethylsilyl ether derivatives and analyzed by gas chromatography/electron 
capture negative chemical ionization mass spectrometry, using an SPB-1 column (15 meters), 
with a temperature gradient from 190°C to 300°C at 20°C/min. The ion corresponding to the 
derivatized TxB2 was monitored by selected ion monitoring (SIM). The signal for TxB2 is m/z = 
622. The signal for the internal standard [2H4] TxB2 is m/z = 618.  
Measurement of 12-HETE: Secretion of 12-HETE was measured from platelet supernatants by 
liquid chromatography LC/APCI/MS/MS following addition of an internal standard (2 ng of 
[2H8] 12-HETE) as described previously 396. The concentration of 12-HETE was determined by 
isotopic dilution. 
cPLA2 activation assay: The effect of the different inhibitors on cPLA2 was tested with 
recombinant human cPLA2 using the enzymatic activity assay described previously 397 with the 
following differences. The inhibitors were added at a final concentration of 50 µM in DMSO 
right before the recombinant enzyme was added to initiate the reaction. After 5 minutes of 
incubation, the products of the reaction were analyzed.  
Platelet Aggregation: Washed platelets were adjusted to a final concentration of 3 x 108 
platelets/ml. Where indicated, platelets were pretreated with 12-LOX inhibitors for 10 minutes or 
PKC inhibitor for 1minute. The aggregation response to PAR1-AP, PAR4-AP or collagen was 
measured using an aggregometer with stirring at 1100 rpm at 37°C. 
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Dense-Granule Secretion: ATP release was assayed as an indication of dense granule secretion. 
For ATP studies, washed platelets adjusted to a final concentration of 3 x 108 platelets/ml were 
pretreated with 12-LOX inhibitors for 10 minutes or PKC inhibitor for 1 minute. ATP release in 
response to agonist was measured using a Lumi-aggregometer at 37°C with stirring at 1100 rpm. 
Flow Cytometry: Integrin αIIbβ3 activation on the surface of the platelet was measured by flow 
cytometry using FITC-conjugated PAC1 (an antibody which only recognizes the active form of 
αIIbβ3). For these experiments, 40 µl aliquots of washed platelets adjusted to a final 
concentration of 2.5 x 107 platelets/ml were pre-treated with inhibitors for 10 minutes. After 
addition of 1 µl of PAC1, platelets were stimulated with agonist for 10 minutes and then diluted 
to a final volume of 500 µl using Tyrode’s buffer. The fluorescence intensity of platelets was 
immediately measured using an Accuri flow cytometer. 
Western Blotting: Washed platelets adjusted to 1 x 109 platelets/ml were stimulated with 
indicated agonists and lysed with 3x Laemmli buffer was then added to the samples, boiled for 5 
minutes, and subjected to Western blot analysis. 
Calcium Mobilization: Platelets were re-calcified to a final concentration of 1 mM followed by 
pre-incubation with Fluo-4 AM for 10 minutes. The platelets were then treated with a 12-LOX 
inhibitor for 10 minutes before stimulation with indicated agonist. Calcium mobilization was 
measured using Accuri C6 flow cytometer. 
Statistical Analysis: Comparison between experimental groups was made using appropriate 
statistical analyses (paired t test program or ANOVA with post-test analysis) using Prism 
software. Differences in mean values (measured as standard error of the mean) were considered 
significant at p < 0.05. 
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5.4 Results 
Specificity of 12-LOX inhibitors. To determine the role of the lipoxygenase pathway in human 
platelet reactivity, the recently identified and highly selective 12-LOX small molecule inhibitor 
NCTT-956 395 and the less selective commercially available 12-LOX inhibitor (baicalein) were 
studied. To assess for possible off-target effects on the related cyclooxygenase-1 pathway which 
leads to formation of thromboxane A2 (Figure 5.1), platelets were treated with deuterated-AA in 
the presence or absence of NCTT-956 or baicalein and the deuterated-TxB2 product was 
measured (Figure 1a). Values are expressed as the % of control to which no inhibitor was added. 
Deuterated-TxB2 was not inhibited by NCTT-956 or Ro 31-8220, indicating that COX-1 and 
thromboxane synthase are not directly inhibited by these pharmacological agents. Treatment with 
baicalein, however, resulted in a significant decrease in the production of [2H8] TxB2 suggesting 
this drug may have a direct inhibitory effect on COX-1 or thromboxane synthase (Figure 5.1a). 
As [2H8] TxB2 was increased in the presence of the PKC inhibitor, the level of 12-HETE 
formation was also measured to determine if Ro 31-2880 directly inhibited 12-LOX. No decrease 
in 12-HETE formation was observed in the presence of Ro 31-2880 (data not shown). To 
confirm that NCTT-956, baicalein, and Ro 31-8220 did not inhibit the release of arachidonic 
acid, cPLA2 activity was measured in the absence or presence of each inhibitor (Figure 5.1b). 
Neither 50 µM NCTT-956 nor 10 µM Ro 31-8220 inhibited cPLA2 activity. 50 µM baicalein, 
however, resulted in almost a 50% decrease in cPLA2 activity (P<0.001) confirming the higher 
level of selectivity of NCTT-956 toward 12-LOX. 
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PKC regulation of platelet aggregation and dense granule secretion. Since PKC plays an 
important role in granule secretion and integrin activation 390, we investigated PKC involvement 
in the transduction of 12-LOX signaling in the platelet. First, we confirmed the role 
 
Figure 5.1 Inhibitor selectivity. 
a) Washed platelets were stimulated with [2H8] arachidonic acid and the level of [2H8] TxB2 relative to no inhibitor treatment 
(control) was measured (N=3). No inhibition of [2H8] TxB2 was observed in the presence of 50 µM NCTT-956 or 10 µM Ro 31-
2880 relative to control. 50 µM baicalein induced an inhibition of [2H8] TxB2 compared to control levels and [2H8] TxB2 
formation in the presence of baicalein was significantly inhibited compared to [2H8] TxB2 in the presence of Ro 31-2880. N=3. b) 
Human recombinant cPLA2 activity in the absence or presence of 50 µM baicalein, 50 µM NCTT-956, or 10 µM Ro 31-2880 
(N=3). AA: arachidonic acid released from vesicles. *, P<0.05; ***, P<0.001. This figure was provided our collaborator Dr. 
Olivier Boutaud. 
 
of PKC in platelet activation by measuring platelet aggregation in the presence of increasing 
concentrations of the pan-PKC inhibitor, Ro 31-8220, following stimulation with 20 µM PAR1-
AP, 200 µM PAR4-AP, or 10 µg/ml collagen (Figure 5.2). Our data show that inhibiting 
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activation of PKC resulted in a dose-dependent attenuation of platelet aggregation, suggesting 
that PKC is important for normal platelet aggregation to occur. 
 
Figure 5.2 PKC regulation of platelet aggregation.  
Platelets were pre-treated with increasing concentrations of pan-PKC inhibitor, Ro 31-8220 from 0 to 10 µM for 1 minute 
followed by stimulation with 20µM PAR1-AP, 200 µM PAR4-AP, or 10 µg/ml collagen and platelets aggregation measured. Pre-
treatment with increasing concentration of Ro 31-8220 attenuated agonist-mediated platelet aggregation in a dose dependent 
manner. The bars represent mean±SEM (*P<0.05; **P<0.001) for aggregation, n=3. This figure was provided by Dr. Patrick 
Apopa. 
To identify if PKC regulates dense granule secretion, washed platelets were stimulated with 20 
µM PAR1-AP, 200 µM PAR4-AP, 10 µg/ml collagen or the PKC activator, PMA (Figure 5.3). 
!
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ATP, which is secreted from the dense granule, was measured by luminescence in the absence or 
presence of increasing concentrations of Ro- 31 8220. As the concentration of the Ro 31-8220 
 
Figure 5.3 PKC is an important determinant of platelet ATP secretion.  
Washed platelets were treated with or without increasing concentrations of pan-PKC inhibitor, Ro 31-8220 for 1 minute and 
platelet ATP secretion was measured following stimulation with (a) 20 µM PAR1-AP, (b) 200 µM PAR4-AP, or (c) 10 µg/ml 
collagen. The right panel graph represents normalized ATP secretion (n=3). This figure was provided by Dr. Patrick Apopa. 
 
was increased, the level of ATP secreted from the dense granule was decreased with full 
inhibition observed at 1 µM Ro- 31 8220 (Figure 5.3a-c).  
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Figure 5.4 PKC activation rescues platelet aggregation downstream of 12-LOX.  
a) Washed human platelets were treated with or without 25 µM NCTT-956 or 50 µM baicalein followed by 250 nM PMA 
stimulation. Platelet aggregation was then measured for 16 minutes. b) Washed platelets were treated with or without baicalein, 
followed by receptor agonist alone, 50 µM PAR4-AP (left panel) or 10 µg/ml collagen (right panel), or receptor agonist plus 
PMA and platelet aggregation measured for 12 minutes. c) Washed platelets were treated with or without, NCTT-956, followed 
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by stimulation with PMA, PAR4-AP, collagen, or a combination of PMA and PAR4-AP (or collagen) and platelet aggregation 
measured. (***P<0.001) for aggregation, n=3. This figure was co-provided by Jennifer Yeung and Dr. Patrick Apopa. 
 
To determine if PKC activation can rescue platelet activation in the absence of 12-LOX 
activation, washed platelets were stimulated with the diacylglycerol mimetic (PMA) in the 
absence or presence of the 12-LOX inhibitors baicalein or NCTT-956 and platelet aggregation 
was measured for 15 minutes (Figure 5.4). Stimulation of washed platelets with 250 nM PMA 
resulted in full platelet aggregation which was sustained over time. PMA-mediated aggregation 
was not affected by either 12-LOX inhibitor, indicating that 12-LOX activation is not required 
for PMA-mediated platelet aggregation (Figure 5.4a). 
 
Figure 5.5 Role of PKC in PAR-mediated integrin αIIbβ3 activation.  
a) Washed platelets were pre-incubated with PAC1 antibody and treated with 2.5 µM or 10 µM pan-PKC inhibitor, Ro 31-8220, 
for 1minute. αIIbβ3 activation by flow cytometry was measured following stimulation with 5 µM PAR1-AP, 25 µM PAR4-AP, 
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or 0.1 µg/ml convulxin for 10 minutes. The histograms shown are representative of three different experiments. b) Washed 
platelets were pre-incubated with PAC1 antibody and treated with the 25 µM NCTT-956 for 10 minutes followed by stimulation 
with PAR1-AP, c) PAR4-AP, or d) convulxin in the presence or absence of 1 µM PMA. αIIbβ3 activation was measured by flow 
cytometry with FITC-PAC1. The bars represent mean±SEM for fluorescence, n=3. *,P<0.05. 
Although stimulation with PMA results in aggregation of washed platelets, we had previously 
shown that PMA does not induce calcium mobilization and neither thromboxane nor 12-
hydroxyeicosatetraenoic acid were produced, giving evidence that PKC activation alone does not 
liberate arachidonic acid from the plasma membrane of the platelet 398. To determine if PKC 
activation acts downstream of 12-LOX, we assessed whether PMA might rescue the aggregation 
defect observed in the presence of the 12-LOX inhibitors. Washed platelets were stimulated with 
either 50 µM PAR4-activating peptide (PAR4-AP) or 10 µg/ml collagen in the absence or 
presence of 12-LOX inhibitors (Figure 5.4b-c). Treatment with either baicalein or NCTT-956 
significantly inhibited PAR4-AP and collagen-induced platelet aggregation. However, addition 
of PMA fully rescued agonist-mediated platelet aggregation in the presence of 12-LOX 
inhibitors suggesting that PKC activation may play a role in 12-LOX-mediated platelet 
aggregation through a number of signaling pathways including PAR4 and collagen. 
Role of PKC in PAR-mediated integrin αIIbβ3 activation.  The primary adhesive receptor 
mediating platelet aggregation is the integrin αIIbβ3. Since there is a direct correlation between 
activation levels of αIIbβ3 and platelet aggregation, the role of PKC in this pathway was 
investigated (Figure 5.5). Washed platelets were stimulated with PAR1-AP, PAR4-AP, or 
convulxin (a snake venom known to activate the collagen GPVI receptor) in the absence or 
presence of two concentrations of the PKC inhibitor and active αIIbβ3 was assessed. For all 
agonists, αIIbβ3 activation was partially blocked in the absence of PKC activity (Figure 5.5a). To 
confirm that PKC could rescue agonist-mediated αIIbβ3 activation in the absence of 12-LOX 
activity, platelets were pre-treated with or without 25 µM NCTT-956 and stimulated with PAR1-
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AP, PAR4-AP, or convulxin in the presence or absence of PMA (Figures 5.5b-d). NCTT-956 
 
Figure 5.6 12-LOX regulates agonist-mediated ERK phosphorylation.  
Washed Platelets were treated with 25 µM NCTT-956 for 10 minutes followed by stimulation with 5 µM PAR1-AP, 25 µM 
PAR4-AP, or 0.1 µg/ml convulxin in the presence or absence of 1 µM PMA for 3 minutes under stirring conditions. The 
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cytosolic fraction was assessed by western blot for phosphorylation of ERK (N=2). Total ERK antibody was used as a loading 
control. This figure was co-provided by Jennifer Yeung and Joanne Vesci. 
 
inhibited more than 50% of PAR4-AP-mediated αIIbβ3 activation (P=0.02), and this inhibition 
was significantly overcome in the presence of PMA (P=0.04), further supporting a role for PKC 
following 12-LOX activation in regulating agonist-mediated platelet activation. By contrast, 
inhibition of 12-LOX by NCTT-956 did not affect PAR1-AP-induced αIIbβ3 activation either 
alone or in combination with PMA, suggesting another pathway of transduction through PAR1 
requiring PKC activation but not 12-LOX (Figure 5.5a). Interestingly, the effect of NCTT-956 
on αIIbβ3 activation in platelets stimulated with convulxin was not rescued by PMA (Figure 
5.5d). These results clearly indicate a very complex agonist-dependent mechanism of regulation 
of integrin activation in platelets. 
12-LOX regulation of p-ERK. To confirm that 12-LOX is an upstream regulator of PKC 
activation, washed platelets were stimulated with PAR1-AP or PAR4-AP in the absence or 
presence of NCTT-956 with or without PMA. Following platelet activation, ERK 
phosphorylation was measured, as ERK has been shown to be partially regulated by PKC in the 
platelet (Figure 5.6). Stimulation with PAR-AP, or PMA resulted in a significant 
phosphorylation of ERK. In the presence of NCTT-956, PAR4-AP-mediated ERK 
phosphorylation was significantly reduced and was partially rescued with the addition of PMA. 
Interestingly, PAR1-AP-mediated ERK phosphorylation was not significantly affected by 
treatment with NCTT-956. To determine if ERK phosphorylation was regulated downstream of 
12-LOX solely through the PAR-4 pathway, platelets were treated with convulxin, the snake 
venom known to specifically activate the collagen receptor. Convulxin alone induced 
phosphorylation of ERK and this phosphorylation event was significantly attenuated in the 
presence of NCTT-956. However, similar to PAR4-AP, the presence of PMA fully rescued 
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NCTT-956-induced inhibition of convulxin-mediated ERK phosphorylation, supporting a 
proximal role for 12-LOX in regulating platelet activation upstream of PKC and ERK. 
 
Figure 5.7 12-LOX inhibition attenuates calcium mobilization in human platelets.  
Calcium mobilization was measured in re-calcified washed platelets in the presence or absence of 12-LOX inhibitors following 
stimulation with 2 nM thrombin, 20 µM PAR1-AP, 200 µM PAR4-AP, or 0.1 µg/ml convulxin. a) Platelets loaded with Fluo-4 
AM for 10 minutes were incubated with NCTT-956 for an additional 10 minutes followed by stimulation with thrombin, PAR1-
AP, PAR4-AP, or convulxin and calcium mobilization was monitored for 8 minutes post-stimulation. Representative curves on 
the left show the fold change in free calcium relative to the unstimulated condition over 8 minutes. The bar graphs on the right 
indicate the maximal increase in calcium mobilization (N=3). b) Platelets incubated with 50 µM baicalein were stimulated with 
thrombin, PAR1-AP, PAR4-AP, or convulxin and calcium mobilization was monitored for 8 minutes post-stimulation. 
Representative curves on the left show the fold change in free calcium relative to the unstimulated condition over 8 minutes. The 
bar graphs on the right indicate the maximal increase in calcium mobilization (N=3). Composite bar graphs are calculated as 
mean ± SEM; *, P<0.05; **, P<0.01; ***, P<0.001. This figure was co-provided by Jennifer Yeung and Joanne Vesci. 
12-LOX inhibition attenuates calcium mobilization in human platelets. It has been reported that 
inhibition of 12-LOX attenuates calcium entry into platelets 196. As calcium mobilization also 
plays a role in regulation of eicosanoid production and platelet activation, calcium levels were 
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monitored following stimulation with thrombin, PAR1-AP, PAR4-AP, or convulxin in the 
absence or presence of 12-LOX inhibitors (Figure 5.7). Agonist stimulation induced a significant 
and transient increase in free calcium in the platelet. In the presence of NCTT-956, free calcium 
in the platelet was significantly diminished following stimulation with thrombin, PARs, or 
convulxin (Figure 5.7a). Inhibition with baicalein more severely attenuated platelet mobilization 
compared to NCTT-956 which may be due to the higher level of selectivity toward 12-LOX 
exhibited with NCTT-956 relative to baicalein (Figure 7b) 395. 
5.5 Discussion 
Platelet reactivity plays a critical role in hemostasis and thrombosis. Much attention has been 
given to limiting unwanted platelet activation and vessel occlusion through inhibition of the ADP 
receptor (P2Y12) and cyclooxygenase-1399,400 . These therapies, while successful in decreasing 
the morbidity due to myocardial infarction and stroke 401,402, have significant shortcomings 
including genetic variability 403 and aspirin resistance 404. 
Furthermore, all of these approaches result in a significant increase in bleeding which can 
be more deleterious than the clot itself. Therefore, alternative approaches with fewer side effects 
are warranted. Targeting 12-LOX, which metabolizes AA in a stereo-specific manner to generate 
12(S)-HpETE, may be one such target 405. 12-LOX and its metabolites have been shown to 
promote cancer progression and metastasis through a MAPK-dependent pathway 406,407. 
Inhibition of 12-LOX in tumor cells was shown to induce apoptosis and was blocked by either 
over expression of 12-LOX or addition of 12-HETE 407,408. In platelets however, the underlying 
signaling mechanisms regulating 12-LOX-mediated platelet reactivity have not been well 
characterized. Our data demonstrates that inhibition of 12-LOX significantly attenuates agonist-
mediated platelet aggregation. This is in line with the pro-thrombotic actions attributed to 
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production of 12(S)-HETE in the platelet 329. Furthermore, we showed for the first time that 12-
LOX-mediated regulation of platelet activity is controlled, at least in part, through activation of 
PKC. 
PKC has been shown to regulate a number of biochemical pathways in platelets, affecting 
platelet physiology by modulating aggregation and dense granule secretion 389,409. While some 
studies have indicated that arachidonic acid may activate PKC directly through 12-HETE 410,411, 
others have proposed an indirect mechanism for eicosanoid regulation of PKC activation 412,413. 
Our present work showed that inhibition of 12-LOX resulted in attenuation of platelet 
aggregation. Similarly, we found that PKC inhibition attenuated PAR-induced platelet 
aggregation. Therefore, we hypothesized that 12-LOX regulation of platelet reactivity may in 
some way be coupled to that of PKC. Through a number of approaches, PKC was determined to 
be downstream of 12-LOX activation, as activation with PMA was able to rescue 12-LOX-
mediated inhibition of platelet aggregation, αIIbβ3 activation, and ERK phosphorylation. 
Together with our earlier work which showed PMA activation of platelet aggregation did not 
result in calcium mobilization or formation of 12-HETE 398, this data is suggestive of a signaling 
cascade in which PKC is downstream of 12-LOX activation. 
Platelet aggregation requires activation of the integrin αIIbβ3. 12(S)-HETE has been 
linked to regulation of integrin activation in other cells 414 and we observed partial inhibition of 
αIIbβ3 activation in platelets in the absence of PKC activity. Similar attenuation of PAR4-
induced integrin activation was observed in the absence of 12-LOX activity, attenuation that was 
also rescued by addition of PMA. These results support a role for 12-LOX-dependent PKC 
regulation of integrin activity following activation of platelets by PAR4-AP. Interestingly, we 
found that the integrin activity induced by PAR1 and by convulxin was not significantly affected 
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by the 12-LOX inhibitor. Together with our observation that the PKC inhibitor attenuates αIIbβ3 
activation induced by these two agonists, our results indicate that, contrary to PAR4, activation 
of the integrin by PAR1 and GPVI agonists is mediated by a 12-LOX-independent, but PKC-
dependent mechanism.  
Although several MAPKs have been identified in platelets including ERK1/2, p38MAPK 
and JNK 415-417, their role in mediating platelet function downstream of 12-LOX activation is 
unclear. 12-HETE has been reported to induce ERK activation in human epidermal carcinoma 
cells and this activation could be inhibited by pertusis toxin suggesting the potential involvement 
of a G protein coupled receptor 407. ERK has also been shown to be regulated following PKA 
activation 418,419. Our data supports a role for 12-LOX regulation of ERK in human platelets as 
well, since inhibiting 12-LOX activation resulted in a partially attenuated activation of ERK by 
PAR4-AP or convulxin. The mechanism by which 12-LOX regulates ERK, whether it be 
through 12-HpETE, 12-HETE, or some other bioactive metabolite, is under current investigation 
and understanding its regulation will significantly aid our understanding of 12-LOX metabolite 
regulation of platelet function. The observation that attenuation of ERK phosphorylation in the 
absence of 12-LOX activation was partially rescued by PMA (Figure 5.6), lends strong support 
for PKC regulation of platelet function downstream of 12-LOX.  
Several isoforms of PKC are activated by calcium in the human platelet 420,421 and 
previous reports have indicated that calcium may be partially regulated by 12-LOX 196. However, 
this study was conducted with the less selective 12-LOX inhibitor, baicalein, which has been 
shown to inhibit a number of enzymes in addition to 12-LOX 243. The current study is the first to 
show that baicalein inhibits a number of enzymes in the bioactive lipid pathways in the platelet 
including cPLA2, COX-1, and perhaps thromboxane synthase, while NCTT-956 was shown not 
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to directly affect any of these off-target enzymes (Figure 5.1). To determine if calcium 
mobilization is specifically regulated by 12-LOX, platelets were treated with the highly selective 
12-LOX inhibitor, NCTT-956, and agonist-induced calcium mobilization was measured (Figure 
5.6). Calcium mobilization was significantly attenuated in the presence of NCTT-956 and 
baicalein, supporting the earlier reports attributing 12-LOX activation to this biochemical step 
196. Since calcium can activate PKC directly, these results give evidence for agonist-mediated 
activation of calcium downstream of 12-LOX activation and upstream of PKC. Interestingly, 
calcium mobilization was not completely inhibited by NCTT-956 following platelet activation 
by either PAR1 or PAR4-AP, suggesting a 12-LOX-independent component of calcium 
signaling. By contrast, after activation by convulxin, calcium mobilization is completely 
abrogated by the 12-LOX specific inhibitor. These data suggest a differential regulation of ERK 
phosphorylation that involves both 12-LOX-dependent and 12-LOX-independent mechanisms 
contingent upon the agonist used to activate the platelets. 
Taken together, our results clearly show that 12-LOX plays an important role in platelet 
reactivity. This is the first report to show that 12-LOX activity occurs upstream of PKC and that 
integrin αIIbβ3 activation occurs downstream of both 12-LOX and PKC in human platelets. 
Importantly, this report also demonstrates the selectivity of 12-LOX sensitivity towards the 
PAR4 activation pathway. Finally, this study identifies PKC as an important biochemical 
intermediate in both 12-LOX-dependent and independent regulation of platelet activation. Future 
investigations will focus on identifying the feedback mechanisms by which 12-LOX regulates 
platelet function, presumably through an eicosanoid-dependent pathway, resulting in PKC-
dependent activation of the human platelet. 
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CHAPTER 6  
 
12-Lipoxygenase Activity Plays an Important Role in PAR4 and GPVI-mediated Platelet 
Reactivity5 
6.1 Summary 
Following initial platelet activation, arachidonic acid is metabolized by cyclooxygenase-1 and 
12-lipoxygenase (12-LOX). While the role of 12-LOX in the platelet is not well defined, recent 
evidence suggests that it may be important for regulation of platelet activity and is agonist-
specific in the manner in which it regulates platelet function. Using small molecule inhibitors 
selective for 12-LOX and 12-LOX-deficient mice, the role of 12-LOX in regulation of human 
platelet activation and thrombosis was investigated. Pharmacologically inhibiting 12-LOX 
resulted in attenuation of platelet aggregation, selective inhibition of dense versus alpha granule 
secretion, and inhibition of platelet adhesion under flow for PAR4 and collagen. Additionally, 
12-LOX-deficient mice showed attenuated integrin activity to PAR4-AP and convulxin 
compared to wild-type mice. Finally, platelet activation by PARs was shown to be differentially 
dependent on COX-1 and 12-LOX with PAR1 relying on COX-1 oxidation of arachidonic acid 
while PAR4 being more dependent on 12-LOX for normal platelet function. These studies 
demonstrate an important role for 12-LOX in regulating platelet activation and thrombosis. 
Furthermore, the data presented here provide a basis for potentially targeting 12-LOX as a means 
to attenuate unwanted platelet activation and clot formation. 
                                                
5 This section has been published in Thrombosis and Hemostasis. Yeung J, Apopa PL, Vesci J, Stolla M, Rai G, Simeonov A, 
Jadhav A, Fernandez-Perez P, Maloney DJ, Boutaud O, Holman TR. 12-lipoxygenase activity plays an important role in PAR4 
and GPVI-mediated platelet reactivity. Thrombosis and haemostasis. 2013 Sep;110(3):569. 
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6.2 Introduction 
Platelet activation plays a crucial role in hemostasis and thrombosis 422,423 and a central 
role in the pathophysiology of cardiovascular disorders such as acute coronary syndrome 424-426. 
Activation of human platelets is initiated through primary signaling by thrombin or collagen and 
reinforced by secondary signaling events initiated by arachidonic acid (AA) release from the 
phospholipids, formation of bioactive metabolites, and granule secretion. The clinical importance 
of this positive feedback to platelet activation is evident by the widespread use of aspirin, which 
specifically blocks AA metabolism to thromboxane A2 427. An equally important metabolic 
pathway which utilizes AA as its substrate is platelet-type 12-Lipoxygenase (12-LOX), resulting 
in the formation of 12-(S)-hydroperoxyeicosatetraenoic acid (12-HpETE) 428,429. 12-LOX is 
primarily expressed in the platelet and megakaryocyte and its metabolic products have been 
shown to play a role in regulating vascular and non-vascular processes such as integrin 
activation, vascular hypertension, and progression of certain types of cancer 196,315,322,405,430-432. 
While we have recently shown an important role for 12-LOX in platelet activation 326, the extent 
to which 12-LOX activation directly regulates platelet activity and its agonist-specific role in 
regulating thrombosis is unclear. We therefore sought to determine if pharmacological inhibition 
or genetic ablation of 12-LOX activity plays a role in PAR and collagen-mediated platelet 
activation and clot formation.  
12-LOX utilizes AA as a substrate to form 12-(S)-hydroperoxyeicosatetraenoic acid (12-
HpETE) 428 which is further metabolized by glutathione peroxidase to form 12-HETE 433. Once 
formed, the majority of 12-HETE is released to the extracellular space and is postulated to signal 
through a number of potential mechanisms including GPCRs 330,434, cytosolic signaling 
complexes, or alternatively incorporation into the plasma membrane 412,435,436. The biological 
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function of 12-LOX activation in platelets has been complicated by the observation that its 
metabolites are reported to mediate both an increase as well as decrease in platelet reactivity 
196,320,326,335,437,438. In support of 12-LOX as a mediator of platelet activation, 12-LOX activity has 
been linked to alpha granule secretion 430 and surface integrin expression and activation in both 
the platelet and tumor cells 326,414,439,440. Additionally, although 12-LOX has been postulated to 
play a role in dense granule secretion in platelets 320, specific inhibitors which would enable 
direct investigation of 12-LOX regulation of platelet reactivity, adhesion, and clot formation 
have been lacking 250,423,441. The recent development, however, of selective platelet 12-LOX 
inhibitors has allowed for a more detailed investigation of how 12-LOX selectively regulates 
platelet reactivity, clot formation, and dense granule secretion in the human platelet 326,395,441. 
While these inhibitors selectively block 12-LOX activity in human platelets while not affecting 
activity of other enzymes in this pathway (5-LOX, 15-LOX, COX-1, thromboxane synthase, 
cPLA2, or PKC) 326,442, their effectiveness in inhibiting the 12-LOX homolog expressed in 
murine platelets (12/15-LOX) is unclear limiting the use of these selective inhibitors in the 
murine system in vivo. 
 Here we show that inhibition of 12-LOX activity inhibits platelet aggregation, which is 
coupled to a significant shift in the ability of the platelet to induce normal integrin activation, 
dense granule secretion, and platelet adhesion under venous shear. Additionally, αIIbβ3 
activation in the 12-LOX-/- mouse is attenuated providing strong evidence for the involvement of 
12-LOX in formation and long-term stability of the platelet clot. Finally, we show that while 
COX-1, but not 12-LOX activation, is essential for normal platelet activation through PAR1 398, 
12-LOX activation plays an important role in normal platelet function through PAR4 326. Thus, 
these studies provide the first reported evidence supporting an important physiological role for 
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12-LOX in adhesion of platelets under shear which is coupled to platelet aggregation, integrin 
activation, and secretion and support further investigation of 12-LOX as a potential target for 
regulation of platelet activation and uncontrolled thrombus formation. 
6.3 Materials and Methods 
Materials: 12-LOX compounds (NCTT-956 and -694) were synthesized at the NIH Chemical 
Genomics Center (Rockville, MD). For a list of all materials, see supplemental methods. 
Human platelets: Human platelets were obtained from healthy volunteers from within the 
Thomas Jefferson University community and the Philadelphia area. These studies were approved 
by the Thomas Jefferson University Institutional Review Board and informed consent was 
obtained from all donors before blood draw. Experiments were performed on both whole blood 
and washed platelets as previously described 443,444. Unless otherwise noted, all experiments were 
conducted with a platelet concentration of 3 X 108 platelets/ml.  
Mice: 12-LOX-/- mice and strain-matched controls (B6129SF2/J) were obtained from Jackson 
Labs. Experimental procedures were approved by the Animal Care and Use Committee of 
Thomas Jefferson University. 
Platelet Aggregation and dense granule secretion: Washed platelets were pretreated with 
inhibitors for 10 min. The aggregation response to agonist was measured using a lumi-
aggregometer (Model 700D, Chronolog Corp) with stirring at 1100 rpm at 37°C. ATP 
luminescence was used to detect dense granule secretion. Aggregation in whole-blood was 
measured with a lumi-aggregometer following manufacturers recommendations. 
Platelet adhesion under flow: In vitro platelet adhesion under venous and arterial shear rates was 
performed in a microfluidic apparatus 445. Whole blood was incubated with NCTT-956 or 
NCTT-694 for 15 minutes followed by incubation with calcein green fluorophore and infused at 
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venous (400-S) or arterial (2000-S) wall shear rates for 5 minutes. Adhesion of platelets was 
monitored continuously with a Nikon Ti-U inverted microscope equipped with a Retiga EXL 
monochrome camera. Images were analyzed using Nikon NIS Elements software. 
Flow Cytometry: P-selectin expression and integrin αIIbβ3 activation on the surface of the 
platelet were measured by flow cytometry (Accuri C6) as a marker of α-granule secretion and 
integrin activation, respectively 326,333. 
Tail-bleeding assay: Tail bleeding of ALOX12-/- and wild-type mice was performed on an 
anesthetized mouse as previously described 446. Time in seconds required for cessation of blood 
flow was recorded. 
Statistical Analysis: Comparison between experimental groups was made using appropriate 
statistical analyses (paired t test program or ANOVA with post-test analysis) using Prism 
software. Differences in mean values (measured as standard error of the mean) were considered 
significant at p < 0.05. 
6.4 Results 
12-LOX inhibition attenuates platelet aggregation 
Platelet aggregation is essential for agonist-mediated clot formation. The role of 12-LOX in 
agonist-induced platelet aggregation was examined by measuring the dose-response for PAR1-
AP, PAR4-AP, collagen, and ADP-mediated aggregation in the absence or presence of NCTT 
956 or baicalein (12-LOX inhibitors). 
In the absence of 12-LOX inhibitors, all agonists were able to induce full and stable aggregation. 
Interestingly, in contrast to PAR1 sensitivity to COX-1 for normal aggregation 398, PAR1-
mediated platelet aggregation was insensitive to 12-LOX inhibition. A significant shift in the 
dose-response for aggregation was observed with all other agonists tested. ADP, which normally 
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induces full aggregation at 5 µM, was not able to overcome the inhibition of 12-LOX and full 
aggregation was not reached even at an ADP concentration of 40 µM. These data support an 
important role for 12-LOX in regulating agonist-induced platelet aggregation through a number 
of receptor pathways. 
 
Figure 6.1 12-LOX is an important determinant of platelet aggregation. 
Washed platelets were treated with or without 50 µM baicalein or 25 µM NCTT-956 and platelet aggregation was measured 
following stimulation with increasing concentrations of collagen, ADP, PAR4-AP, or U46619. All agonists tested showed a shift 
to the right in the EC50 for platelet aggregation (N=3). *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. This figure was co-
provided by Jennifer Yeung, Joanne Vesci and Dr. Patrick Apopa 
12-LOX regulation of dense granule secretion. As granule secretion plays an important role in 
the regulation of platelet clot growth and stability, secretion of dense granules was measured in 
platelets treated with or without 12-LOX inhibitors (Figure 6.2). Treatment with the active 12-
LOX inhibitor (NCTT-956) resulted in complete inhibition of PAR1-AP and PAR4-AP-induced 
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ATP secretion, while treatment with the inactive analog (NCTT-694) had no effect on dense 
granule secretion at concentrations as high as 100 µM NCTT-694 (Figure 6.2A). The effects of 
NCTT-956 were also compared to the 12-LOX inhibitor baicalein. Similar to NCTT-956, 
baicalein induced a dose-dependent inhibition of PAR1-AP-mediated dense granule secretion. 
To ascertain that the analogs did not interfere directly with the luciferase-based assay of ATP 
release, control reactions were performed where a known concentration of ATP was measured in 
presence of analogs or vehicle. The results showed that neither NCTT-956 nor NCTT-694 inhibit 
the luciferase assay (Supplemental Figure 1). This was a surprising result based on the 
observation in figure 6.1 that inhibition of 12-LOX attenuated PAR4, but not PAR1-mediated 
platelet aggregation. However, this is in line with the observation that PAR4 is more sensitive to 
positive feedback through secretion and ADP compared to PAR1 444. 
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Figure 6.2 12-LOX activation is required for dense granule secretion in platelets.  
Washed platelets were treated with active or inactive 12-LOX inhibitors and the level of dense granule secretion was monitored 
by measuring ATP release following stimulation with different agonists. A) ATP release induced by 20 µM PAR1-AP with 
increasing concentration of NCTT-956 (N=5) or NCTT-694 (N=3). Composite analysis of dose-response for dense granule 
secretion with PAR1-AP in the presence of increasing concentrations of NCTT-956 (N=5) and NCTT-694 (N=3). ***, P<0.001. 
C) Representative and composite for dense granule secretion following PAR1-AP in the presence of increasing concentrations of 
baicalein (N=3). Structure of NCTT-956, NCTT-694, and baicalein are shown for comparison. B) Composite analysis of ATP 
secretion in the presence of the 100 µM aspirin or 100 nM SQ29548 followed by stimulation with 10 nM thrombin, 20 µM 
PAR1-AP, or 200 µM PAR4-AP for 10 minutes. C) Dense granule secretion was measured in absence or presence of 12-LOX 
metabolites to determine their role in the regulation of agonist-mediated secretion. Washed platelets were treated with either 250 
nM 12(S)-HETE (N=3) or 12(S)-HpETE (N=3). Dense granule secretion was measured following activation with PAR1-AP. ***, 
P<0.001; *, P<0.05. This figure was co- provided by Dr. Patrick Apopa and Joanne Vesci 
 To determine if 12-LOX regulation of dense granule secretion was agonist specific, the 
same experiments were repeated with a number of agonists known to induce dense granule 
secretion (Supplemental Figure 2). Inhibition of 12-LOX completely eliminated dense granule 
secretion induced by thrombin, PAR4-AP, collagen, U46619 (an agonist for the TPα receptor), 
and ADP, giving strong evidence that 12-LOX activation is important to platelet dense granule 
secretion. To determine if inhibition of dense granule secretion was due to an inhibition of 12-
LOX signaling or a potential indirect effect on thromboxane signaling, platelets were treated 
without or with 100 µM aspirin (COX-1 inhibitor) or 100 nM SQ29548 (TPα inhibitor) followed 
by stimulation with 10 nM thrombin, 20 µM PAR1-AP, or 200 µM PAR4-AP. Neither inhibition 
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of COX-1 nor TPα resulted in a significant change in agonist-mediated dense granule secretion 
(Figure 6.2B). 
Role of 12-HETE in dense granule release. To determine if 12-HETE, or its precursor, 12-
HpETE, plays a role in regulation of agonist-induced secretion, dense granule secretion was 
measured following PAR1-AP stimulation either in the presence or absence of exogenous 
metabolite (250 nM 12-HETE or 12-HpETE). Exogenous 12-HETE and 12-HpETE significantly 
increased PAR1-AP-mediated dense granule secretion by 20% compared to agonist alone 
(Figure 6.2C) while metabolite alone did not induce dense granule secretion. These data are in 
agreement with other published work implicating 12-HETE as a potential modulator of platelet 
function 320 and our current observation that absence of 12-LOX activity and 12-HETE results in 
inhibition of agonist-mediated dense granule secretion. Exogenously added 12-HpETE resulted 
in an even larger increase in PAR1-AP-induced dense granule secretion of 60% compared to 
control suggesting a potential role for other 12-LOX metabolites in modulating agonist-mediated 
platelet activation. 
12-Lipoxygenase does not regulate α-granule secretion. Secretion of α-granules from human 
platelets is induced by both PAR1 and PAR4 443,447. To assess if 12-LOX specifically regulates 
dense granule secretion or both dense and α-granule secretion, platelets were treated with or 
without NCTT-956, NCTT-694, or baicalein for 10 minutes followed by stimulation with 
thrombin, PAR1-AP, or PAR4-AP. α-granule secretion was determined by measuring P-selectin 
levels on the platelet surface by flow cytometry (Figure 6.3). α-granule secretion was not 
significantly attenuated following 12-LOX inhibition in the presence of all three agonists. These 
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data suggest that α-granule secretion is not regulated via the 12-LOX pathway.  
 
Figure 6.3 12-LOX is not critical for agonist-mediated α-granule secretion.  
α-granule secretion was determined following stimulation of platelets with 10 nM thrombin, 20 µM PAR1-AP, or 200 µM PAR4-
AP in the presence or absence of active and inactive 12-LOX inhibitors (N=4). P-selectin expression following treatment with 25 
µM NCTT-956, 50 µM baicalein, or 25 µM NCTT-694 was not significantly different from control. 
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Regulation of platelet function in vivo by 12-LOX. To determine if 12-LOX plays a role in 
platelet function in vivo, bleeding time was assessed in 12-LOX-/- and strain-matched wild-type 
mice using the tail-bleeding assay 446 (Figure 6.4A). While wild-type mice showed a normal 
cessation time for bleeding following clipping of the tail vein (N=4), the time to cessation of 
bleeding in 12-LOX-/- mice was significantly prolonged (N=11). 
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Figure 6.4 Inhibition of 12-LOX in whole blood attenuates platelet aggregation and adhesion.  
Platelet aggregation and clot formation was measured in whole blood to determine the role of 12-LOX in regulating ex vivo 
platelet activation in the presence of confounding factors present in the blood. A) Whole blood aggregometry was performed in 
the absence or presence of the 12-LOX inhibitor, NCTT-956 or the negative analog, NCTT-694. Blood was treated with or 
without 100 µM NCTT-956 or -694, stimulated with 5 µg/ml collagen, and impedance aggregometry was measured for 10 
minutes post-stimulation (N=3). A significant decrease in impedance was observed in the presence of NCTT-956 but not NCTT-
694 (**, P<0.01; NS, not significant). B) Platelet clot formation over a collagen strip under low or high shear conditions (400 sec-
1 or 2000 sec-1, respectively) was measured either with ( )  or without (•) 100 µM NCTT-956 or NCTT-694 (Δ) (N=4). The rate 
of clot formation was significantly delayed and attenuated following inhibition of 12-LOX compared to control. This figure was 
co-provided by Moritz Stolla, Jennifer Yeung, and Joanne Vesci 
Regulation of whole blood aggregation and adhesion by 12-LOX. Although aggregation in 
washed platelets shows sensitivity to 12-LOX activation (Figure 6.1), its role in whole blood has 
not been well defined. To determine if platelet aggregation is altered in whole blood, freshly 
drawn human blood was treated with or without NCTT-956 or NCTT-694 for 10 minutes 
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followed by stimulation with collagen (the first step in platelet activation following vessel 
injury). Using impedance aggregometry a significant decrease in platelet aggregation was 
observed in the presence of the 12-LOX inhibitor compared to untreated platelets or platelets 
treated with the negative analog (Figure 6.4B). To determine if 12-LOX plays a role in platelet 
adhesion and clot formation under flow, whole blood treated with or without NCTT-956 or 
NCTT-694 was flowed over a collagen strip at low and high shear rates (400 and 2000 sec-1) 
(Figure 6.4C). Although untreated blood showed significant clot growth within one to three 
minutes, inhibition of 12-LOX at low shear resulted in a significant delay in platelet adhesion as 
well as attenuation of the overall area and intensity of adhesion to collagen. Blood treated with 
the inactive analog NCTT-694 however, exhibited no delay in adhesion or clot growth. At high 
shear, 12-LOX activation did not appear to be essential as there was no observable difference in 
area coverage or clot formation at any time point measured.  These data provide strong evidence 
that platelet reactivity and haemostasis rely in part on the enzymatic activity of platelet 12-LOX 
and supports a potential role for 12-LOX in the recruitment and activation of platelets into a 
growing clot. 
12-LOX activity is important for haemostasis and thrombosis in the mouse. While murine 12-
LOX is highly homologous to human, its enzymatic activity is less selective and is known to 
form at least two products from AA, 12-HETE and 15-HETE. Due to its altered enzymatic 
activity, the 12-LOX inhibitors directed toward the human enzyme do not bind with high 
efficacy to mouse 12-LOX. To determine if the observed 12-LOX effects identified in human 
platelets with the 12-LOX inhibitor are due to inhibition of 12-LOX activity, platelets from 12-
LOX-/- and strain-matched wild-type mice were assessed for αIIbβ3 activity. Washed platelets 
were stimulated with either PAR4-AP or convulxin (Figure 6.5) and the level of αIIbβ3 was 
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measured. Mice deficient in 12-LOX showed a significant attenuation of αIIbβ3 activation for 
both agonists compared to wild-type mice. This data confirms an important role for 12-LOX in 
regulating platelet activation, thrombosis, and haemostasis. 
 
Figure 6.5 12-LOX-/- mice have impaired platelet activation and hemostasis.  
Platelet function was measured in wild-type and 12-LOX-/- mice. Washed platelets were stimulated with either PAR4-AP (50 µM 
and 100 µM) or convulxin (CVX) (50 ng/ml or 100 ng/ml) for 10 minutes and αIIbβ3 activity was measured by flow cytometry 
using the JON/A antibody (N=3). 
Agonist-dependent regulation of platelet activation through COX-1 and 12-LOX. Previously, we 
have shown that inhibition of thromboxane formation perturbs PAR1-mediated platelet 
activation to a much larger extent compared to PAR4 suggesting that PAR4 may rely on a 12-
LOX signal for normal platelet activation as opposed to COX-1 398. To assess if this is the case, 
platelet aggregation and αIIbβ3 activation were measured in response to PAR1-AP or PAR4-AP 
in the presence of aspirin, NCTT-956, or both (Figure 6.6). PAR1-AP showed no sensitivity to 
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NCTT-956 even at low agonist concentrations but aggregation was significantly shifted to the 
right in the presence of aspirin. Treatment with both aspirin and NCTT-956 was not significantly 
different from aspirin alone. PAR4 showed no significant shift in the presence of aspirin at any 
concentration tested while treatment with NCTT-956 significantly shift the dose-response for 
aggregation to the right. Treatment with both aspirin and NCTT-956 was no different than 
NCTT-956 alone (Figure 6.6A). To confirm the observed selective inhibition of PAR1 and 
PAR4 signaling with aspirin and NCTT-956, respectively, integrin αIIbβ3 activation was 
measured under the same conditions (Figure 6.6B). Similar to what was observed for 
aggregation, PAR1-AP-induced αIIbβ3 activation was significantly attenuated in the presence of 
aspirin, but not NCTT-956, while PAR4-AP-induced αIIbβ3 activation was significantly 
attenuated in the presence of NCTT-956, but not aspirin. Dual treatment in either case had no 
additional inhibitory effect on either PAR-AP suggesting these signaling pathways are not 
synergistic in nature.  
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Figure 6.6 COX-1 and 12-LOX regulation of PAR-mediated platelet activation.  
Washed platelets were assessed for differences in sensitivity to COX-1 and 12-LOX following stimulation with either PAR1-AP 
or PAR4-AP. A) Platelet aggregation was measured following 10 minute stimulation with increasing concentrations of either 
PAR1-AP or PAR4-AP in the absence or presence of 25 µM NCTT-956, 100 µΜ aspirin (ASA), or both (N=4-11). On the left 
are representative aggregation curves and on the right is the composite data for each agonist. B) αIIbβ3 activation was measured 
under the same conditions (N=3-11). On the left are representative histograms and on the right is the composite data for each 
agonist. N.S., not significant; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. 
 
6.5 Discussion 
 
Regulation of platelet activation is crucial in the treatment of a number of pathophysiological 
conditions including cardiovascular disease and diabetes and positive feedback plays a 
significant role in stable clot formation in vivo 423. Although anti-platelet therapies targeting 
positive reinforcement by inhibition of COX-1 (aspirin) or the P2Y12 receptor (clopidogrel) have 
succeeded in reducing morbidity and mortality due to clot formation and stroke, new approaches 
are warranted to further decrease the level of platelet reactivity. We have investigated an 
alternative approach to attenuating platelet activation and clot formation and have shown that 
targeting 12-LOX activation with selective platelet 12-LOX inhibitors may represent a viable 
approach to anti-platelet therapy. Inhibition of 12-LOX in human platelets resulted in agonist-
specific attenuation of platelet aggregation and agonist-independent inhibition of dense granule 
secretion (Figures 6.1, 6.2). Since dense granule is thought to be a major reinforcement pathway 
leading to secretion of platelet agonists such as ADP, 5-HT, and epinephrine 423,447, 12-LOX 
inhibition of dense granule secretion may partially explain the observed deficit in normal platelet 
aggregation and adhesion as well as an inability to form stable clots under shear conditions. 
Further, attenuation of platelet adhesion and clot growth indicates a potential benefit inhibition of 
12-LOX may present as an approach to anti-platelet therapy. Finally, while PAR1-mediated 
platelet activation is sensitive to inhibition of COX-1 but not 12-LOX, PAR4-mediated platelet 
activation is significantly attenuated in the absence of 12-LOX activity but not COX-1. Taken 
together, these data yield strong evidence that selective 12-LOX inhibitors have the potential to 
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decrease the severity of platelet clot formation and minimize vessel occlusion, which in turn may 
lead to a reduction in the incidence and severity of cardiovascular events. 
Lipoxygenases play a role in a number of pathophysiological processes ranging from 
atherosclerosis and clot formation to cancer and essential hypertension. Elucidating the role of 
12-LOX in regulation of platelet reactivity, however, has posed a significant challenge based in 
part on the lack of specific inhibitors 243,250. Baicalein was initially used in human platelets to 
pharmacologically show that 12-LOX plays a role in calcium mobilization and aggregation 196. 
This work was the first evidence that 12-LOX may play an important role in the regulation of 
platelet reactivity. Although baicalein is now viewed as a relatively non-specific 12-LOX 
inhibitor 326,441, the observation that inhibition of 12-LOX activity resulted in attenuation of 
calcium mobilization and perturbed resultant platelet activation steps helped to form the basis for 
the current study. The development of selective inhibitors targeting platelet 12-LOX has allowed 
us to investigate its potential role in the progression of platelet-mediated clot formation 
commonly observed in cardiovascular disease 326,395,441. While the current study strongly 
supports a primary role for 12-LOX in regulation of normal platelet function through a number 
of signaling pathways including collagen and PAR4, the underlying mechanisms mediating the 
differential regulation of PAR1 versus PAR4 by COX-1 and 12-LOX, respectively, will also 
need to be delineated in order to fully appreciate the unique roles these receptors play in 
regulating platelet activation following injury. 
Secretion and positive feedback are thought to be important events in clot formation and 
irreversible platelet activation. Our data suggest that 12-LOX regulates dense granule secretion 
in an agonist-independent manner but selectively attenuates platelet aggregation by collagen and 
PAR4-AP, while sparing the PAR1 pathway. This observation is in line with previous reports 
 
 
112 
showing dense granule secretion being more important for PAR4-induced aggregation compared 
to PAR1 444. Similarly, 12-LOX has recently been shown to regulate PKC activity which plays a 
role in dense granule secretion 326,446,448. The current study also showed that while aspirin does 
not inhibit dense granule secretion in platelets, it prevents formation of thromboxane A2 which is 
important for PAR1, but not PAR4-mediated platelet aggregation 398. Hence, PAR1 appears to 
require COX-1 for normal platelet activation while PAR4 requires 12-LOX (Figure 6.6). The 
complex interactions between these receptor pathways and the oxygenases in the platelet may 
represent unique approaches for regulating these disparate pathways and an opportunity for the 
development of highly targeted anti-platelet therapeutics. The mechanistic differences mediating 
COX-1 and 12-LOX regulation of platelet activity are currently being investigated. 
While inhibition of 12-LOX blocks dense granule secretion and 12-HETE formation, our 
data support the hypothesis that other 12-LOX metabolites formed following platelet activation 
may play an important role in regulating secretion since addition of 12-HpETE, the direct 
product of 12-LOX, exerts an even stronger effect than its reduced form. Several products may 
be formed following 12-LOX metabolism of AA, including 12-HETE and hepoxilins 449,450. 
Furthermore, 12-LOX can oxidize any number of fatty acids present on the platelet membrane 
following cleavage with cPLA2 333,441, suggesting that other metabolites may be contributing to 
the regulation of platelet activation and thrombosis. 
To differentiate between regulation of dense granule secretion and alpha granule 
secretion, P-selectin was measured as a surrogate for α-granule secretion (Figure 6.3). Our 
results show that 12-LOX was not required for α-granule secretion in the platelet. The potential 
role for 12-LOX in P-selectin secretion has been postulated by others 430 and agrees with the 
recently proposed model suggesting that a number of discrete pools of α-granules exist in the 
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platelet which are differentially secreted in an agonist-dependent manner 451. This is an active 
area of investigation which will need to be elucidated in order to understand the extent to which 
12-LOX regulates platelet function. 
 Although 12/15-LOX knockout mice have been generated to study lipoxygenase function 
in mice 320,  this study is the first to identify the role of 12-LOX for regulation of platelet 
reactivity in regulation of aggregation, secretion, and adhesion in human platelets. The mouse 
homolog of 12-LOX is similar in structure to that of the human protein; however significant 
species differences do exist. For example, 12-LOX in the human solely produces 12-HETE from 
arachidonic acid, while 12/15-LOX in the mouse is known to produce both 12-HETE and 15-
HETE, the latter product recently being shown to be essential for ischemia-induced angiogenesis 
452. With these limitations in mind, it is likely that the murine 12-LOX-deficient mouse shares 
some functional similarities to pharmacological inhibition of 12-LOX in the human as we show 
here that platelets isolated from 12-LOX-/- mice show significant attenuation of αIIbβ3 activation 
following PAR4-AP or convulxin compared to wild-type mice. 
Our data support a physiologically important role for 12-LOX in mediating a number of 
pro-thrombotic processes, which are key in the formation of a stable platelet clot formation. 
Adequate regulation of platelet activation has been a central focus in clinically treating a number 
of diseases including acute coronary syndrome and cardiovascular disease as well as the 
cardiovascular complications often associated with metabolic syndrome and diabetes. Although 
several inhibitors of the reinforcement pathways are currently in use including aspirin and 
clopidogrel, a need exists for the development of alternative strategies to control platelet 
reactivity and minimize the occurrence of thrombotic events in patients diagnosed with a number 
of cardiovascular risks 76. Hence, 12-LOX inhibition may represent a new approach to anti-
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platelet therapy as it not only targets platelet aggregation, dense granule secretion, and adhesion 
to collagen under shear, but shows significant agonist-dependence specifically targeting collagen 
and PAR4 while sparing PAR1 signaling 326 (figure 6.6). Taken together, these findings provide 
impetus for studies to further identify how 12-LOX regulates platelet activity at a mechanistic 
level through PAR4 and collagen, and further probe the potential for 12-LOX inhibitors as a next 
generation of anti-platelet therapeutic agents either alone or in combination with existing anti-
platelet approaches 453-456
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CHAPTER 7  
 
12-Lipoxygenase Modulates FcγRIIa Signaling in Platelets6 
7.1 Summary 
Platelets are essential in maintaining hemostasis following inflammation or injury to the 
vasculature. Dysregulated platelet activity often results in thrombotic complications leading to 
myocardial infarction and stroke. Activation of the FcγRIIa receptor leads to immune-mediated 
thrombosis which is often life-threatening in patients undergoing heparin-induced 
thrombocytopenia or sepsis. Inhibiting FcγRIIa-mediated activation in platelets has been shown 
to limit thrombosis and is the principal target for prevention of immune-mediated platelet 
activation. Here we show for the first time that platelet 12(S)-lipoxygenase (12-LOX), a highly 
expressed oxylipin-producing enzyme in the human platelet, is an essential component of 
FcγRIIa-mediated thrombosis. Pharmacological inhibition of 12-LOX in human platelets resulted 
in significant attenuation of FcγRIIa-mediated aggregation. 12-LOX was shown to be essential 
for FcγRIIa-induced PLCγ2 activity leading to activation of calcium mobilization, Rap1 and 
PKC activation, and subsequent activation of the integrin αIIbβ3. Additionally, platelets from 
transgenic mice expressing human FcγRIIa but deficient in platelet 12-LOX failed to form 
normal platelet aggregates and exhibited deficiencies in Rap1 and αIIbβ3 activation. These results 
                                                
6 This has been published in Blood. Yeung J, Tourdot BE, Fernandez-Perez P, Vesci J, Ren J, Smyrniotis CJ, Luci DK, Jadhav A, 
Simeonov A, Maloney DJ, Holman TR. Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation. Blood. 2014 Oct 
2;124(14):2271-9. 
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support an essential role for 12-LOX in regulating FcγRIIa-mediated platelet function and 
identify 12-LOX as a potential therapeutic target to limit immune-mediated thrombosis. 
7.2 Introduction 
Platelet activation is essential for maintaining normal hemostasis following vascular 
insult or injury 457. While formation of the platelet plug is a required step in primary hemostasis, 
under certain conditions activation of platelets with the surrounding environment results in the 
formation of an occlusive thrombus resulting in myocardial infarction and stroke 423. One mode 
of platelet activation involves the platelet signaling through an immune response via 
immunoreceptors on the platelet surface 423,458-461.  Human platelets express a number of 
receptors containing or associated with immunoreceptor tyrosine-based activation motif (ITAM) 
containing transmembrane receptors including glycoprotein VI (GPVI) 462, C-type lectin-like 
receptor 2 (CLEC-2) 463, and the IgG immune complex receptor FcγRIIa 50. Ligation of ITAM-
containing receptors on the platelet has been previously shown to lead to a shared downstream 
signaling pathway resulting in platelet activation 463-465. While activation of each of these 
receptors contributes in distinct ways to physiologic hemostasis and thrombosis 57,466-469, they 
have non-redundant pathophysiological functions. In particular FcγRIIa, which is present on the 
surface of human but not mouse platelets 470, is best known for its pathophysiological role in 
immune-mediated thrombocytopenia and thrombosis, a family of disorders including 
thrombocytopenia associated with sepsis, thrombosis due to certain therapeutic monoclonal 
antibodies and heparin-induced thrombocytopenia (HIT) 460,471,472. Selectively inhibiting the 
FcγRIIa signaling pathway in platelets for prevention of immune-mediated thrombocytopenia 
and thrombosis has been a long sought approach for prevention of HIT 473.  
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Platelet 12(S)-lipoxygenase (12-LOX), an oxygenase highly expressed in platelets, has 
been shown to potentiate the activation of select signaling pathways including protease-activated 
receptor 4 (PAR4) and an ITAM-containing receptor complex (GPVI-FcRγ) 196,325,474,475. The 
most well understood function of 12-LOX is production of oxylipins, most notable being the 
conversion of arachidonic acid (AA) to 12-hydroxyeicosatretraenoic acid (12-HETE) upon 
agonist stimulation of platelets through both GPCR- and non-GPCR-mediated pathways 475. 12-
HETE is an oxylipin that has been shown to be pro-thrombotic in platelets 476,477. While the 
mechanism by which 12-LOX regulates platelet activity is not fully understood, previous 
publications have demonstrated the ability of 12-LOX activity to augment key signaling 
components of platelet activation including Rap1, Ca2+ mobilization, αIIbβ3 activation, and 
dense granule secretion 196,325,474,477. As 12-LOX activity was recently shown to be required for 
normal GPVI-mediated platelet activation 325,474, we sought to determine if 12-LOX activity is an 
essential component of FcγRIIa signaling in platelets 464.  
In this study, human platelets were treated with the selective 12-LOX inhibitor ML-355 
478 or vehicle control prior to FcγRIIa stimulation to determine if 12-LOX plays a role in the 
FcγRIIa signaling pathway. Pharmacological inhibition of 12-LOX activity in human platelets 
attenuated FcγRIIa-mediated platelet aggregation. Consistent with our human studies, murine 
platelets isolated from mice expressing human FcγRIIa in their platelets and deficient in 12-LOX 
had an attenuated response to FcγRIIa stimulation compared to littermates expressing 12-LOX. 
The activity of 12-LOX was further demonstrated to be essential for a number of biochemical 
steps known to be essential for FcγRIIa signaling in the platelet. Hence, this study is the first to 
identify 12-LOX activity as a critical component of normal FcγRIIa signaling in platelets. 
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Further, the results of this study suggest for the first time that 12-LOX may represent a novel 
therapeutic target to treat immune-mediated thrombocytopenia and thrombosis. 
7.3 Materials and Methods 
Preparation of washed human platelets: Prior to blood collection written informed consent was 
obtained under approval of the Thomas Jefferson University Institutional Review Board. Washed 
platelets were resuspended in Tyrodes buffer as previously described 325 at a concentration of 3 
x108 platelets/mL unless otherwise indicated.  
Mice and platelet preparation: FcγRIIA transgenic mice (hFcR/ALOX12+/+) on C57BL/6J 
background 52 were bred with platelet 12-lipoxygenase knockout (ALOX12-/-) mice 320,325 on 
C57BL6/129S2 background to generate FcγRIIA transgenic mice deficient in platelet 12-
lipoxygenase (hFcR/ALOX12-/-). The newly generated hFcR/ALOX12-/- mice appear 
phenotypically normal compared to hFcR/ALOX12+/+ with similar body size, platelet counts, 
WBCs and RBCs profiles (Supplemental 1). All mice were housed in the AALAC-approved 
mouse facility of Thomas Jefferson University (TJU). Experimental procedures were approved 
by the Animal Care and Use Committee of TJU. Blood was drawn from the inferior vena cava of 
12 week-old anesthetized mice using a syringe containing sodium citrate. Mouse platelet 
preparation was prepared as previously described 325. Murine platelets of 2.5 x108 platelets/mL 
were resuspended in Tyrodes buffer containing human fibrinogen (75 µg/mL) and CaCl2 (1 
mM).   
Reagents: Human FcγRIIa (IV.3 (CD32), StemCell Technologies), human fibrinogen (type I) 
(Sigma-Aldrich), goat anti-mouse IgG (Fab’2, Santa Cruz, Biotechnology), mouse anti-CD9 (BD 
Biosciences), Fluo-4AM (Life Technologies), PAC1-FITC (BD Biosciences), P-Selectin-PE 
(CD62P, BD Biosciences), antibody (Cell Signaling), ATP standard (Chronolog), Chronolume 
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(Chronolog), Accur C6 (BD Biosciences), Secondary rabbit and mouse antibodies (LI-COR), 
Y759 PLCγ2 antibody (Cell Signaling), glutathione beads for Rap1 pull down (GE-Healthcare), 
Fibrinogen from human plasma (Sigma).  
FcγRIIa-mediated platelet activation: FcγRIIa-mediated platelet activation was initiated by two 
distinct models; either 1) FcγRIIa antibody cross-linking or 2) CD9 monoclonal antibody 
stimulation. To cross-link FcγRIIa, washed platelets were incubated with IV.3, an FcγRIIa mouse 
monoclonal antibody, for one minute followed by the addition of a goat anti-mouse (GAM) IgG 
antibody to cross-link FcγRIIa. The concentration of FcγRIIa cross-linking antibodies used for 
each experiment is indicated in the text. Alternatively, washed human platelets were stimulated 
with an anti-CD9 monoclonal antibody to activate FcγRIIa. Due to inter-individual variability in 
anti-CD9 response, a range of anti-CD9 concentrations (.25 – 1 µg/ml) was used to achieve 
aggregation at each donor’s EC80.  In studies using the 12-LOX inhibitor (ML355), washed 
platelets were incubated with either ML355 (20 µM), or DMSO (vehicle control) for 15 minutes 
prior to FcγRIIa stimulation.  
Platelet aggregation: Platelet aggregation was measured with a lumi-aggregometer (Chronolog 
Corp, Model 700D, Havertown, PA) under stirring conditions at 1,100 rpm at 37°C. 
Quantification of 12 HETE: 12-D8-HETE (1 ng) was added to the samples as an internal 
standard.  Platelets pretreated with DMSO or ML355 were stimulated with FcγRIIa cross-linking 
and quenched with 1% formic acid in acetonitrile at the indicated time points. To prepare the 
sample for LC/MS injection, the sample was extracted twice with hexane, dried under N2 gas, 
reconstituted with ACN/water (1:1, v/v), and centrifuged at 20,000 g for 5 min at 4° C.  
LC/MS/MS analysis of the samples was performed on an ACQUITY UPLC system coupled to a 
Xevo TQ-S MS/MS (Waters Corp), an electrospray ionization triple quadrupole mass analyzer 
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system. The instrument was operated in the negative mode. The ion source voltage was set at -
2.0 kv and desolvation temperature was set at 550° C.  12-HETE was quantified by monitoring 
specific multiple reaction monitoring (MRM) transitions. The MRM transitions of 12-HETE and 
D-8-12-HETE, the internal standard, were m/z 319 to m/z 179 and m/z 327 to m/z 184. 
Chromatographic analysis was performed on the ACQUITY UPLC® BEH C18 column (1.7 
mm, 100 x 2.1 mm internal diameter). LC mobile phase was composed of 0.25% acetic acid in 
water solution (solvent A) and isopropanol/acetonitrile (90:10, v/v) (solvent B). Solvent B was 
increased from 30% to 44% at 1 min, 60% at 6.3 min and 7.3 min, 30% at 8 min.  The detection 
limit of 12-HETE was 0.2 pg/l. The linear range of 12-HETE was from 0.5 pg/l to 50 pg/l. 
PLCγ2 phosphorylation: Washed human platelets were adjusted to 5x108 platelets/mL and 
stimulated in an aggregometer by antibody cross-linking of FcγRIIa and lysed at designated 
times with 5X Laemmli reducing buffer (1.5 M Tris-Cl pH 6.8, glycerol, β-mercaptoethanol, 
10% SDS, 1% bromophenol blue) to stop the reaction. Samples were separated on a 7.5% SDS-
PAGE gel. Antibodies to PLCγ2 and phospho-Y759 PLCγ2, (Cell Signaling Technology, 
Danvers, MA) a marker of PLCγ2 activation, were used to evaluate the relative levels of total 
and active PLCγ2, respectively.   
Calcium mobilization: Intracellular calcium release was measured as previously described 326. 
Briefly, washed human platelets were resuspended at 1.0 x 106 platelets/mL in Tyrodes buffer 
containing 1 mM calcium.  Platelets were incubated with Fluo-4-AM (Life Technologies, 
Carlsbad, CA), a cell permeable calcium sensitive dye, for ten minutes prior to stimulation. 
Platelets were stimulated by FcγRIIa antibody cross-linking and fluorescence intensity was 
measured in real-time by flow cytometry in an Acurri C6 flow cytometer. Data are reported as 
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the fold change in the fluorescence intensity comparing maximum fluorescence intensity relative 
to fluorescence intensity prior to platelet stimulation.  
Rap1 activation: Washed human platelets were stimulated by FcγRIIa antibody cross-linking for 
five minutes and aggregation was stopped with 2X platelet lysis buffer. RalGDS-Rap binding 
domain (RalGDS-RBD), a truncated form of RalGDS (788-884aa) that contains the Rap1 
binding domain specific for the GTP bound form of Rap1, was used to selectively precipitate the 
active conformation of Rap1 from the platelet lysate as previously described 479. Total platelet 
lysate and Rap1 pull-down samples were run on a SDS-PAGE gel and identified by Western blot 
with a Rap1 antibody. The levels of active Rap1 were normalized to the amount of total Rap1 
contained in each sample. 
PKC activation assay:  Washed platelets were stimulated by FcγRIIa antibody cross-linking 
under stirring conditions (1100 rpm) in an aggregometer at 37°C. Reactions were stopped by the 
addition of 5X Laemmli sample buffer at the indicated times.  As a positive control platelets 
were treated with PMA (1 mM), a direct PKC agonist, for one minute.  Samples were run on an 
SDS-PAGE gel and Western blots were performed using antibodies specific for PKC substrate 
phosphorylation and pleckstrin.  
Dense granule secretion: ATP release was measured from washed platelets as surrogate for 
dense granule secretion. Prior to activation washed platelets were incubated with Chronolume 
Reagent, an ATP sensitive dye, for one minute. Platelets were stimulated with an FcγRIIa 
antibody under stirring conditions and fluorescence was measured in real-time using a lumi-
aggregometer.  
Alpha granule release and αIIbβ3 activation:  Prior to stimulation, human washed platelets were 
pre-incubated with either FITC-conjugated P-selectin antibody or FITC-conjugated PAC-1, an 
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antibody specific for the active conformation of αIIbβ3. Platelets were stimulated with an 
FcγRIIa antibody and reactions were stopped by the addition of 2% formaldehyde at indicated 
times. Fluorescence intensity was measured by flow cytometry.  Results are reported as mean 
fluorescence intensity.  
Western Blotting: Standard Western blots for Rap1 activation, PKC substrates, and PLCγ2 
phosphorylation were used and band intensity were quantified with the Odyssey Infrared 
Imaging System (LIC-OR Biosystems). 
Statistical analysis:  Where applicable, the data represents the mean ± S.E.M.  Statistical 
significance was determined with unpaired one-tailed t-test using GraphPad Prism software. A p 
value less than 0.05 was considered significant. 
7.4 Results  
12-LOX regulates FcγRIIa-mediated platelet aggregation.  
Our group previously showed that pharmacological inhibition of 12-LOX activity resulted in 
attenuation of GPVI- or PAR4-mediated platelet activation 325,474. In platelets, FcγRIIa utilizes 
many of the same downstream signaling effectors as GPVI-FcRγ 464. To determine if 12-LOX 
plays a role in FcγRIIa-mediated platelet aggregation, washed human platelets were treated with 
increasing concentrations of ML355, a recently identified highly selective 12-LOX inhibitor 478, 
or DMSO (vehicle control) prior to FcγRIIa stimulation. Treatment of platelets with ML355 at a 
concentration of 10 or 20 µM resulted in significant attenuation of FcγRIIa-mediated platelet 
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aggregation via FcγRIIa antibody cross-linking (Figure 7.1A). To assess if the  
 
Figure 7.1 12-LOX modulates FcγRIIa-mediated platelet aggregation.  
A) The aggregation of washed human platelets was measured following FcγRIIa crosslinking (IV.3 + GAM) in the presence of 
increasing concentrations of ML355, a 12-LOX inhibitor, ranging from 1-20 µM (n= 5) or DMSO (vehicle control, n= 5). The 
left panel shows the representative dose response of ML355 affecting FcγRIIa-induced aggregation. The right panel is a 
composite of ML355 doses.   B) Following FcγRIIa cross-linking (IV.3 + GAM), the production of 12-HETE, the predominant 
12-LOX oxylipin, was measured in platelets pretreated with concentrations of ML355 ranging from 1 – 20 µM (n= 4) or DMSO 
(n= 4). C) 12-HETE production was measured in FcγRIIa cross-linked platelets at increasing time points in the presence of 
DMSO or ML355 (20 µM) (n=4).  D) Washed human platelets were pretreated with DMSO (n=4) or ML355 (20 µM) (n=8) and 
platelet aggregation was measured following FcγRIIa stimulation (anti-CD9). Error bars indicate SEM. *, p<0.05;  **, p<0.01. 
This figure was co-provided by Jennifer Yeung and Johnny Yu (12-HETE measurement) 
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attenuation of aggregation observed in figure 7.1A correlated with the ability of ML355 to 
inhibit 12-LOX activity, 12-HETE (the predominant 12-LOX product) production was measured 
in FcγRIIa-stimulated platelets pre-treated with DMSO or ML355. Stimulation of FcγRIIa with 
GAM + IV.3 stimulated platelets with ML355 (20 µM) significantly decreased 12-HETE 
production (Figure 7.1B). We observed 20 mM of ML355 as the lowest concentration that 
efficiently blocked both FcγRIIa-induced platelet aggregation and 12-HETE production 
independent of inter-individual variability in response to the inhibitor, therefore this 
concentration of inhibitor was used in all subsequent assays in this study. The kinetics of 12-
HETE production in PAR stimulated platelets was previously determined 398; however, the 
kinetics of 12-HETE production in FcγRIIa stimulated platelets is unknown. Therefore, we 
sought to determine the kinetics of 12-HETE production in FcγRIIa stimulated platelets.  12-
HETE formation is significantly enhanced at 15 seconds in DMSO treated platelets stimulated 
with FcγRIIa agonist (P=.0143) and continues to increase through all times measured (Figure 
1C).  The production of 12-HETE in FcγRIIa stimulated platelets is significantly attenuated by 
ML355 (20 µM) (Figure 7.1C). FcγRIIa-mediated platelet aggregation in response to a second 
agonist for FcγRIIa, anti-CD9, was also found to be attenuated in the presence of 20 µM of 
ML355 (Figure 7.1D). To confirm the decrease in FcγRIIa-mediated platelet aggregation was 
due to pharmacological inhibition of 12-LOX and not a potential off-target effect of the ML355, 
ex vivo platelet aggregation was measured following anti-CD9 stimulation in humanized FcγRIIa 
(hFcR) transgenic mice expressing 12-LOX (ALOX12+/+) or deficient in 12-LOX (ALOX12-/-). 
Platelets from mice deficient in 12-LOX (hFcR/ALOX12-/-) showed a delayed (Figure 7.2B) and 
attenuated (Figure 7.2C) aggregation in response to anti-CD9 stimulation (.125 and .25 µg/mL) 
when compared to platelets from mice expressing functional 12-LOX (hFcR/ALOX12+/+). These 
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data suggest that platelets lacking 12-LOX activity through pharmacological or genetic ablation 
exhibit a significantly attenuated platelet aggregation response to FcγRIIa activation.  
 
Figure 7.2 Murine platelets require 12-LOX for normal FcγRIIa-induced platelet aggregation.  
A dose response of anti-CD9-induced platelet aggregation was performed with washed platelets from hFcR/ALOX12+/+ or 
hFcR/ALOX12-/- mice. Prior to aggregation, fibrinogen (75 µg/mL) and CaCl2 (1 mM) were added to platelets. A) Washed 
platelets from hFcR/ALOX12+/+ (grey tracings) and hFcR/ALOX12-/- (black tracings) were measured for aggregation in response 
to .25, .5 and 1 µg/mL of mouse anti-CD9 for 10 minutes. Inset: Western blots for 12-LOX, FcγRIIa, and GAPDH were 
performed with platelet lysate from hFcR/ALOX12+/+ or hFcR/ALOX12-/- mice. The B) lag time and C) final aggregation was 
measured in hFcR/ALOX12+/+ (grey bars) and hFcR/ALOX12-/- (black bars) washed platelets stimulated with increasing doses of 
anti-CD9 (n = 3-6 per group). Error bars indicate SEM. *, p<0.05    
 
12-LOX regulates αIIbβ3 and Rap1 activity in FcγRIIa stimulated platelets.  
Figures 1 and 2 suggest 12-LOX is essential for normal FcγRIIa-mediated platelet aggregation; 
however, the component(s) in the FcγRIIa pathway regulated by 12-LOX remain unclear. As the 
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activation of integrin αIIbβ3 is required for platelet aggregation 480,481, the potential role of 12-
LOX in mediating αIIbβ3 activation in FcγRIIa-stimulated platelets was investigated. αIIbβ3 
activation was measured by PAC1-FITC binding to FcγRIIa-stimulated platelets treated with 
DMSO or ML355 in flow cytometry. FcγRIIa activation resulted in a large increase in active 
αIIbβ3 on the platelet surface. Treatment with ML355 prior to stimulation resulted in a 
significant reduction in PAC1 binding to platelets (Figure 7.3A) relative to the DMSO control.   
 
Figure 7.3 FcγRIIa-mediated Rap1 and integrin αIIbβ3 activation are potentiated by 12-LOX.  
A) Washed human platelets pre-treated with ML355 or DMSO were stimulated by FcγRIIa crosslinking (IV.3 + GAM) and 
αIIbβ3 integrin activation (n=3 for DMSO and n=6 for ML355) and B) Rap1 activation (n=4) were assessed. C) 
hFcR/ALOX12+/+ and hFcR/ALOX12-/- platelets were stimulated with .125 and .25 µg/mL of mouse anti-CD9 and replicates of 
n=5 were assessed for Rap1 activation. PAC1-FITC was used to measure αIIbβ3 activation by flow cytometry. A composite bar 
graph of PAC1-FITC fold changes relative to the unstimulated PAC1-FITC fluoresence. Activated Rap1 was pulled down using 
Ral-GDS and blotted with a Rap1 antibody. Active Rap1 was measured using LI-COR and then normalized to total Rap1 and 
unstimulated for fold change in Rap1 activity.  Error bars indicate SEM. **, p<0.01    
 
While αIIbβ3 activation is under the control of a complex milieu of signaling proteins 
including Talin, RIAM1, and Rap1 482. Rap1, a small G protein regulated by calcium and PKC, 
is known to play a central role in inside-out activation of αIIbβ3 465,483-486. Therefore, Rap1 
activation was measured following FcγRIIa stimulation for five minutes in washed human 
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platelets treated with or without ML355 (Figure 7.3B). FcγRIIa stimulation of platelets (control) 
resulted in a significant increase in active Rap1 (Rap1-GTP). However, platelets treated with 
ML355 and subsequently stimulated through FcγRIIa failed to activate Rap1. To confirm that the 
inhibition of Rap1 was not due to the vehicle, platelets were treated with DMSO and stimulated 
with FcγRIIa. Treatment with DMSO did not result in attenuation in Rap1 activation compared 
to untreated control. 
While unlikely, it is possible that ML355 inhibits Rap1 in a 12-LOX-independent 
manner. To determine if this is the case, Rap1 activation was measured in platelets from mice 
expressing human FcγRIIa and 12-LOX (hFcR/ALOX12+/+) or deficient in 12-LOX 
(hFcR/ALOX12-/-). FcγRIIa-mediated Rap1 activation in the platelet was measured following 
stimulation with anti-CD9 (Figure 7.3C). Rap1 activity was significantly increased in mouse 
platelets expressing both human FcγRIIa and endogenous 12-LOX. Genetic ablation of 12-LOX 
however (hFcR/ALOX12-/-) resulted in a significant attenuation of anti-CD9-mediated Rap1 
activation confirming the importance of 12-LOX in this process.  
12-LOX regulates dense and alpha granule secretion in FcγRIIa activated platelets.  
The release of alpha and dense granules from activated platelets serves to amplify platelet 
aggregation 487-490 and are important components in normal agonist-induced platelet activation. 
To determine if 12-LOX plays a role in FcγRIIa-mediated granule secretion, surface expression 
of P-selectin was used as a surrogate marker to measure alpha granule secretion in FcγRIIa-
stimulated platelets and measurement of ATP release was assessed as a measure of agonist-
induced dense granule secretion. FcγRIIa-stimulated platelets treated with ML355 showed a 
significant decrease in the percentage of platelets that expressed P-Selectin on their surface 
compared to DMSO treated platelets (Figure 7.4A). Additionally, FcγRIIa-stimulated platelets 
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treated with ML355 showed a significant attenuation in ATP release compared with DMSO 
treated platelets (Figure 7.4B). The data strongly supports a role for 12-LOX regulation of 
FcγRIIa-mediated platelet secretion through release of dense and partial regulation of alpha 
granule secretion. 
12-LOX modulates proximal signaling components of the FcγRIIa pathway in human 
platelets.  
As shown in Figures 7.1-7.3, 12-LOX activity is required for the normal activation of distal 
signaling components of the FcγRIIa pathway (Rap1, αIIbβ3, and platelet aggregation). We 
sought to identify the earliest biochemical steps in the FcγRIIa pathway which are regulated by 
12-LOX. The earliest signaling observed following FcγRIIa activation is ITAM phosphorylation 
which has been shown to result in Syk activation 491-494. Syk activation leads to activation of 
phospholipase gamma 2 (PLCγ2) resulting in calcium release and PKC activation, both of which 
are critical for platelet activation 394,495. To determine where in this complex signaling milieu 12-
LOX plays an essential role in FcγRIIa signaling in the platelet, a number of the signaling 
components directly downstream of FcγRIIa activation were assessed in the presence or absence 
of ML355. To investigate whether 12-LOX directly regulated phosphorylation of the FcγRIIa 
receptor, the first step in FcγRIIa-mediated platelet activation, FcγRIIa was immunoprecipitated 
from IV.3+GAM-stimulated platelets treated with ML355 or DMSO and immunoblotted for 
phosphorylation of FcγRIIa. Stimulation of FcγRIIa resulted in a noticeable increase in receptor 
phosphorylation. Treatment with ML355 failed to cause a reduction in FcγRIIa phosphorylation 
(Figure 7.5). This data suggests that 12-LOX activity is not required for phosphorylation of 
FcγRIIa itself.  
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Figure 7.4 Granule secretion mediated by FcγRIIa activation is regulated by 12-LOX.  
Washed human platelets treated with DMSO or ML355 were stimulated by FcγRIIa crosslinking in which IV.3 (2 µg/mL) + 
GAM (10 µg/mL) were used for A) alpha granule secretion. Alpha granule secretion was measured by using P-selectin-PE 
conjugated antibody in a flow cytometer. To obtain the percentage of platelets that were positive for P-Selectin, approximately 
10% of the unstimulated platelet population was gated (shown in the histogram) and then applied to ML355 and DMSO treated 
platelets in order to quantify percentage of platelets that were positive for P-Selectin. A composite bar graph shows the percent of 
platelets positive for P-selectin in ML355 and DMSO treated platelets (n=5). B) IV.3 (2 µg/mL) + GAM (5 µg/mL) were used to 
stimulate ATP secretion as a surrogate marker for dense granule secretion in a lumi-aggregometer. A bar graph of DMSO or 
ML355 treated platelets measured for ATP secretion following FcγRIIa crosslinking (n=4). Error bars indicate SEM. **, p<0.01. 
To assess if 12-LOX regulates PLCγ2 activation downstream of FcγRIIa, 
phosphorylation of PLCγ2 was measured in washed human platelets in the presence or absence 
of ML355. Platelets stimulated through FcγRIIa were phosphorylated within 15 seconds 
following stimulation. Platelets treated with ML355; however, showed significantly attenuated 
PLCγ2 phosphorylation at 15 seconds compared to control conditions (Figure 7.6A).  
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Figure 7.5 The role of 12-LOX in regulating the FcγRIIa signaling complex.  
Washed human platelets were treated with ML355 (20 µM) or vehicle control prior to stimulation by crosslinking (IV.3 + GAM). 
Immunoprecipitation of FcγRIIa was conducted at 15, 30, and 60 seconds post crosslinking and phosphorylation of FcγRIIa was 
measured via Western blot. A bar graph of immunoprecipitated FcγRIIa that had been treated with DMSO or ML355 following 
FcγRIIa crosslinking were assessed for phosphorylation (n=7). Error bars indicate SEM. This figure was provided by Dr. 
Benjamin Tourdot. 
Since 12-LOX attenuated FcγRIIa-mediated PLCγ2 activation, its effects on intracellular 
calcium release were measured. FcγRIIa was stimulated in washed human platelets treated with 
or without ML355 and calcium release was measured. Platelets treated with ML355 exhibited a 
decrease in intracellular calcium following platelet stimulation compared to DMSO treated 
platelets (Figure 7.6B) supporting a physiological role for both PLCγ2 and calcium in 12-LOX 
regulation of FcγRIIa. As PLCγ2 activation leads to activation of PKC in platelets through 
calcium mobilization, the potential regulation of FcγRIIa-mediated PKC activity by 12-LOX was 
also evaluated. Platelets stimulated through the FcγRIIa pathway showed a high level of PKC-
mediated phosphorylation as measured by a phospho-substrate PKC antibody. A significant 
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decrease in PKC activation was observed in platelets treated with ML355 at 30 and 60 seconds 
compared to platelets treated with the vehicle control (Figure 6.7C). This regulation of PKC by 
ML355 was determined to be indirect since PKC activation by PMA, a direct PKC activator, 
showed no difference in its ability to activate PKC either in control or ML355 treated platelets.  
 
Figure 7.6 12-LOX modulates early signaling components of the FcγRIIa pathway in human platelets.  
Washed human platelets were treated with ML355 (20 µM) or vehicle control prior to stimulation by crosslinking (IV.3 + GAM).  
A) A time course of PLCγ2 phosphorylation at site Y759 was assessed by western blot analysis. All samples were normalized to 
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total PLCγ2 and fold changes were quantified relative to the unstimulated condition. The bar graph comprises of n=7 individuals. 
B) Following crosslinking (IV.3 + GAM), calcium mobilization was measured by flow cytometry. Representative curves were 
quantitated in fold change of free calcium relative to the unstimulated condition over four minutes. Bar graphs represent the ratio 
of the fold change in calcium mobilization (n=5). C) N=7 stimulated human platelets with or without ML355 were analyzed for 
PKC activity following CD32 crosslinking and PMA rescue comprises of n=3. A PKC substrate was blotted as a surrogate for 
PKC activation and Pleckstrin phosphorylation. Data represents mean ± S.E.M. *, p<0.05; **, p<0.01. This figure was co-
provided by Jennifer Yeung (PLCγ2 phosphorylation and calcium flux) and Dr. Benjamin Tourdot (PKC substrate 
phosphorylation) 
 
7.5 Discussion 
12-LOX has recently been shown to be an important regulator of GPVI-mediated platelet 
activation 325,474. As FcγRIIa and GPVI are purported to signal via a conserved pathway, we 
postulated that 12-LOX may play an essential role in the regulation of FcγRIIa signaling in 
human platelets. This study is the first to demonstrate that 12-LOX is an essential component of 
FcγRIIa immune-mediated platelet activation. Human platelets treated with a highly selective 12-
LOX inhibitor, ML355 478, or FcγRIIa transgenic mouse platelets deficient in 12-LOX, showed 
significantly attenuated aggregation in response to FcγRIIa-mediated activation. To investigate 
the underlying mechanism by which 12-LOX regulates FcγRIIa-mediated platelet activation, the 
activity of multiple signaling intermediates in the FcγRIIa pathway were assessed in the presence 
of the 12-LOX inhibitor ML355. Following stimulation, platelets treated with ML355 were 
significantly attenuated along multiple signaling steps in the immune-mediated FcγRIIa 
activation pathway including αIIbβ3, Rap1, Ca2+, PLCγ2, PKC, and granule secretion (Figure 
7.7).  
The best studied function of 12-LOX is to produce oxylipins (such as 12(S)-HETE) from 
free fatty acids in the cell membrane. While previous work showed that selective 12-LOX 
inhibitors significantly reduced oxylipin production and were associated with reduced platelet-
mediated reactivity, the role of these bioactive metabolites in platelet activation remains unclear. 
Our study demonstrates that a significant increase in 12-HETE formation is reproducibly 
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observed within 15 seconds following FcγRIIa crosslinking-mediated 12-LOX oxidation of AA 
(P=0.0143) (Figure 7.1C). Our data suggest that 12-LOX may partially regulate FcγRIIa-induced 
platelet activation either through oxylipin formation and subsequent metabolite signaling 329,330, 
or directly through a protein complex formation within the cell 496-498. While both of these 
regulatory mechanisms are plausible, the kinetics by which 12-LOX inhibition attenuates 
FcγRIIa signaling may favor a direct role for 12-LOX in regulating the FcγRIIa pathway through 
non-enzymatic regulation of the FcγRIIa signaling cascade.   
Although 12-LOX activity is required for normal FcγRIIa-mediated platelet activation, 
the direct molecular component by which 12-LOX activity is required has yet to be determined. 
12-LOX was not required for FcγRIIa phosphorylation, suggesting 12-LOX activity is not 
directly regulating Src family kinase activity. However, 12-LOX activity was shown to be 
important for early PLCγ2 activation, indicating 12-LOX may be an important regulator in the 
kinetics of PLCγ2 activation affecting downstream effectors.  The delay in PLCγ2 activation due 
to 12-LOX inhibition may be attributed to direct regulation of PLCγ2 or regulation of upstream 
effectors such as LAT or BTK. The data presented here narrows the scope of where 12-LOX 
impinges on the FcγRIIa pathway to a proximal point in the signaling pathway between the 
receptor and PLCγ2.  
The role of FcγRIIa signaling is well established in the pathogenesis of immune-mediated 
thrombosis such as heparin-induced thrombocytopenia and thrombosis (HIT), an iatrogenic 
disorder characterized by immune-mediated platelet activation that can lead to life threating 
thrombosis. HIT is a paradigm of the ITT disorders, immune-mediated thrombocytopenia and 
thrombosis. Alternative therapeutic interventions, such as direct thrombin inhibitors (DTIs), have 
been considered for anti-coagulation therapy; however, complications of bleeding remains a 
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primary concern 499. Even with this potentially fatal complication, heparin remains the standard 
anticoagulant for prevention and treatment of thrombosis. Therefore, there is a need for novel 
therapeutic approaches that directly treat the pathogenesis of HIT. The activation of platelets by 
pathogenic HIT immune complexes requires FcγRIIa signaling, which makes it an attractive 
target. While the pathogenesis of HIT is complex, we have provided strong evidence supporting 
12-LOX as a key regulator of FcγRIIa-mediated platelet activation. Hence, this study has 
delineated for the first time a novel approach in regulation of HIT and potentially other ITT 
disorders through inhibition of human platelet 12-LOX. 
 
Figure 7.7 Schematic model of 12-LOX role in the regulation of FcγRIIa pathway.  
12-LOX regulates early PLCγ2 activation-mediated by FcγRIIa stimulation, which is essential for full calcium release in the 
platelets.  Calcium flux is required for cPLA2 activity to generate free fatty acids, such as arachidonic acid (AA). Subsequently, 
Rap1 activation is also dependent on 12-LOX activity in order to activate integrin αIIbβ3 for platelet aggregation. This 
illustration was generated by Dr. Benjamin Tourdot. 
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CHAPTER 8  
 
Investigations of Human Platelet-type 12-Lipoxygenase: Role of Lipoxygenase Products in 
Platelet Activation7 
 
8.1 Summary 
Human platelet-type 12-lipoxygenase (12-LOX) has recently been shown to play an 
important role in regulation of human platelet function by reacting with arachidonic acid (AA). 
However, a number of other fatty acids are present on the platelet surface which, when cleaved 
from the phospholipid, can be oxidized by 12-LOX. We sought to characterize the substrate 
specificity of 12-LOX against six essential fatty acids: AA, dihomo-gamma-linolenic acid 
(DGLA), eicosapentaenoic acid (EPA), alpha-linolenic acid (ALA), eicosadienoic acid (EDA) 
and linoleic acid (LA). Three fatty acids were comparable substrates (AA, DGLA and EPA), one 
was 5-fold slower (ALA), and two showed no reactivity with 12-LOX (EDA and LA). The 
bioactive lipid products resulting from 12-LOX oxidation of DGLA, 12-(S)-hydroperoxy-
8Z,10E,14Z-eicosatrienoic acid (12(S)-HPETrE), and its reduced product, 12(S)-HETrE, 
resulted in significant attenuation of agonist-mediated platelet aggregation, granule secretion, 
αIIbβ3 activation, Rap1 activation, and clot retraction. Treatment with DGLA similarly inhibited 
PAR1-mediated platelet activation as well as platelet clot retraction. These observations are in 
surprising contrast to our recent work showing 12(S)-HETE is a pro-thrombotic bioactive lipid 
                                                
7 This section has been published in Journal of Lipids Research. Ikei KN, Yeung J, Apopa PL, Ceja J, Vesci J, Holman TR, 
Holinstat M. Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation. Journal 
of lipid research. 2012 Dec 1;53(12):2546-59. 
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and supports our hypothesis that the overall effect of 12-LOX oxidation of fatty acids in the 
platelet is dependent on the fatty acid substrates available at the platelet membrane. 
8.2 Introduction 
In the human platelet, hydroperoxidation of polyunsaturated fatty acids using molecular 
oxygen is accomplished by the human lipoxygenase (LOX) isozyme family 500. 5-LOX, 12-LOX 
and 15-LOX are the three main LOX’s and are named according to their positional specificity on 
arachidonic acid (AA), producing their respective hydroperoxyeicosatetraenoic acid (HPETE) 
products. The HPETE products are subsequently reduced by cellular peroxidases to the bioactive 
lipid, hydroxyeicosatetraenoic acid (HETE). The LOX products are responsible for human 
inflammatory responses 501, and are also implicated in a variety of human diseases. 5-LOX is 
involved in asthma 502 and cancer 503,504. 12-LOX is involved in psoriasis 505, hypertension 431,432, 
hemostasis 196,322,506,507, diabetes 508,509, and cancer 504,510,511, and 15-LOX is involved in 
atherosclerosis 512 and cancer 504,513.  
Two 12-LOX isozymes are expressed in humans, platelet-type 12-LOX (12-LOX) 514 and 
epithelial 12-LOX 515. The former isozyme (12-LOX), makes the S-product and is primarily 
expressed in megakaryocytes and platelets, while the latter makes the R-product and is primarily 
expressed in epithelial tissue. Recently, 12-LOX has been implicated in platelet activation, which 
is known to play a central role in the pathophysiology of cardiovascular disease 329,398,441,476,507. 
Following initial activation of human platelets by primary signals such as thrombin and collagen, 
secondary signals mediated by bioactive lipids (thromboxane A2 and 12(S)-HETE) and secreted 
molecules (ADP) are essential for recruitment and activation of platelets.  
12-LOX acts upon fatty acid substrates that are released from the phospholipid membrane in 
the platelet by cytosolic phospholipase A2 (cPLA2) 516. The composition of the phospholipids in 
 
 
137 
the platelet membrane is dynamic in nature and since many of the fatty acids that make up the 
phospholipid bilayer are not produced in the body, their content is primarily regulated by dietary 
intake 517-520. Although AA makes up a large proportion of the phospholipid content, other fatty 
acids are also available from the platelet membrane and their content, relative to AA, has been 
shown to fluctuate depending on diet 518,520,521. While the catalysis of 12-LOX with AA has been 
studied previously 398,514,522,523, little is known about the relative 12-LOX kinetic rates of the 
other fatty acid substrates and their physiological effects on platelet activation. LOX’s are known 
to have promiscuous substrate selectivity and can react with a variety of fatty acids, ranging from 
18 to 22 carbons long and having 2 to 6 sites of un-saturation. Based on this knowledge, the 
current study investigated the substrate specificity and reactivity of 12-LOX with six fatty acids. 
In addition, the substrates and their 12-LOX products were screened for the potential to regulate 
platelet reactivity and thrombosis. Interestingly, we were able to determine that some, but not all 
of the fatty acids and their bioactive metabolites, directly regulate the level of agonist-mediated 
platelet activation, albeit in a different manner than the AA product, 12(S)-HETE.
8.3 Materials and Methods 
Materials: All commercial fatty acids were purchased from Nu-Check prep with purities of 
99.0% or greater. HPLC grade solvents were used for both semi-preparative HPLC purification 
and analytical HPLC analysis of 12-LOX products. Large scale product purification was 
achieved by using a C18 HAIsil 250 x 10 mm semi preparative column, whereas the C18 HAIsil 
250 x 4.6 mm analytical column was used for product separation in tandem with MS/MS 
analysis. Both columns were purchased from Higgins Analytical (Mountain View, Ca). All other 
chemicals were reagent grade or better and were used without further purification. PAR1-AP 
(SFLLRN) was purchased from GL Biochem (Shanghai, China). Aggregometers, chronolume 
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reagent, collagen, and other aggregation supplies were purchased from Chrono-Log Corp. 
(Havertown, PA). Anti-Rap1 primary antibody was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Thrombin was purchased from Enyzme Research Labs (South Bend, IN). 
Anti-Rabbit-800nM secondary antibody was purchased from Rockland Antibodies and Assays 
(Gilbertsville, PA). ADP and Acetylsalicylic acid (aspirin) was purchased from Sigma-Aldrich 
(St. Louis, MO). PAC1 and CD62P were purchased from BD Biosciences (San Jose, CA). 
Convulxin was purchased from Centerchem (Stamford, CT). 
Large scale generation of 12-LOX products: LOX products were generated by reacting an 
individual substrate with 12-LOX in 1,000 mL of 25 mM HEPES (pH 8.0) with 25-50 µM 
substrate and run to completion. Reactions were quenched with 5 mL acetic acid, extracted three 
times with 30% volume of dichloromethane, evaporated to dryness, and reconstituted in MeOH 
for HPLC purification. The reduced products were generated by selectively reducing the 
hydroperoxide product to the alcohol, with trimethylphosphite. Products were purified by HPLC 
using a C18 HAIsil 250 x 10 mm semi prep column. Solution A was 99.9% MeOH and 0.1% 
acetic acid; Solution B was 99.9% H2O and 0.1% acetic acid. An Isocratic gradient of 75% A 
and 25% B was used to purify products. Products were stored at -80o C for a maximum of 6 
months. The purity and identity of the products were confirmed by using a Thermo-Electron 
LTQ liquid chromatography-tandem mass spectrometer (LC-MS-MS). 
Overexpression and Purification of 12-LOX.  Human platelet-type 12-LOX was expressed as an 
N-terminally, His6-tagged protein and purified to greater than 90% purity, as evaluated by SDS-
PAGE analysis 524,525. Concentration of 12-LOX was determined by using the method of 
Bradford, with a bovine serum albumin standard, where 1 mg/ml solutions were equivalent. Iron 
content of 12-LOX was determined with a Finnigan inductively coupled plasma mass 
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spectrometer (ICP-MS), using cobalt-EDTA as an internal standard. Iron concentrations were 
compared to standardized iron solutions and used to normalize enzyme concentrations.  Protein 
expression yields and iron content of 12-LOX were similar to previously published results 522,523.  
12-LOX Product Identification and Distribution. Product identification was achieved by using a 
Thermo-Electron LTQ liquid chromatography-tandem mass spectrometer (LC-MS/MS). Product 
separation was achieved by using a C18 HAIsil 250 x 4.6 mm analytical column from Higgins 
Analytical. Solution A was 99.9% acetonitrile and 0.1% acetic acid; Solution B was 99.9% H2O 
and 0.1% acetic acid. An isocratic gradient of 55% A and 45% B was used to purify products. 
The identification of 12-LOX products was achieved by comparing MS-MS fragments with 
known standards at www.lipidmaps.org. In cases where MS-MS fragmentation standards were 
not available, products were identified by comparing fragment masses with predicted fragment 
masses mediated by the hydroxy group near an unsaturated carbon 526. The mechanism is 
described as charge remote allylic fragmentation (Supplemental Figure S1) and gives rise to a 
negatively charged carboxylic fragment that can identify the regio-specificity of the product. 
Product distribution of the products was analyzed by comparing the total ion count of single 
oxygenated product versus double and triple oxygenated products by parent mass and fragment 
mass. 
Steady-State Kinetic Measurements. LOX rates were determined by following the formation of 
the conjugated diene product at 234 nm with either a Perkin-Elmer Lambda 40 or a Shimadzu 
(UV-2401PC) UV-Vis spectrophotometer. Molar extinction coefficients for 12-LOX products of 
each substrate at 234 nm were measured in the enzymatic buffer and are as follows: 13(S)-
HPOTrE (ALA product) ε = 22,500 M-1 cm-1, 12(S)-HPETE (AA product) ε = 22,500 M-1 cm-1, 
12(S)-HPETrE (DGLA product) ε = 14,300 M-1 cm-1, 12(S)-HPEPE (EPA product) ε = 18,400 
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M-1 cm-1. Molar extinction coefficients were calculated by first weighing the substrate on an 
analytical balance, then dissolving the substrate with a measured mass of HPLC grade methanol 
to achieve a stock substrate/methanol solution. Small aliquots of this solution were then diluted 
into a quartz cuvette containing a Teflon stir bar and 2 mLs of 25 mM HEPES buffer pH 7.5 at 
room temperature 22o C. Diluted samples were mixed thoroughly for 20 minutes and baseline 
stability was monitored at 234 nm before proceeding. The substrate buffer solution was reacted 
with small amounts of purified 12-LOX and the final absorbance at 234 nm was determined. A 
small aliquot of soybean LOX-1 was added at the end of the reaction to assure all substrate was 
converted to product. At a minimum three independently weighed substrate measurements and 
UV-Vis assays were performed and averaged to achieve the extinction coefficients listed above. 
The extinction coefficient of 12(S)-HPETE determined by this method was within error of the 
published values by Graff et al., after correcting for differences in solvent conditions 527. Kinetic 
assays were carried out in 25 mM HEPES buffer (pH 7.5) with substrate concentrations ranging 
from 1 µM – 20 µM, and were initiated by the addition of enzyme (approximately 20 nM 12-
LOX). The 12-LOX displays variable behavior at low substrate concentrations (< 1 µM), 
resulting in large errors in the KM values. To circumvent this inherent problem, we determined 
that adding the 12-LOX first, and then quickly initiating the reaction with the addition of the 
appropriate amount of substrate, yielded significantly more reproducible results. Substrate 
concentrations were quantitatively determined by allowing the enzymatic reaction to go to 
completion with soybean LOX-1. Kinetic data were obtained by recording initial enzymatic rates 
at each substrate concentration and then fitting them to the Michaelis-Menten equation using the 
Kaleida Graph (Synergy) program to determine kcat and kcat/KM values. It should be noted that the 
steady state kinetics with AA were slightly higher than our previously published data 523, which 
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we ascribe to differences in the extinction coefficients used and a more active 12-LOX 
preparation. 
Determination of LOX Product Stereochemistry. Determining the stereochemistry of the 
secondary alcohol LOX products was achieved by mosher ester analysis 528. HPLC purified LOX 
product (evaporated in a glass vial) was reacted with 39 equivalents of anhydrous pyridine, 100 
uL of anhydrous deuterated chloroform, and 16 equivalents of either (S)-(+)-α-Methoxy-α-
trifluoromethylphenylacetyl chloride or (R)-(–)-α-Methoxy-α-trifluoromethylphenylacetyl 
chloride. The reaction was completed after one hour and esterfication was checked by thin layer 
chromatography. Samples were then diluted with deuterated chloroform to a final volume of 700 
uL then transferred to a 5 mm NMR tube and both 1D proton and 2D COSY spectra were taken 
(Varian 600 MHz NMR). The non-modified LOX product was also analyzed in a similar manner 
for comparison and the proton assignments determined. The differences in proton chemical shifts 
between R and S mosher esterfied products were tabulated (Supplemental Figures S2-S22). 
Subtracting the chemical shifts between S and R spectra yields a positive or negative value, 
which indicates the priority of each side of the alcohol in regards to the Chan Ingold Prelog 
convention and thus allows the determination of the absolute configuration of the secondary 
alcohol. A LOX product with known stereochemistry, 13-(S)-HODE from soybean LOX-1 
catalysis, was first analyzed by mosher ester analysis before proceeding with the analysis of 
12(S)-HETrE and 13(S)-HOTrE. The stereochemistry of the vinyl groups were also assigned 
based on the proton coupling constants, with the Z-vinyl protons having J-values of 
approximately 10 Hz and those of the E-vinyl protons having approximately 16 Hz. These 
coupling values along with the proton signal positions were consistent with the values found for 
our standard LOX product, 13(S)-HODE. 
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Human Platelets. Human platelets were obtained from healthy volunteers from within the 
Thomas Jefferson University community and the Philadelphia area. These studies were approved 
by the Thomas Jefferson University Institutional Review Board and informed consent was 
obtained from all donors before blood draw. Washed platelets were prepared as previously 
described 398,444. The final platelet concentration of washed platelets in Tyrodes buffer was 
adjusted to a physiological concentration of 3 X 108 platelets/ml. Reported results are the data 
obtained using platelets from at least three different subjects. 
Platelet Aggregation. 250 µl of washed platelets were pretreated with or without varying 
concentrations (0 to 40 µM) of fatty acid metabolites for 7 minutes followed by stimulation with 
20 µM protease-activated receptor-activating peptide (PAR1-AP), 20 µM ADP, or 100 ng/ml 
convulxin. The aggregation response was measured in real-time using a lumi-aggregometer with 
stirring at 1100 rpm at 37°C.  
Human Platelet Dense Granule Secretion. ATP release was used as a measure of dense granule 
secretion in washed platelets. For ATP studies, 240 µl aliquots of washed platelets were pretreated 
with or without varying concentrations of fatty acid metabolites for 7 minutes. After addition of 10 
µl of chronolume reagent, ATP release in response to 20 µM PAR1-AP was measured in real-time 
using a Lumi-aggregometer at 37°C with stirring at 1100 rpm. 
Measurement of Rap1 Activity. Rap1 activity was measured using GST-RalGDS-Rap1-binding 
domain that specifically interacts with activated Rap1 as described elsewhere 479,529. Activated 
Rap1 was detected by immunoblotting with the anti-Rap1 antibody. In parallel experiments 
using whole platelet lysate, Rap1 expression was analyzed to confirm equal protein loading. 
Flow cytometric measurements of αIIbβ3 and P-selectin. αIIbβ3 activity and surface 
expression of P-selectin were measured by flow cytometry with the FITC- PAC1 (an antibody 
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which only recognizes the active conformation of αIIbβ3) and PE-conjugated CD62P, which 
recognizes P-selectin on the surface of the cell. 40 µl aliquots of washed platelets adjusted to a 
final concentration of 2.5 X 107 platelets/ml were pretreated with metabolites for 15 minutes 
followed by addition of 2 µl PAC1 and 2µl CD62P. Platelets were stimulated with agonist for 10 
minutes and diluted to a final volume of 500 µl using tyrodes buffer. The fluorescence intensity 
of platelets was immediately measured using an Accuri flow cytometer. 
Clot Retraction Assay. Clot retraction experiments were performed as previously described 530. 
Briefly, platelet rich plasma (PRP) was adjusted to a platelet count of 3 X 108 platelets/ml in 
glass tubing. Following treatment with fatty acids or metabolites, clot formation and retraction 
was initiated with 10 nM thrombin. Pictures were taken of the clots at 10 minute intervals and 
the size of the clot was quantified using Image-J software from NIH. Statistical significance was 
determined by student t-test. 
Statistical Analysis. Comparison between experimental groups was made using paired t-test or 
2-way ANOVA with post-test analysis with the software program, Prism. Differences in mean 
values ± standard error of the mean were considered significant at p < 0.05. 
8.4 Results 
12-LOX Product Identification and Distribution 
Of the six fatty acids tested as substrates for 12-LOX catalysis, two fatty acids, linoleic acid (LA) 
and eicosapentaenoic acid (EDA), were found not to be suitable as substrates for 12-LOX. This 
is possibly due to improper positioning of the activated methylene, whose position near the 
active site iron is critical for hydrogen atom abstraction. As shown in Figure 8.1, the substrates 
are positioned with the methyl-end of the substrate entering the cavity first, as previously 
determined 531. In this configuration, the activated methylene moieties for EDA and LA are not 
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positioned properly due to length for the iron-hydroxide moiety to abstract a hydrogen atom. 
However, it should be noted that other factors, such as conjugation could also play an important 
part in substrate activity. Of the four other fatty acids that were screened, AA, dihomo-gamma-
linolenic acid (DGLA), eicosapentaenoic acid (EPA) and alpha-linolenic acid (ALA), they all 
produced over 90% of a single oxygenated product, whose retention time, parent peak mass, and 
main fragmentation peaks are listed in Tables 8.1 and 8.2. Interestingly, ALA produces 
predominately one product, 13(S)-HPOTrE, but it is unclear how it is positioned for hydrogen 
atom abstraction (vide infra). The methyl-end first binding of ALA positions it in a similar 
manner to that of LA and EDA, however those fatty acids are not substrates. 
 
Table 8.1 Primary product distribution.  
The primary products for 12-LOX are singly oxygenated species. The percent distribution was determined by tabulating total ion 
count of the singly oxygenated species in comparison with double or triply oxygenated species. It should be noted that the S-
configuration of 12(S)-HPEPE was not directly determined but assumed, since the configuration of  12(S)-HPETrE and 13(S)-
HPOTrE was determined directly. 
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Figure 8.1 12-LOX product regio-specificity and substrate comparison.  
A) The substrates are positioned methyl-end first, relative to the active site iron. The carbon atoms that are labeled with numbers 
indicate location of oxygenation. B) Stereochemical structures of 12(S)-HETrE and 13(S)-HOTrE. This illustration was provided 
by our collaborator Dr. Theodore Holman’s group. 
 
Kinetics of 12-LOX 
The kinetics of 12-LOX with the four active substrates were measured and reported in Table 3. 
The kcat and kcat/KM values indicate that the substrates can be categorized into two groups. The 
longer substrates, with 20 carbon atoms (AA, DGLA, and EPA) have over 10-fold greater kcat 
and kcat/KM values than the shorter substrate, with 18 carbon atoms (ALA), suggestive that length 
is a key factor in the rate of substrate capture and product release. These data could be due to the 
fact that ALA appears not to have an activated methylene positioned for hydrogen atom 
abstraction (vida supra, Figure 8.1), and thus ALA may have a less than optimal binding 
conformation.  
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Determination of LOX Product Stereochemistry 
LOX’s typically generate one stereospecific product due to the antrafacial oxygen insertion 532. It 
has been previously reported that 12-LOX generates an S-configured  product (12(S)-HPETE) 
when AA is used as a substrate 525. DGLA is similar to AA with respect to length, and one would 
predict that the oxygenated DGLA product (12(S)-HPETrE) would have the same 
stereochemistry as the oxygenated AA product (12(S)-HPETE), due to the stereospecific nature 
of the active site. Mosher ester analysis of the reduced 12(S)-HETrE product indicates that this is 
indeed the case and it does have an S-configuration, secondary alcohol. For 13(S)-HPOTrE, the 
12-LOX product of ALA, the stereochemistry was determined in the same manner and found to 
also be of an S-configuration. The stereochemistry of the vinyl groups were assigned based on 
the proton signal positions and their coupling constants, as compared to our standard, 13(S)-
HODE. The 12(S)-HETrE configuration was determined to be 12-(S)-hydroxy-8Z,10E,14Z-
eicosatrienoic acid and the 13(S)-HOTrE configuration was 13-(S)-hydroxy-9Z,11E,15Z-
octadecatrienoic acid (Figure 8.1b). 
 
Table 8.2 Primary Product Identification by Mass Spectrometry.  
The retention times are for the method described in the text, with subsequent MS/MS analysis. The mass of the primary 
identifying fragment is listed.  
 
Human Platelet Aggregation Dependence of Fatty Acid Metabolites 
Fatty acid metabolites play an important role in regulation of platelet activation and normal 
hemostasis. Although AA is widely studied in platelets, 12-LOX may oxidize a number of other 
fatty acids on the platelet membrane following stimulation 476,533. Since thrombin is the most 
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potent activator of platelet function, we investigated the ability of these metabolites to modulate 
platelet activation following stimulation of the thrombin receptor, protease-activated receptor-1 
(PAR1). The hydroperoxide metabolites of 12-LOX catalysis are reduced to hydroxymetabolites 
in the presence of peroxidases, therefore the hydroxymetabolites were evaluated for their 
potential regulation of human platelet function. Platelets were treated with increasing 
concentrations of each fatty acid metabolite followed by stimulation with 20 µM PAR1-
activating peptide (PAR1-AP) and subsequent platelet aggregation was measured. PAR1-AP 
alone resulted in more than 80% aggregation in less than one minute, which was stable for the 
duration of the experiment (Figure 8.2). Platelet aggregation was sensitive to treatment with 
12(S)-HETrE, showing inhibition in the presence of 40 µM 12(S)-HETrE (Figure 8.2a), a 
clinically relevant concentration following fatty acid supplementation 534,535. Not all metabolites 
were shown to attenuate platelet aggregation, as 12(S)-HEPE and 13(S)-HOTrE had no 
observable effect on PAR1-AP-mediated aggregation. Even at higher concentrations, only 12(S)-
HETrE was shown to attenuate PAR1-AP-induced platelet aggregation (Figure 8.2b). In 
comparison, exposure to increasing concentrations of 12(S)-HETE, the predominant product of 
AA and 12-LOX in human platelets, did not result in attenuation of PAR1-AP-mediated platelet 
aggregation at any concentration tested. This is consistent with the observation that 12(S)-HETE 
is pro-thrombotic in human platelets 329. 
Human Platelet Dense Granule Secretion is Sensitive to Fatty Acid Metabolites 
Thrombin activation of human platelets involves a number of biochemical steps. One of the 
biochemical steps important for the stability of clot formation is secretion of the dense granule 
which contains small molecules that are essential for autocrine and paracrine reinforcement of 
the platelet clot (including ATP, ADP, and 5-HT). PAR1-AP-mediated ATP secretion was 
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measured as a surrogate for dense granule secretion (Figure 8.3). Only the presence of increasing 
concentrations of 12(S)-HETrE resulted in complete inhibition of dense granule secretion clearly 
showing 12(S)-HETrE signals in a specific, dose-dependent manner, unlike the other metabolites 
tested. 
 
 
Figure 8.2 Fatty acid metabolites regulate platelet aggregation.  
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Washed human platelets were treated with or without increasing concentrations of the exogenously added fatty acid metabolites 
12(S)-HETrE, 12(S)-HEPE, 13(S)-HOTrE, or 12(S)-HETE. a) Representative curves for platelets treated with 20 µM PAR1-AP 
in the absence (control) or presence of each metabolite. The level of platelet aggregation was measured for 10 minutes post-
stimulation (N=3 for each condition). b) Composite for all replicates in the presence of increasing concentrations of each 
metabolite ranging from 0 to 80 µM (N=3). Replicates were graphed for the maximal level of platelet aggregation 10 minutes 
post-stimulation for each condition. *, P<0.05; ***, P=0.002. 
 
 
Table 8.3 Steady state kinetics of substrates.  
Kinetic measurements were measured in 25 mM HEPES buffer (pH 7.5) at room temperature. Error values are shown in 
parentheses. 
 
DGLA Inhibits PAR-Mediated Platelet Activation 
It is possible that although the bioactive metabolite 12(S)-HETrE inhibits platelet 
aggregation, the substrate responsible for its formation, DGLA, is not oxidized by 12-LOX in the 
platelet and therefore has no effect on platelet function. To confirm that the observed inhibition 
of platelet activation in the presence of 12(S)-HETrE is due to 12-LOX oxidation of DGLA, 5 
µM DGLA was added to washed platelets followed by addition of 20 µM PAR1-AP (Figure 
8.4a). When the platelets were incubated with DGLA for 10 minutes followed by addition of 
PAR1-AP, maximal platelet aggregation was attenuated and quickly reversed within 1 minute 
following addition of PAR1-AP. This observation is similar to an earlier study which showed 
that addition of DGLA to the human platelet resulted in a partial inhibition of collagen-mediated 
platelet aggregation 536. Likewise, DGLA completely inhibited PAR1-AP-mediated dense 
granule secretion similar to what was observed when treating platelets with the reduced 12-LOX 
oxidation product of DGLA, 12(S)-HETrE (Figures 8.2 and 8.3). Finally, to confirm DGLA 
regulates platelet aggregation in part through 12-LOX, washed platelets were stimulated with 
PAR1-AP following treatment with DGLA or DGLA in combination with baicalein (12-LOX 
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inhibitor) or aspirin. The absence of either 12-LOX or COX-1 activity resulted in a partial rescue 
of platelet aggregation (Figure 8.4a). 
 
Figure 8.3 Fatty acid regulation of platelet dense granule secretion.  
Washed human platelets were treated with or without increasing concentrations of the exogenously added fatty acid metabolites 
12(S)-HETrE, 12(S)-HEPE, 13(S)-HOTrE, or 12(S)-HETE. The maximal level of ATP secretion was measured post-stimulation 
(N=3 independent donors for each condition). *, P<0.05; **, P<0.01. 
 
12-LOX metabolite inhibition of ADP- and GPVI-induced platelet activation 
 To identify if 12-LOX eicosanoids produced from DGLA regulate platelet activation 
through multiple agonist pathways, platelets were treated with either 12(S)-HETrE or its 
peroxidated precursor, 12(S)-HPETrE, followed by stimulated with PAR1-AP, collagen, or ADP 
(Figure 8.4b-d). Similar to the observed sensitivity to 12(S)-HETrE in Figure 8.2, platelet 
aggregation induced by ADP and collagen were attenuated following treatment with 12(S)-
HETrE. Additionally, treatment with 12(S)-HPETrE significantly attenuated platelet aggregation 
following stimulation with ADP, collagen, or PAR1-AP (Figure 8.4b). To determine if these 
eicosanoids affected activation of the integrin αIIbβ3, an essential integrin in the activation of 
platelets, platelets treated with either eicosanoid were stimulated with ADP, PAR1-AP, or 
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convulxin (direct activator of the collagen receptor GPVI). αIIbβ3 activation was attenuated in 
the presence of either 12(S)-HETrE or 12(S)-HPETrE (Figure 8.4c). Finally, to identify if alpha 
granule secretion is affected by the presence of 12(S)-HETrE or 12(S)-HPETrE, P-selectin (a 
marker of alpha granule secretion) surface expression was measured following treatment with 
either eicosanoid (Figure 8.4d). Treatment with either eicosanoid attenuated alpha granule 
secretion following stimulation with ADP, PAR1-AP, or convulxin. While both metabolites 
attenuate platelet function, 12(S)-HPETrE was found to have a lower IC50 compared to 12(S)-
HETrE for inhibition of platelet aggregation (5 µM versus 40 µM, respectively). Considering the 
only difference between 12(S)-HPETrE and 12(S)-HETrE is the their oxidation state, it is 
possible that either the structural difference between the hydroperoxide and the alcohol affect 
receptor binding or that the increased reactivity of the hydroperoxide could generate a different 
species (i.e. oxidation to the ketone). These two explainations are currently being investigated 
further. 
 
Bioactive Metabolite Regulation of Rap1 Activity 
Platelet activation is regulated in large part by the small GTPase, Rap1 529. To identify if 12-
LOX metabolites from the various fatty acids regulate the level of Rap1 activation, washed 
platelets treated with or without 40 µM of each metabolite (12(S)-HETE, 12(S)-HETrE, 12(S)-
HEPE, or 13(S)-HOTrE) or 10 µM fatty acid (AA, DGLA, EPA, LA, or EDA) followed by 
stimulation with PAR1-AP for 5 minutes (Figure 8.5). The level of Rap1 activation was 
measured as a fold change relative to the unstimulated condition. While PAR1-AP induced a 
large increase in the level of active Rap1, treatment with 12(S)-HETrE prior to PAR1-AP 
stimulation fully inhibited Rap1 activation (Figure 8.5a). No significant difference in the level of 
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Rap1 activity was observed with the other metabolites tested (N=3). Similarly, when platelets 
were treated with fatty acids prior to stimulation with PAR1-AP, DGLA completely inhibited 
Rap1 activation while treatment with the other fatty acids did not appear to significantly alter the 
level of PAR1-AP-induced Rap1 activation (Figure 8.5b). 
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Figure 8.4 Agonist-independent regulation of platelet activity by 12-LOX metabolites.  
 
 
154 
a) Washed human platelets were treated with or without 5 µM DGLA for 10 minutes followed by stimulation with 20 µM PAR1-
AP (PAR1-AP) for 10 minutes. PAR1-AP induced an immediate and stable platelet aggregation when added to platelets. 
Addition of vehicle (DMSO) had no effect on platelet activation. Maximal and final platelet aggregation following treatment with 
DGLA was significantly attenuated. Additionally, treatment of DGLA resulted in inhibition of dense granule secretion in the 
presence of PAR1-AP (N=3). b) Platelet aggregation was measured following 10 minutes stimulation with PAR1-AP, 20 µM 
ADP, or 5 µg/ml collagen in the presence of 40 µM 12(S)-HPETrE or 40 µM 12(S)-HETrE (N=4-9). c) αIIbβ3 activation was 
measured by flow cytometry following 10 minutes stimulation with PAR1-AP, ADP, or 100 ng/ml convulxin in the presence of 
12(S)-HPETrE or 12(S)-HETrE (N=4-10). d) α-granule secretion was assessed by measuring P-selectin surface expression on the 
platelet by flow cytometry following 10 minutes stimulation with PAR1-AP, ADP, or 100 ng/ml convulxin in the presence of 
12(S)-HPETrE or 12(S)-HETrE (N=4-10). *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. 
 
DGLA and EPA Prevent Clot Retraction 
As Rap1 is an upstream regulator of integrin activation in platelets, we sought to 
determine if the fatty acids regulate integrin-dependent platelet-mediated clot retraction. To 
determine if any of the fatty acids play a role in clot retraction, which involves the consolidation 
of integrin-dependent retraction of platelets within the clot 537, platelet-rich-plasma (PRP) was  
treated with each fatty acid (Figure 8.6). 10 nM thrombin was added to the PRP for each 
condition in the presence or absence of 25 µM fatty acid (Figure 8.6a) and a picture of the clot 
was taken at several time points following stimulation. The size of the clot was quantified using 
NIH Image J software. The PRP clotted with thrombin in the absence of fatty acid within 60 
minutes. Following treatment with DGLA or EPA, clot retraction was significantly delayed and 
attenuated. However, pre-treatment with AA, LA, or EDA had no effect. To identify if DGLA 
inhibition of clot retraction was due to COX-1 or 12-LOX activity, platelets were treated with 
aspirin, 12(S)-HPETrE, aspirin + 12(S)-HPETrE, or aspirin + DGLA, followed by stimulation 
with thrombin (Figure 8.6b). Inhibition of COX-1 with aspirin did not significantly inhibit 
thrombin-induced clot retraction. Additionally, aspirin did not rescue clot retraction in the 
presence of DGLA. However, treatment with high concentration of 12(S)-HPETrE (200 µM) in 
the presence or absence of aspirin significantly inhibited thrombin-induced clot retraction 
suggesting that 12-LOX oxidation of DGLA plays at least a partial role in DGLA inhibition of 
platelet clot retraction. 
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Figure 8.5 12-LOX metabolite regulation of Rap1.  
Washed platelets were treated with 12-LOX metabolites or various fatty acids for 10 minutes prior to stimulation with 20 µM 
PAR1-AP in order to determine their regulatory effects on the level of PAR1-AP-mediated Rap1 activation. a) Platelets were 
treated with or without 40 µM 12(S)-HETrE, 12(S)-HETE, 12(S)-HEPE, or 13(S)-HOTrE for 10 minutes. Following 12-LOX 
metabolite treatment, Rap1 activation was measured after stimulation with PAR1-AP for 5 minutes (N=3 independent 
experiments). PAR1-AP alone induced a significant increase in Rap1-GTP levels. Treatment with 12(S)-HETrE significantly 
attenuated PAR1-AP-induced Rap1 activation. Treatment with 12(S)-HETE, 12(S)-HEPE, or 13(S)-HOTrE had no significant 
effect on PAR1-AP-induced Rap1 activation. b) Platelets were treated with or without 10 µM AA, DGLA, EPA, LA, or EDA for 
10 minutes. Following fatty acid treatment, Rap1 activation was measured after stimulation with PAR1-AP for 5 minutes (N=6). 
Treatment with DGLA and EPA significantly attenuated PAR1-AP-induced Rap1 activation. Treatment with AA, LA, or EDA 
had no significant effect on the level of Rap1 activity. *, P < 0.05. This figure was co-provided by Jennifer Yeung and Joanne 
Vesci 
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8.5 Discussion 
Although fatty acid regulation of hemostatic function, including platelets, has been studied by 
various research groups 519, a consensus is lacking on the importance of fatty acid intake to the 
role of platelets in regulating hemostasis. This is in part due to the small number of studies, small 
number of subjects in each study, and the differences in study design between research groups. 
However, human subject studies support an important role in the type of fatty acid supplemented 
in the diet to overall regulation in platelet function and hemostasis 518,538. GLA supplementation 
has been shown to increase DGLA content in the serum by 3-fold, as GLA is quickly converted 
to DGLA enzymatically 518. While a significant increase in the amount of DGLA was shown to 
be incorporated into the neutrophil membrane, no observable change in AA was measured 
suggesting DGLA incorporation does not displace AA on the membrane 518.  
DGLA was initially identified as a fatty acid which produced potentially inhibitory 
metabolites such as PGE1 through COX-1 and 12(S)-HETrE through 12-LOX 539,540. Although 
PGE1 is known to be a potent anti-platelet eicosanoid, its role in platelet function deriving from 
DGLA as a substrate is controversial with research groups identifying that while PGE1 and 
thromboxane B1 are produced by DGLA through COX-1, their levels are much smaller than that 
of 12-hydroxyheptadecadienoic acid and may not play a significant role in DGLA-induced 
inhibition of platelet activity 277,536. 12(S)-HETrE formation through 12-LOX oxidation of 
DGLA, which has not been as widely studied, was shown here to play an important role in 
DGLA-mediated inhibition of platelet function by significantly attenuating a number of 
biochemical endpoints. Hence, inhibitory activity of DGLA is mediated through a number of 
eicosanoids produced from both 12-LOX and COX-1 and formation of these metabolites results 
in attenuation of agonist-induced platelet activation.  
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Polyunsaturated fatty acid content in the platelet membranes varies, depending on diet. The 
most abundant phospholipid in the platelet is phosphatidylcholine, containing a number of 
polyunsaturated fatty acids (PUFAs) including AA (13.5%), LA(7.9%), DGLA (2.1%), EDA 
(0.6%), docosahexaenoic acid (DHA) (0.6%), EPA (0.2%), ALA (0.1%), and gamma-linolenic 
acid (GLA) (0.07%) 517. Our laboratories investigated the kinetic and biological effects of these 
fatty acids as potential 12-LOX substrates. Other PUFAs found in the platelet such as DHA and 
GLA, displayed multiple enzymatic products and due to this complexity will be the subject of 
subsequent investigations. From this work, it was determined that 12-LOX has selective 
substrate preferences, with two fatty acids not being substrates (LA and EDA) and 4 producing 
only one oxygenated fatty acid (AA, DGLA, ALA, EPA). The fatty acids with 20 carbon atoms 
and more than 2 sites of unsaturation had the fastest kcat/KM values. These relative kinetic values 
can be directly related to fatty acid metabolism in the platelet, where substrate concentration is 
low. ALA is 10-fold slower than the other four fatty acid substrates, which could be indicative of 
a distinct binding mode. In analysis of the placement of these substrates in the active site, with 
the substrate binding methyl-end first, as previously determined 531, there is no activated 
methylene close to the iron-hydroxide moiety for LA, ALA and EDA (Figure 8.1). This is in 
contrast to what is seen for AA, DGLA, and EPA, where an activated methylene is located in 
close proximity to the iron. Therefore, to position the C10 of ALA close to the iron to generate 
the 13-product, the substrate would have to be inserted only partially into the active site. In 
contrast, 12-LOX does not react with LA, so it appears that the additional ω-3 unsaturation for 
ALA affects its positioning in the active site, possibly by allowing the carboxylate or pi-bond 
active site interaction to supersede the methyl-end active site interaction 541, leading to partial 
insertion of ALA into the active site. Another possible explanation could be that ALA binds in 
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the opposite direction, with its carboxylate moiety entering the active site first producing the R-
isomer of the product, which has been previously seen with soybean LOX-1 542. This hypothesis, 
however, is unlikely since only the S-isomer of 13(S)-HPOTrE is observed, which supports the 
partial substrate active site insertion hypothesis.  
In addition to being catalyzed at different rates, the effects of these 12-LOX products on the 
platelets were also markedly different. Following treatment with PAR1-AP, 12(S)-HETrE 
significantly attenuated platelet aggregation, the release of ATP, and Rap1 activation at 40 µM 
concentration. This result is in contrast to comparable concentrations of 12(S)-HETE, where 
agonist-mediated aggregation and ATP release were potentiated, suggesting a substrate specific 
regulation of 12-LOX in platelet reactivity. Under ex vivo conditions, platelets spiked with high 
levels of DGLA or its 12-LOX metabolites inhibited platelet activation following stimulation 
with a number of agonists. While it may be possible to reach circulating fatty acid concentrations 
of 40 µM following fatty acid supplementation 534, it is unlikely that all of the DGLA would be 
incorporated into the platelet membrane and converted by 12-LOX to 12(S)-HETrE as several 
12-LOX products have been previously identified through catalysis of DGLA 540.  Further, the 
readout of these assays may be overestimated due to the fact that endogenous AA is present in 
the platelet leading to production of 12(S)-HETE. The endogenous 12(S)-HETE could then 
compete with the exogenous 12(S)-HETrE, thus counterbalancing both of their effects and 
dampening the inhibitory effect of 12(S)-HETrE on the platelet. Nonetheless, 12(S)-HPETrE is 
over 8-fold more potent than that of 12(S)-HETrE, making its concentration biologically 
relevant. However, due to the high level of peroxidases present in the platelet, the biological 
effect of 12(S)-HPETrE on the platelet clot may be limited to localized regions of metabolite 
production. Taken together, these observations further support a potential role for unique pools 
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of AA and DGLA in the platelet which are independently regulated to mediate either a pro-
thrombotic or anti-thrombotic environment dependent on a number of factors including 12-LOX 
localization, fatty acid compartmentalization and specific agonist used 398. 
The mechanism by which these fatty acids regulate platelet function through catalysis by 12-
LOX is not well understood. While the receptor for 12(S)-HETE has been recently identified 543, 
the underlying mechanism by which other metabolites, such as 12(S)-HETrE, regulate the 
platelet are unknown. Here we have shown that 12(S)-HETrE, as well as its substrate, DGLA, 
inhibit Rap1 activation. Rap1 is an essential GTPase involved in regulation of platelet function 
and inhibiting its activation in the presence of a strong activating agonist such as PAR1-AP 
suggests an important regulatory role for 12-LOX metabolites such as 12(S)-HETrE in mediating 
this process. Our previous work showing direct inhibition of 12-LOX activity attenuates calcium 
mobilization 507, a key step in activation of Rap1, further supports a role for 12-LOX products in 
regulation of platelet function through Rap1. Additionally, since Rap1 is known to be important 
for integrin activation, it is not surprising that addition of DGLA results in attenuation of 
thrombin-induced clot retraction 530. Finally, 12-LOX metabolite formation from catalysis of 
DLGA attenuates platelet aggregation, integrin αIIbβ3 activation, and alpha granule secretion. 
Inhibition of these biochemical endpoints in the presence of 12(S)-HPETrE and 12(S)-HETrE 
supports a potentially protective role for 12-LOX metabolites in preventing unwanted platelet 
activation resulting in occlusive thrombotic events. As both the peroxidated and non-peroxidated 
products of DGLA attenuate platelet function and DGLA inhibition of platelet activity is 
stronger than either of the 12-LOX products, it is likely that multiple 12-LOX-dependent and 
independent products of DGLA are involved in protection against platelet activation and 
thrombosis 540,544,545. 
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It has long been postulated that fatty acid content in the diet can affect human health 546. 
Dietary fatty acid formulation has been shown to inhibit leukotriene biosynthesis 547 and DGLA 
specifically can be converted to the anti-inflammatory prostaglandin, PGE1, by COX 548, which 
is implicated in the inhibition of platelet activation 545 and in diminishing atherosclerosis 549,550 
and ocular discomfort symptoms 551. In this study, we have shown a direct anti-platelet 
phenotype of the 12-LOX product of DGLA, which supports the role of this and potentially other 
fatty acids as protective agents against unwanted platelet activation and thrombosis. Considering 
the recent de-orphanization of GPR31 as the 12(S)-HETE receptor 543, the data presented here 
supports the possibility that a unique receptor may exist on the surface of the platelet which, like 
PGE1, may act as a protective signal inhibiting excessive platelet activation and thrombosis. 
Given the similar 12-LOX kinetics against AA and DGLA and the fact that the concentration of 
DGLA can become elevated in the blood with specific diets 518,552, it is possible that the level of 
coagulation and thrombosis in circulating blood could be regulated in part by modifications in 
the diet 553,554. Currently, we are testing this hypothesis in animal models in the hopes of 
confirming both the beneficial and detrimental roles of 12-LOX in blood coagulation as well as 
the level of metabolite produced in vivo. 
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Figure 8.6 Fatty acid regulation of platelet-mediated clot retraction.  
Platelet rich plasma (PRP) was treated with fatty acids, inhibitors, or eicosanoids followed by stimulation with thrombin. The rate 
at which thrombin caused a platelet-dependent clot retraction of the PRP was determined. Pictures were taken at several time 
points following stimulation (0, 30 minutes, 60 minutes, and 90 minutes). The size of the clot was quantified using NIH Image J. 
PRP formed a complete clot retraction within 60 minutes without fatty acid treatment. a) PRP treated with 25 µM fatty acid (AA, 
DGLA, EPA, LA, or EDA) followed by stimulation with 10 nM thrombin. The rate of clot retraction was not affected by 
treatment with AA, LA, or EDA, but was significantly attenuated by DGLA and EPA (N=4-6). b) PRP treated with 100 µM 
aspirin for 40 minutes, 25 µM DGLA for 10 minutes, or 200 µM 12(S)-HPETrE for 10 minutes, were stimulated with thrombin 
(N=3-5).  NS= not significant; ***, P<0.001; ****, P<0.0001. This figure was provided by Joanne Vesci.  
 
 
162 
CHAPTER 9 
 
12-HETrE, a 12-Lipoxygenase Oxylipin of Dihomo-γ-Linolenic Acid, Inhibits Thrombosis 
via Gα s Signaling in Platelets 
 
9.1 Summary 
Dietary supplementation with polyunsaturated fatty acids (PUFAs) has been widely used for 
primary and secondary prevention of CVD in individuals at risk; however, the cardioprotective 
benefits of PUFAs remain controversial due to lack of mechanistic and in vivo evidence. We 
present direct evidence that an omega-6 PUFA, dihomo-γ-linolenic acid (DGLA), exhibits in 
vivo cardioprotection through 12-lipoxygenase (12-LOX) oxidation of DGLA to its reduced 
oxidized lipid form, 12(S)-HETrE, inhibiting platelet activation and thrombosis. 
DGLA inhibited ex vivo platelet aggregation and Rap1 activation in wild-type mice, but not in 
mice lacking 12-LOX expression (12-LOX-/-). Similarly, wild-type mice treated with DGLA 
were able to reduce thrombus growth (platelet and fibrin accumulation) following laser-induced 
injury of the arteriole of the cremaster muscle, but not 12-LOX-/- mice, supporting a 12-LOX 
requirement for mediating the inhibitory effects of DGLA on platelet-mediated thrombus 
formation. Platelet activation and thrombus formation were also suppressed when directly treated 
with 12(S)-HETrE. Importantly, two hemostatic models, tail bleeding and arteriole rupture of the 
cremaster muscle, showed no alteration in hemostasis following 12(S)-HETrE treatment. Finally, 
the mechanism for 12(S)-HETrE protection was shown to be mediated via a Gαs-linked GPCR 
pathway in human platelets. 
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This study provides the first direct evidence that an omega-6 PUFA, DGLA, inhibits injury-
induced thrombosis through its 12-LOX oxylipin, 12(S)-HETrE, which strongly supports the 
potential cardioprotective benefits of DGLA supplementation through its regulation of platelet 
function. Furthermore, this is the first evidence of a 12-LOX oxylipin regulating platelet function 
in a Gαs-linked GPCR-dependent manner. 
9.2 Introduction  
 Platelet activation plays a critical role in the thrombotic complications associated with 
life-threatening cardiovascular ischemic events, such as myocardial infarction and stroke. 
Inhibiting platelet activation in individuals at risk for thrombotic events through the use of 
aspirin and P2Y12 receptor antagonists has significantly decreased morbidity and mortality 
associated with these debilitating conditions 555,556. Nonetheless, the fact that the rate of ischemic 
events still remains high in individuals on antiplatelet agents 557 stresses the need to investigate 
alternative therapies that reduce occlusive thrombotic events without promoting an increased risk 
of bleeding. Dietary supplementation with polyunsaturated fatty acids (PUFAs) are commonly 
used for their potential cardioprotective effects including their antiplatelet effects; but, the 
evidence supporting this claim in vivo remains unclear. 
 Dihomo-γ-linolenic acid (DGLA), an ω-6 polyunsaturated fatty acid (PUFA), has been 
suggested to play a role in inhibiting platelet aggregation ex vivo 545,558,559. While these studies 
support DGLA as a potential inhibitor of platelet function, the underlying mechanism by which 
DGLA elicits its antiplatelet effect and the in vivo relevance of this inhibition have remained 
elusive. PUFAs are primarily thought to exert their regulatory effects on platelet function 
through their conversion into bioactive lipids (oxylipins) by oxygenases 281. In platelets, DGLA 
can be oxidized by cyclooxygenase-1 (COX-1) or platelet 12-lipoxygenase (12-LOX) 540 
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following its release from the phospholipid bilayer predominately through the actions of 
cytoplasmic phospholipase A2 560,561. While both COX-1 and 12-LOX are able to oxidize DGLA 
to their respective metabolites, the relative contributions of these oxylipin products to the 
inhibitory effects of DGLA on platelet function remain unclear. Further, the antiplatelet effects 
of DGLA have been primarily attributed to the COX-1-derived metabolites that have been shown 
to inhibit platelet activation 545,558,559,562.  However, the DGLA derived products of COX-1 
(TXA1 and PGE1) are liable and produced in low amounts in platelets 277,563-565. Additionally, a 
recent study demonstrated for the first time that 12(S)-hydroxyeicosatetrienoic acid (12-HETrE), 
the 12-LOX-derived oxylipin of DGLA, exhibits a potential antiplatelet effect ex vivo 333. Hence, 
it is important to delineate if 12-LOX is required for DGLA-mediated inhibition of platelet 
function in vivo and whether DGLA and 12-HETrE play an essential role in regulation of 
thrombosis.  
This study showed for the first time that an ω-6 PUFA, DGLA, inhibited platelet 
thrombus formation in vivo following an insult to the vessel wall. Interestingly, DGLA was 
unable to inhibit thrombus formation in 12-LOX-/- mice suggesting the antithrombotic effects of 
DGLA were mediated by 12-LOX. The 12-LOX-derived oxylipin of DGLA, 12-HETrE, potently 
impaired thrombus formation following vessel injury irrespective of 12-LOX expression. 
Importantly, the antithrombotic effects of 12-HETrE did not disrupt primary hemostasis or result 
in increased bleeding. Finally, the antiplatelet effect of 12-HETrE was delineated here for the 
first time and shown to inhibit platelet function through activation of the Gαs signaling pathway 
leading to formation of cAMP and PKA activation in the platelet. Hence, these findings are the 
first to demonstrate an antithrombotic role of DGLA 12-HETrE at both the mechanistic and in 
vivo levels. 
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9.3 Materials and Methods 
Preparation of washed murine platelets. The 12-LOX null C57BL/6 (12-LOX-/-) mice, generated 
using homozygous breeding pairs, and wild-type (WT) C57BL/6 (12-LOX+/+) mice were 
purchased from Jackson Laboratory. The Institutional Animal Care and Use Committees 
(IACUC) at the University of Michigan and Thomas Jefferson University approved all 
experimental procedures in this study involving mice. Blood was drawn from the inferior vena 
cava of anesthetized 8-12 week old mice with a 21-gauge needle attached to a 1 mL syringe 
containing 100 µl of 3.8% sodium citrate. Mouse blood was diluted with equal volumes of 
Tyrode’s buffer and centrifuged at 200 g. Platelet-rich-plasma (PRP) was transferred to a tube 
containing 10x acid citrate dextrose solution (ACD) and apyrase (.02 U/mL) and centrifuged at 
2000 g. Platelet count was adjusted to 3x108 platelets/mL with Tyrode’s buffer for all studies.    
Preparation of washed human platelets.  University of Michigan and Thomas Jefferson 
University Institutional Review Boards approved all protocols involving human subjects.  In 
accordance with the Declaration of Helsinki, written informed consent was obtained from 
healthy donors prior to each blood draw. Blood was collected as previously described 333 and 
washed platelets were resuspended in Tyrode’s buffer at 3x108 platelets/mL, unless otherwise 
specified. 
Extraction, liquid chromatography, and mass spectrometry (LC/MS) quantification of oxylipins. 
Washed human platelets were treated with agonists in the presence of vehicle control or specific 
fatty acids and acidified with 40 µL of 1M hydrochloric acid to pH of 3. Extraction standards 
were then added to the samples: 20ng each of PGE1-d4 and 13(S)HODE-d4. Oxylipids were 
extracted with dichloromethane, reduced with trimethylphosphite, and dried under nitrogen gas. 
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The samples were reconstituted in methanol containing 10 ng of each of the internal standards 
and transferred to MS vials with inserts.  
Chromatographic separation was performed on a Dionex UltiMate 3000 UHPLC with a C18 
column (1.7 µm, 150 mm x 2.1mm). The autosampler was held at 4oC and injection volume was 
30 µL. Mobile phase A consisted of water with 0.1% (v/v) formic acid and mobile phase B was 
acetonitrile with 0.1% formic acid. Flow rate was 0.400mL/min. The initial condition (30% B) 
was maintained for 2.33 minutes. Mobile phase B was then ramped to 65% over 28.67 minutes, 
held at 65% for 1 minute, ramped to 100% over 0.1min, held at 100% for 7 minutes, and finally 
returned to 30% to equilibrate for 7 minutes. The chromatography system was coupled to a Velos 
Pro linear ion trap for mass analysis. Analytes were ionized via heated electrospray ionization 
with -4.0kV spray voltage, 60, 10, and 0 arbitrary units for sheath, auxiliary, and sweep gas, 
respectively. All analyses were performed in negative ionization mode at normal resolution 
setting. MS2 was performed in both a data dependent and targeted manner, simultaneously from 
ions detected in a full scan with a mass-to-charge ratio (m/z) range of 200-400. The targeted MS2 
were selected for the parent ions of the analytes that were contained in a mass list –TxB1(m/z = 
371.2), TxB2(m/z = 369.2), TxB2-d4(m/z= 373.3), PGE1(m/z = 353.2), PGE2(m/z = 351.2), 
PGE1-d4(m/z = 357.2), PGE2-d4(m/z = 355.2), 12HETE(m/z = 319.2) , 12HETrE(m/z =321.2), 
12(S)HETE-d8(m/z = 327.3), 13(S)HODE-d4(m/z = 299.3).       
Mass spectrometry analysis, normalization, and relative quantitation of oxylipins. Retention 
times and fragmentation patterns of all analytes were determined with lipid standards prior to 
sample analyses. Total ion counts (TIC) of the m/z transitions of each analyte peak were used for 
relative quantitation. The m/z transitions of all analytes and standards were as follows: TxB1(m/z 
= 371.2à197), TxB2(m/z = 369.2à195), TxB2-d4(m/z= 373.3à199), PGE1(m/z = 353.2à317), 
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PGE2(m/z = 351.2à315), PGE1-d4(m/z = 357.2à321), PGE2-d4(m/z = 355.2à319), 
12HETE(m/z = 319.2à179) , 12HETrE(m/z =321.2à181), 12(S)HETE-d8(m/z = 327.3à184), 
and 13(S)HODE-d4(m/z = 299.3à198). Nanograms of 12-HETE and 12-HETrE present in 
sample were estimated based on TICs of 12-HETE and 12-HETrE relative to the TIC of 10 ng of 
12-HETE-d8. These nanogram estimates were then corrected for extraction efficiency by the 
percent recovery of 13-HODE-d4 in each sample. The TIC of TxB1, TxB2, PGE1, and PGE2 were 
normalized to PGE1-d4 for extraction. For ionization, TxB1 and TxB2 were normalized to TxB2-
d4, and PGE1 and PGE2 were normalized to PGE2-d4.  
Platelet aggregation. A lumi-aggregometer (Chrono-log model 700D) was used to measure 
platelet aggregation under stirring conditions (1100 rpm) at 37°C. Prior to agonist stimulation 
platelets were incubated with a preselected PUFA or oxylipin for 10 minutes.  
Rap1 activation. Washed platelets were incubated with PUFAs or oxylipins for 10 minutes prior 
to stimulation with PAR4-AP. Following 1 minute of stimulation, platelets were lysed and Rap1 
activity was assessed by western blot analysis as previously described333.  
Laser-induced cremaster arteriole thrombosis model. WT or 12-LOX-/- mice (12 weeks of age) 
were anesthetized by intraperitoneal injection of ketamine/xylazine (100 mg/kg) prior to the 
exposure of the cremaster muscle arterioles under a dissecting microscope with constant 
perfusion of preheated bicarbonate-buffered saline566-568. Anti-platelet (DyLight 488 anti-GPIb, 1 
µg/g) and anti-fibrin (Alexa Fluor 647, 0.3 µg/g) antibodies were administered via jugular vein 
catheter prior to intravital microscopy. DGLA or DMSO were dissolved in a formulation of 5% 
DMSO and 45% PEG300 in sterile 1X PBS and intravenously injected into mice 10 minutes 
prior to induction of thrombosis. 12-HETrE or equal volume of DMSO was intravenously 
injected into mice 10 minutes prior to induction of thrombosis. Multiple thrombi were induced in 
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the arterioles (30-50 µm diameter) in each mouse by a laser ablation system (Ablate! photo-
ablation system; 3I). Images of thrombus formation were acquired in real-time under 63X water-
immersion objective with a Zeiss Axio Examiner Z1 fluorescent microscope equipped with solid 
laser launch system and high-speed sCMOS camera. All captured images were analyzed on 
Slidebook. 
Tail bleeding assay. Mice were anesthetized with ketamine/xyzaline and placed on a heating pad 
in prone position, the tip of the tail (5 mm) was excised with a sterile scalpel, and the tails were 
immediately immersed into isotonic saline solution (.9%) warmed to 37°C. Bleeding time was 
assessed until cessation of blood flow from the tail for 1 minute.  
Cremaster muscle arterial puncture model of hemostasis. Mice were anesthetized, tail vein 
injected with anti-platelet and anti-fibrin antibodies and their cremaster muscle arterioles were 
prepared as described above.  A high intensity laser pulse from the laser ablation system was 
used to puncture a hole in the cremaster muscle arteriole wall as visualized by red blood cell 
(RBC) leakage from the vessel. Images of RBCs leakage and hemostatic plug formation were 
acquired in real-time with a fluorescent microscope as described above. Arterial bleeding time 
was defined as the time from laser pulse injury until cessation of RBC leakage from the vessel. 
Liquid chromatography extraction and mass spectrometry (LC/MS) quantification of cAMP. 
Washed human platelets were treated with the specific ligand or vehicle control for 1 min at 
room temperature, and quenched with an equal volume of ice-cold 2x platelet lysis buffer 
containing protease and phosphatase inhibitors. Lysed platelet samples were centrifuged to pellet 
cytoskeleton and the supernatant was stored in -80°C.  
To prepare the sample for LC/MS injection, 200 µL of the supernatant were spiked with 400 pg 
of adenosine-3’,5’-cyclic-13C5 monophosphate (13C5-cAMP) and 600 µL of LC/MS grade 
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acetonitrile. The sample was vortexed and centrifuged for 10 min. The supernatants were dried 
and reconstituted in 200 µL of LC/MS grade water, centrifuged for 5 min at 4°C, and used for 
LC/MS injection.  
The separation and detection of cAMP was performed on a Waters ACQUITY UPLC 
system equipped with a Xevo Triple Quadrupole Mass Spectrometer (TQ-S MS/MS). The 
extraction/purification of cAMP from the sample was carried out using a Waters HSS C18 
column (1.8 µm, 2.1*100mm). The sample (10 µL) was then injected. 
The mass spectrometer was operated with an ESI source in positive mode. The 
electrospray voltage was 3.9kv. The source temperature was maintained at 150°C, and the 
desolvation temperature was 525 °C with a nitrogen desolvation gas flow of 1000L/h.  cAMP 
was quantitated using 13C5-cAMP as the internal standard. For cAMP monitoring in the MRM 
mode with a collision energy of 22 volts, 330/136 mass transition was used, and for 13C5-cAMP, 
335/136 was used. 
VASP phosphorylation in human platelets. Washed platelets were treated with PUFA or PUFA 
metabolite for one minute then directly lysed in 5x Laemmeli sample buffer. The samples were 
boiled for five minutes and assayed by western blot for total and phospho-VASP (serine 157).  
Membrane preparation and [35S]GTPγS binding. PRP was isolated from whole blood as 
described above and incubated with 1 mM aspirin for 1 hour at 37°C. Washed platelets were 
prepared as previously described. The platelets were flash frozen with liquid nitrogen and 
resuspended in cold detergent-free TME buffer (50 mM Tris-HCl, pH 7.5, 20 mM MgCl2, 2 mM 
EDTA, and 100 mM NaCl) with 1 µM GDP and protease and phosphatase inhibitors to lyse the 
platelets. The lysed platelets were centrifuged at 1500 g at 4°C for 5 min. The supernatant was 
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collected and centrifuged at 100,000 g for 30 min at 4°C. The pelleted membranes were 
resuspended in TME buffer with 1 µM GDP and stored at -80°C prior to use.  
Fatty acid metabolites, agonists, or DMSO and [35S]GTPγS (10 nM) were added to 
platelet membranes and the tubes were immediately transferred to a 30°C water bath shaker for 
20 min. The reaction was terminated by the addition of ice-cold IP buffer (50 mM Tris-HCl, pH 
7.5, 20 mM MgCl2, 150 mM NaCl, .5% Nonidet P-40, .33% aprotinin, .1 mM GDP, and .1 mM 
GTP). The samples were pre-cleared with Protein A agarose beads and normal rabbit IgG and 
aliquoted equally into two tubes containing either normal rabbit IgG or a Gas antibody that had 
been conjugated to Protein A agarose beads.  The samples were incubated on a nutator for 1 hr at 
4°C and washed 4 times with IP buffer and 1 time in TME buffer. The samples were boiled in 
.5% SDS for 30 sec and the supernatants were collected following brief centrifugation. The 
supernatants were analyzed in 8 mL of scintillation fluid. The background counts for the normal 
rabbit IgG (50-200 cpm) for each sample were subtracted from the anti-Gs immunoprecipitated 
samples prior to analyzing the data. 
Statistics. Unpaired, paired two-tailed student t-tests, and two-way analysis of variance 
(ANOVA) were used to compare between experimental groups with Prism 6.0 software 
(GraphPad). Where appropriate the statistical test used is contained in the figure legend. Data 
represents mean values +/- SEM.  
9.4 Results 
DGLA inhibits platelet aggregation and thrombus growth in a 12-LOX dependent manner 
Treatment of human platelets with either DGLA 545,558,559 or its 12-LOX-derived metabolite, 12-
HETrE, potently inhibited platelet aggregation 333; however, the relative contribution of 12-LOX 
to DGLA-mediated inhibition of platelet activation was unclear. To assess the role of 12-LOX in 
 
 
171 
DGLA-mediated platelet inhibition, washed platelets from WT or 12-LOX-/- mice were 
stimulated with an EC80 concentration of either protease-activated receptor-4-activating peptide 
(PAR4-AP) or collagen in the presence or absence of DGLA. As previously reported, platelets 
from 12-LOX-/- mice were hypoactive compared to platelets from WT mice 325, hence, requiring 
a higher concentration of agonist to reach EC80. Pretreatment of platelets from WT mice with 
DGLA resulted in significant inhibition of aggregation compared to DMSO treated platelets in 
response to PAR4-AP or collagen stimulation (Figure 9.1A and 9.1B). Conversely, DGLA 
treatment of platelets from 12-LOX-/- mice failed to inhibit platelet aggregation in response to 
PAR4-AP or collagen stimulation (Figure 9.1A and 9.1B). To fairly compare the concentrations 
of the higher PAR4-AP concentration used on 12-LOX-/- platelets, WT platelets treated with 
DGLA were also stimulated with higher PAR4-AP concentration, resulting in significant 
inhibition of platelet aggregation compared to vehicle control (data not shown).   As the observed 
DGLA-mediated inhibition of aggregation may be due to the modification of the lipid membrane 
structure thus affecting platelet signaling or activation, other PUFAs including linoleic acid (LA) 
and AA were used as controls to rule out a lipid-membrane insulating effect in platelet activation 
569. Pretreatment of platelets with either LA or AA had no inhibitory effect on PAR4-AP or 
collagen-mediated platelet aggregation compared to vehicle alone (Figure 9.1A and 9.1B).  
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Figure 9.1 12-LOX is required for DGLA inhibition of platelet aggregation and thrombus formation.  
Representative tracings and combined aggregation data of (A) WT (n=4) or (B) 12-LOX-/- (n=4) platelets stimulated with EC80 
concentration of PAR4-AP (WT 100 µM; 12-LOX-/- 200 µM) or collagen (WT 5 µg/mL; 12-LOX-/- 2 or 5 µg/mL) in the 
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presence or absence of 10 µM of PUFAs (DGLA, AA, or LA). Aggregation was monitored for 10 minutes. Data represents mean 
± SEM. *P<.05 two-tailed unpaired t-test.  (C) Active Rap1 (Rap1-GTP) was selectively precipitated from the lysates of platelets 
isolated from WT or 12-LOX-/- mice incubated with vehicle control or 10 µM DGLA (n= 3 to 4 mice) prior to stimulation with 
increasing concentrations of PAR4-AP (50, 100, and 200 µM). Active Rap1 was normalized to the total amount of Rap1 in each 
sample, and each bar graph represents a percentage of vehicle control for each PAR4-AP concentration. Data represent mean ± 
SEM. **P<.01, ***P<.001 two-tailed unpaired t-test. (D) Representative images of laser-induced injury of the cremaster 
arterioles, platelet (green) and fibrin (red) accumulation monitored in real-time to assess thrombus growth in the WT vehicle 
control (n=3 mice, 10-15 thrombi per mouse), DGLA treated group (n=3 mice, 10-15 thrombi per mouse), 12-LOX-/- vehicle 
control (n=3 mice, 10-15 thrombi per mouse), and 12-LOX-/- treated with DGLA (n=3 mice, 10-15 thrombi per mouse). Scale 
bar: 40 µm. Mean fluorescence intensity (MFI) of platelet and fibrin accumulation at the site of injury were recorded over time in 
(E) WT and (F) 12-LOX-/- mice. Data represents mean ± SEM; two-way ANOVA. This figure was co-provided by Jennifer 
Yeung (aggregation and Rap1) and Dr. Reheman Adili (in vivo thrombosis). 
 
 To determine if DGLA inhibited platelet aggregation by impinging on intracellular 
signaling, the activation of Rap1, a common signaling effector required for integrin αIIbβ3 
activation (Shattil et al., 2010; Shattil and Newman, 2004) was assessed in DGLA treated 
platelets stimulated with PAR4-AP 8,328,570. In platelets isolated from WT mice, DGLA inhibited 
Rap1 activation at all concentrations of PAR4-AP tested (Figure 9.1C). Since DGLA was unable 
to inhibit platelet aggregation in 12-LOX-/- mice, we assessed if 12-LOX was also necessary for 
DGLA inhibition of Rap1 activation in platelets. Consistent with the platelet aggregation data, 
DGLA was unable to inhibit Rap1 activation in platelets from 12-LOX-/- mice at any of the 
concentrations of PAR4-AP tested (Figure 9.1C). Together, these data demonstrate that the 
antiplatelet effects mediated by DGLA require 12-LOX.  
 To determine whether the antiplatelet effects of DGLA observed ex vivo could 
contribute to the inhibition of platelet thrombus formation in vivo, a laser-induced cremaster 
arteriole thrombosis model was employed to examine thrombus formation (platelet and fibrin) in 
WT mice 571 (Figure 9.1D-F). Mice were intravenously injected with either vehicle control 
(DMSO) or 50 mg/kg of DGLA 10 minutes prior to the initiation of thrombosis by laser injury. 
Following vessel injury of vehicle control treated WT mice, fluorescently labeled platelets 
rapidly accumulated at the site of vascular injury then drastically diminished in size as the clot 
was resolved (Figure 9.1D and 9.1E; and Supplementary video 1). Simultaneously, fibrin  
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Figure 9.2 12-HETrE inhibits platelet aggregation and thrombus formation.  
Representative tracings and combined aggregation data of washed platelets from (A) WT (n=4) or (B) 12-LOX-/- (n=4) mice pre-
treated with 25 µM 12-LOX oxylipins (12-HETrE, 12-HETE, or 12-HEPE) for 10 minutes prior to stimulation with an EC80 
 
 
175 
concentration of PAR4-AP (WT 100 µM; 12-LOX-/- 200 µM) or collagen (WT 5 µg/mL; 12-LOX-/- 2 or 5 µg/mL) in an 
aggregometer.  Data represents mean ± SEM. *P<.05 two-tailed unpaired t-test. (C) Active Rap1 (Rap1-GTP) was selectively 
precipitated from the lysates of platelets isolated from WT or 12-LOX-/- mice incubated with vehicle control or 25 µM 12-HETrE 
(n= 3 to 4 mice) prior to stimulation with increasing concentrations of PAR4-AP (50, 100, and 200 µM). Active Rap1 was 
normalized to the total amount of Rap1 in each sample, and each bar graph represents a percentage of vehicle control for each 
PAR4-AP concentration. Data represent mean ± SEM. *P<.05 , **P<.01, ***P<.001 two-tailed unpaired t-test. (D) 
Representative images of laser-induced injury of the cremaster arterioles, platelet (green) and fibrin (red) accumulation monitored 
in real-time to assess thrombi growth in the WT vehicle control (n=3 mice, 10-15 thrombi per mouse), 12-HETrE treated group 
(n=3 mice, 10-15 thrombi per mouse, 10-15 thrombi per mouse), 12-LOX-/- vehicle control (n=3-4 mice, 10-15 thrombi per 
mouse), and 12-LOX-/- treated with 12-HETrE (n=3 mice, 10-15 thrombi per mouse). 12-LOX-/- vehicle control data is the same 
set as 12-LOX-/- vehicle control used for 12-LOX-/- DGLA treated comparison in figure 1F. Scale bar: 40 µm. Mean fluorescence 
intensity (MFI) platelet and fibrin accumulation at the site of injury were recorded over time in (E) WT and (F) 12-LOX-/- mice. 
Data represents mean ± SEM; two-way ANOVA.  This figure was co-provided by Jennifer Yeung (aggregation and Rap1) and 
Dr. Reheman Adili (in vivo thrombosis). 
formation can be seen at the base of the developing thrombus of vehicle control treated WT mice 
(Figure 9.1D and 9.1E; and Supplementary video 1). WT mice treated with DGLA showed a 
significant reduction in platelet, but not fibrin accumulation (Figure 9.1D and 9.1E; and 
Supplementary video 2). 
 Figures 9.1A-C suggests a requirement for 12-LOX in DGLA-mediated inhibition of 
platelet activation ex vivo. To determine if this observation translates to an attenuation of platelet 
reactivity in vivo, thrombus formation was measured in 12-LOX-/- mice following laser-induced 
injury of the cremaster arteriole (Figure 9.1D and 9.1F). As previously reported, platelets from 
12-LOX-/- mice exhibited a bleeding diathesis compared to WT mice as determined by the tail-
bleeding assay 325. Therefore, it would be expected that the 12-LOX-/- mice show a significant 
attenuation of thrombus following injury compared to the WT (Figure 9.1D and 9.1F). 
Interestingly, the accumulation of platelet and fibrin in thrombi between DGLA-treated 12-LOX-
/- and vehicle control did not differ (Figure 9.1D and 9.1F; and Supplementary videos 3 and 4) 
supporting the ex vivo observation that 12-LOX is required to mediate DGLA-dependent 
inhibition of platelet function as well as thrombosis.  
The 12-LOX oxylipin, 12-HETrE, inhibits platelet aggregation and thrombus growth 
 To confirm that 12-HETrE was the 12-LOX product of DGLA mediating the inhibitory 
effects observed in figure 9.1, washed platelets from either WT or 12-LOX-/- mice were treated 
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with 12-HETrE followed by stimulation with either PAR4-AP or collagen. Notably, 12-HETrE 
(25 µM) inhibited the aggregation of platelets from WT and 12-LOX-/- mice similarly in response 
to PAR4-AP or collagen (Figure 9.2A and 9.1B). As expected, no decrease in collagen- or 
PAR4-AP-mediated platelet aggregation was observed in either WT or 12-LOX-/- platelets pre-
treated with 12-HETE, the pro-thrombotic 12-LOX-derived oxylipin of AA, compared to vehicle 
control. Additionally, incubation of platelets with 12-HEPE, a 12-LOX-derived oxylipin of 
eicosapentaenoic acid (EPA) with no known effects on aggregation 333,572,573, did not inhibit 
collagen- or PAR4-AP-induced aggregation in platelets from either WT or 12-LOX-/- mice.    
 To determine if 12-HETrE inhibited intracellular signaling, the activation of Rap1 was 
measured in PAR4-AP stimulated platelets in the presence of 12-HETrE or vehicle control. 12-
HETrE suppressed Rap1 activation compared to vehicle control in platelets from either WT or 
12-LOX-/- mice (Figure 9.2C). Thus, 12-HETrE was able to inhibit platelet aggregation and Rap1 
activity independent of 12-LOX expression. 
Although 12-HETrE significantly attenuated platelet activation, it remained unclear if 12-
HETrE could directly inhibit platelet thrombus formation in vivo. To evaluate the effects of 12-
HETrE on thrombus formation, the size and kinetics of the growing arterial thrombus were 
assessed following laser-induced injury of the cremaster muscle arterioles in WT and 12-LOX-/- 
mice treated with vehicle control or 6 mg/kg of 12-HETrE (Figure 9.1D and 9.2D). Following 
injury, platelets and fibrin were observed to rapidly accumulate at the injured arteriole wall in 
WT control mice (Figure 9.2D and Supplementary video 1). In contrast, WT mice treated with 
12-HETrE had significantly smaller and less stable thrombi in response to laser injury as 
assessed by both platelet and fibrin accumulation (Figure 9.2D and 9.2E; Supplementary video 
5). 
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Figure 9.3 Exogenous DGLA enhances platelet production of metabolites.   
12-LOX and COX-1 metabolites from washed human platelets (n=7) treated with DGLA (10 µM) or DMSO for 10 minutes prior 
to stimulation with PAR4-AP (200 µM) were detected using mass spectrometry. Data represents mean ± SEM; **P<.01, 
***P<.001 two-tailed unpaired t-test. This figure co- provided by Jennifer Yeung and Cody Freedman (Dr. Theodore Holman’s 
group). 
12-LOX-/- mice treated with vehicle control exhibited a significant decrease in thrombus 
formation (platelet and fibrin accumulation) (Figure 9.2D and 9.2F; Supplementary video 3) 
compared to WT control mice following injury (Figure 9.2D and 9.2E; Supplementary video 1). 
Additionally, 12-LOX-/- mice treated with 12-HETrE exhibited significant inhibition of platelet 
accumulation compared to 12-LOX-/- alone (Figure 9.2F; Supplementary video 6). However, no 
difference in fibrin accumulation was observed between vehicle control and 12-HETrE treatment 
of 12-LOX-/-. 
DGLA-induced oxylipin production 
Endogenously, only minute amounts of DGLA metabolites are produced by COX-1 (PGE1 and 
TxB1) or 12-LOX (12-HETrE) due to the low abundance of DGLA in the platelet plasma 
membrane 255. To determine if the exogenous addition of DGLA (10 µM) increases the 
production of 12-LOX and COX-1 metabolites, the lipid releasate from platelets stimulated with 
PAR4-AP in the presence of vehicle control or DGLA was measured by LC/MS/MS. As 
expected, the amount of DGLA-dependent COX-1 and 12-LOX oxylipins was significantly 
potentiated in the DGLA-treated group compared to the DMSO control group (Figure 9.3A and 
9.3B). The amount of AA-dependent metabolites from either 12-LOX (12-HETE) or COX-1 
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(TxB2 or PGE2) was unaltered in platelets incubated with DGLA (Figure 9.3A and 9.3B) 
supporting 12-LOX being in excess such that competition for the substrate is not necessary. This 
is a reasonable presumption based on previously published work showing that in the human 
platelet transcriptome, the mRNA for 12-LOX, ALOX12, is expressed in the top 8% of all 
transcripts in the platelet 574.  
 
Figure 9.4 Hemostasis is not affected by 12-HETrE.  
Mice were retro-orbitally injected with DMSO or 12-HETrE dissolved in saline prior to tail-bleeding. (A) Mean tail-bleeding 
time of control (n=12) or 12-HETrE (n=13) treated mice is denoted by the horizontal line. Arterial hemostasis induced by laser-
induced puncturing of the cremaster muscle arterioles was performed to assess the kinetics of hemostatic plug formation. (B) 
Representative images of hemostatic plug formation, composed of platelet (green) and fibrin (red) were acquired over time. Blue 
arrows denote the site of vessel rupture and leakage of RBCs. (C) Time to form hemostatic plug in control (n=7) and 12-HETrE 
(n=6) mice as assessed by RBC leakage.  Data represent mean ± SEM; two-tailed unpaired t-test. This figure co-provided by 
Jennifer Yeung (tail bleeding) and Dr. Reheman Adili (in vivo rupture). 
12-HETrE does not disrupt hemostasis 
Since 12-HETrE potently attenuated platelet accumulation in the laser-induced cremaster 
arteriole injury model of thrombosis, it is possible 12-HETrE also alters hemostasis resulting in 
increased bleeding. To determine if 12-HETrE treatment resulted in an increased bleeding 
diathesis, two hemostatic models were used to assess the impact of 12-HETrE on bleeding. First, 
the tail-bleeding time assay was utilized to determine the effects of 12-HETrE on primary 
hemostasis. 12-HETrE-treated mice showed no significant difference in tail bleeding time 
compared to the control mice following excision of the distal segment (5 mm) of the tail (Figure 
9.4A). To confirm this assay was accurately reporting bleeding risk, heparin-treated mice were 
also assayed for bleeding time and observed to have a severe bleeding diathesis (data not shown). 
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A second hemostatic model was used to confirm hemostasis was not significantly altered 
following treatment with 12-HETrE. This model involved arteriole puncture of the cremaster 
muscle induced by severe laser injury 575 in order to monitor the cessation time of RBC leakage 
from the punctured arteriole wall (Figure 9.4B; Supplementary videos 7 and 8). No significant 
difference in the duration of RBC leakage was observed between 12-HETrE and control treated 
mice. In both the control and 12-HETrE-treated mice, a stable, non-occlusive clot formed in 
response to laser puncture of the vessel wall, resulting in cessation of RBC leakage from the 
vessel. Both distinct hemostatic models suggested 12-HETrE did not disrupt hemostasis. 
 
Figure 9.5 12-HETrE activates adenylyl cyclase-mediated signaling in platelets.  
(A) Mass spectrometry quantification of cAMP was performed on lysed washed human platelets (n=5) incubated with DMSO, 
12-HETrE (25 µM), 12-HpETrE (25 µM), or forskolin (.5 µM) for 1 minute. (B) Washed human platelets (n=4) were pre-treated 
with an adenylyl cyclase inhibitor, SQ22536 (25 µM), or DMSO for 20 minutes and then incubated with 12-HETrE (7.5 to 25 
µM) or iloprost (.2 to .4 nM) for 1 minute prior to stimulation. Platelet aggregation induced by an EC80 concentration of PAR4-
AP (35 to 50 µM) was measured for 10 minutes. Representative tracings of aggregation are shown on the left and bar graphs of 
the final aggregation of 4 independent experiments are shown on the right. (C) VASP phosphorylation was measured by western 
blot analysis on lysates from washed human platelets (n=8) incubated with DMSO, DGLA (10 µM), 12-HETrE (25 µM), 12-
HpETrE (25 µM), or forskolin (.5 µM) for 1 minute using antibodies specific for phospho-VASP (p157 VASP) or total VASP. 
Phosphorylated VASP was normalized to total VASP and DMSO for fold change in 157 VASP phosphorylation. (D) Gαs was 
immunoprecipitated following incubation of human platelet membranes with DMSO, 12-HETrE (25 µM), 12-HpETrE (25 µM), 
Iloprost (10 µM) or PAR4-AP in the presence of [35S]GTPγS. The immunoprecipitates (n=6) were then counted and background 
counts from normal IgG controls were subtracted.  Data represent mean ± SEM.  * P<.05, **P<.01, ***P<.001 two-tailed 
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unpaired t-test (A-D). This figure co-provided by by Jennifer Yeung (GTPγS binding and adenylyl cyclase inhibition rescue) and 
Dr. Benjamin Tourdot (VASP phosphorylation). 
12-HETrE inhibits platelets in a Gα s-linked GPCR-dependent manner  
 COX-derived oxylipins that inhibit platelet function primarily exert their inhibition 
through the activation of a GPCR coupled to Gαs resulting in adenylyl cyclase (AC) activation 
576,577 and the generation of cAMP 578-582. To determine if the DGLA-derived 12-LOX oxylipin 
12-HETrE could be regulating platelet reactivity in a similar manner, cAMP formation was 
measured in washed human platelets stimulated with 12-HETrE or 12-HpETrE, a peroxidated, 
labile precursor of 12-HETrE. Following a 1 minute stimulation with 12-HETrE or 12-HpETrE 
333, human platelets exhibited a significant increase in the level of intracellular cAMP compared 
to vehicle treated (DMSO) platelets (Figure 9.5.A). As expected, platelets stimulated with 
forskolin, a direct activator of AC, also showed an increase in cAMP levels. 12-HETrE-induced 
cAMP production was supportive of 12-HETrE inhibiting platelets through the activation of AC. 
To assess if 12-HETrE inhibited platelet aggregation in an AC-dependent manner, platelets were 
pre-treated with SQ 22536, an AC inhibitor 583 prior to incubation with 12-HETrE or iloprost, a 
prostacyclin receptor agonist known to signal through AC 584,585. Iloprost and 12-HETrE were 
unable to inhibit PAR4-AP-mediated platelet aggregation in platelets pre-treated with SQ 22536 
(Figure 9.5B), supporting an AC-dependent mechanism of platelet inhibition by 12-HETrE. 
The cAMP activated kinase, protein kinase A (PKA), phosphorylates multiple proteins in 
platelets including vasodilator-stimulated phosphoprotein (VASP). Since serine 157 (S157) in 
VASP is a known PKA substrate 586, VASP phosphorylation was used as a surrogate readout for 
PKA activation. Washed human platelets treated with DGLA or its 12-LOX metabolites (12-
HETrE, or 12-HpETrE) for 1 minute had enhanced VASP phosphorylation compared to DMSO 
treated platelets (Figure 9.5.C). As expected, forskolin treated platelets also had an increase in 
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VASP phosphorylation. This data demonstrates that the cAMP produced in platelets following 
exposure to 12-HETrE is capable of eliciting physiological effects.  
 The activation of a GPCR coupled to Gαs leads to the dissociation of GDP and the 
subsequent binding of GTP to Gαs initiating a well-established signaling cascade resulting in 
increases in cAMP levels through the activation of AC 587,588. Since 12-HETrE was shown to 
induce cAMP formation and inhibit platelet activation in an AC-dependent manner, we sought to 
determine if 12-HETrE could activate Gαs.  Activation of Gαs was assessed by measuring the 
incorporation of the radiolabeled, non-hydrolyzable analog, [35S]GTPγS, to Gαs, 
immunoprecipitated from isolated human platelet membranes following treatment 589 with 
vehicle control (DMSO), 12-HETrE, 12-HpETrE, PAR4-AP, or iloprost. Treatment of human 
platelet membranes with 12-HETrE, 12-HpETrE, and iloprost elicited a significant increase in 
[35S]GTPγS binding to immunoprecipitated Gαs compared to platelet membranes incubated with 
DMSO (Figure 9.5D). Activation of PAR4, a receptor that is known to selectively activate Gq 
and G12/13, showed no [35S]GTPγS binding confirming the selectivity for Gαs activation in the 
assay.  
9.5 Discussion 
 Advances in antiplatelet therapy have significantly decreased the risk for morbidity and 
mortality due to thrombosis. However, even with the current standard-of-care antiplatelet 
therapies available, myocardial infarction and stroke due to occlusive thrombotic events remains 
one of the primary causes of morbidity and mortality globally. Therefore, identification of novel 
therapies remains an unmet clinical need. One potential approach to reduce thrombus formation 
is the dietary intake of DGLA, a naturally occurring ω-6 PUFA, which has been shown to 
attenuate platelet aggregation ex vivo 545,558,559. However, to date the mechanism by which this 
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inhibition is regulated and the ability of DGLA to inhibit thrombus formation in vivo have not 
been elucidated. Recently, our lab identified a 12-LOX-derived oxylipin of DGLA, 12-HETrE, 
which inhibits human platelet activation 333. In the current study, we sought to determine the 
relative contribution of 12-LOX-derived metabolites in DGLA-mediated inhibition of platelet 
function and thrombosis in vivo. In contrast to the previously reported dependence of DGLA-
mediated inhibition of platelet function on COX-derived metabolites 545,558,559,562, we show here 
that DGLA, but not 12-HETrE, was unable to inhibit platelet aggregation in 12-LOX-/- mice 
suggesting that 12-LOX plays a key role in facilitating DGLA’s antiplatelet effects.  
 In mice 12-LOX was required for DGLA to impinge on platelet activation (Figures 9.1 
and 9.2), suggesting that 12-LOX metabolites are responsible for the predominance of DGLA 
inhibitory effects in mice. Interestingly, human platelets stimulated with DGLA had higher 
VASP phosphorylation than those treated with 12-HETrE (Figure 9.5C), indicating other DGLA 
metabolites, such as COX-1 derived oxylipins (Figure 9.3B), may also contribute to VASP 
phosphorylation. This observation is supported by previous data that COX-1 or 12-LOX 
inhibitors partially suppresses the ability of DGLA to inhibit human platelet aggregation 333. 
 The proposed inhibitory effect mediated through 12-LOX appears paradoxical based on 
previous work in our lab and others showing that 12-LOX is a positive mediator of platelet 
function 196,325,328,329. However, due to the fact that 12-LOX is an enzyme whose function is to 
add an oxygen to a free fatty acid in order to produce a bioactive oxylipin, it is reasonable to 
conclude from the data presented here and elsewhere 540,545 that the substrate for 12-LOX is the 
determining factor in its effect on platelets and ultimately thrombosis. This conclusion is 
supported by work in COX which shows that oxidation of AA results in a pro-thrombotic milieu 
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of oxylipins 252,590 while other substrates such as DGLA can result in production of anti-
thrombotic oxylipins 540,545,548,558,559. 
 The potent inhibition of thrombus formation by both DGLA and 12-HETrE, raises the 
potential that 12-HETrE will cause excessive bleeding similar to other antiplatelet agents 591-593. 
Two hemostatic assays, the tail-bleeding assay and a second hemostatic model recently 
developed, the laser-induced cremaster arteriole puncture model, were used in this study to 
determine if the DGLA metabolite 12-HETrE prolonged bleeding following vascular injury. The 
mouse tail-bleeding assay for hemostasis is a physiological model, involving the measurement of 
cessation of bleeding following the excision of 5 mm of the distal tail, showed no prolonged 
bleed times in mice treated with 12-HETrE compared to the control. However, prolonged 
bleeding was observed in tail-bleeding following heparin administration (data not shown), 
supporting the sensitivity of the tail-bleeding assay approach. A second hemostatic assessment, 
the laser-induced cremaster arteriole puncture model, was performed by laser puncturing a hole 
through the cremaster arterial followed by the time measurement of fibrin and platelet plug 
formation in the mice. Similarly, no difference in bleeding times between control and 12-HETrE-
treated mice was observed, supporting the hypothesis that 12-HETrE exerts an antithrombotic 
effect while at the same time maintaining primary hemostasis. These data support 12-HETrE 
either given directly or formed through ω-6 DGLA supplementation as a viable approach for 
prevention of thrombosis without creating a bleeding diathesis.  
  12-HETrE was shown here to directly activate a yet to be determined Gαs-coupled 
GPCR. Direct addition of 12-HETrE to purified platelet membranes was shown to increase the 
binding of [35S]GTPγS, the hydrolysis-resistant GTP analog, to the Gαs-subunit resulting in 
cAMP formation, activation of PKA, and phosphorylation of VASP  (Figure 9.6). Further studies 
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are required to identify if 12-HETrE is binding to a novel receptor or a previously characterized 
Gαs-coupled GPCR on the human and mouse platelet. Identification of this receptor will be 
essential to determine if the mechanism of action elicited by 12-HETrE is mediated through 
binding the GPCR in an allosteric or orthosteric manner and how this binding compares to other 
previously identified oxylipins shown to signal the platelet in a Gαs-dependent manner.  
The discovery of 12-HETrE regulation of platelet function at both the ex vivo and in vivo 
levels and the delineation of the mechanism of action through the Gαs-coupled GPCR establishes 
this oxylipin as an important eicosanoid in platelet biology. Beyond the platelet, it is also 
possible that 12-HETrE plays an important role in the regulatory function of other vascular cells 
similar to what is observed with other key oxylipins produced in the platelet, such as 
prostacyclin, PGE, PGD, and thromboxane. Further, this study describes for the first time how an 
omega-6 essential PUFA such as DGLA, can be used to alter the platelet signalosome in order to 
attenuate unwanted platelet activation and occlusive thrombus formation common in 
atherothrombotic diseases often leading to myocardial infarction and stroke. Future studies will 
seek to understand more fully how this newly discovered regulatory pathway limits platelet 
function and thrombotic risk while minimizing the risk of bleeding. This study fully supports 
future efforts to target the 12-HETrE pathway through the identification of the 12-HETrE 
receptor as a first-in-class antiplatelet therapeutic with minimal risk of bleeding. 
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Figure 9.6 Proposed model of 12-HETrE inhibitory signaling in platelets.  
Within platelets, 12-lipoxygenase (12-LOX) metabolizes free DGLA into the bioactive lipid, 12-HETrE. 12-HETrE can passively 
diffuse through the plasma membrane and presumably bind to an unidentified Gαs-coupled receptor in a paracrine or autocrine 
manner. Gαs activates adenylyl cyclase, which increases the intracellular level of cyclic AMP (cAMP). Elevated cAMP activates 
protein kinase A (PKA), which phosphorylates a number of proteins, including vasodilator-stimulated phosphoprotein (VASP), 
leading to platelet inhibition in response to either GPCR- or ITAM-mediated platelet activation. This illustration was generated 
and kindly provided by Dr. Benjamin Tourdot. 
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CHAPTER 10 
 
Discussion  
 
Summary and significance 
Regulation of platelet function is essential for the prevention and treatment of cardiovascular-
related or immune-mediated thrombotic disorders, which can lead to stroke or myocardial 
infarction. Although current antiplatelet drugs effectively inhibit unwanted platelet activation 
and prevent thrombotic complications, these treatments are often associated with risk for 
bleeding. Therefore, identification of novel or alternative antiplatelet targets is warranted to 
prevent unwanted platelet activated as well as treat thrombotic disorders with minimal bleeding 
risk.  In the context of my thesis studies described in chapters 5-9, 12-LOX has been 
demonstrated for the first time to play an important, but versatile role not only in modulating 
platelet activation involved in thrombotic pathologies, but also generating oxylipins from PUFAs 
that regulate platelet function. These studies established that targeting 12-LOX or utilizing its 
endogenous mechanism could represent potential avenues for antiplatelet therapy.  
To support the claim that 12-LOX potentiates platelet activation, both pharmacological inhibition 
and genetic knockout of 12-LOX models were utilized to demonstrate 12-LOX activity was 
diminished or ablated resulting in attenuated platelet response. In chapter 5, one of the early 
generations of selective 12-LOX inhibitors, NCTT-956, attenuated human platelet activation 
(integrin αIIbβ3, calcium mobilization, PKC) in response to PAR4-AP and collagen agonists. 
12-LOX inhibition could be overcome with the DAG mimetic, PMA, suggesting that PKC was 
upstream of 12-LOX activity326. Additionally, the work presented in chapter 6 demonstrated that 
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targeting platelet 12-LOX to prevent clot formation under shear stress may be superior than the 
current targeting strategy of inhibiting COX-1 with aspirin. I was also able to show that 12(S)-
HETE directly enhanced dense granule secretion mediated by PAR1-AP compared to vehicle 
control treated platelets (chapter 6). Thus, this implicated the role of 12-HETE generated by 12-
LOX in potentiating platelet activation. A modified and more potent 12-LOX inhibitor analog, 
ML355, described in chapter 7, also showed the benefits of using ML355 to attenuate ITT 
disorders, such as HIT. ML355 significantly attenuated human platelets response (aggregation, 
calcium flux, Rap1b activation, integrin αIIbβ3, dense and α-granules, and PKC) to immune 
complex crosslinking of the FcγRIIa receptor328. One of the proximal effectors of ITAM 
signaling, PLCγ2 phosphorylation, which is critical for its activation, was also demonstrated to 
be delayed when 12-LOX activity was inhibited. This suggested that 12-LOX activity was 
important for early PLCγ2 activation, affecting downstream effectors. In contrast, 
pharmacological inhibition of 12-LOX did not alter FcγRIIa phosphorylation, indicating 12-LOX 
does not directly regulate Src family kinases. Therefore, the data presented in chapter 8 suggest 
that 12-LOX may impinge on other early effectors preceding PLCγ2 activation, which includes 
the LAT signalosome components, Btk, Vav or Gads.  
While 12-LOX predominantly oxidizes free AA into 12(S)-HETE in platelets, dietary 
supplementation can also modify the lipid content as well as eicosanoid generation. Although 
past studies have reported that higher intakes in animals and human of DGLA are 
cardioprotective, the mechanism by which dietary DGLA may provide cardioprotective benefits 
had not been fully elucidated. I had demonstrated (chapters 8, 9) that DGLA could not only be 
oxidized by COX-1 to PGE1, but also by 12-LOX to 12(S)-HETrE. Wild-type and 12-LOX-/- 
mice were used to demonstrate that DGLA-mediated platelet inhibition required the presence of 
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12-LOX; however, the antiplatelet effects of 12(S)-HETrE did not depend on the expression of 
12-LOX. These data strongly implicated the inhibitory role of DGLA was due to its oxidation of 
12(S)-HETrE. 12(S)-HETrE was found to exert its anti-platelet effect through a Gαs signaling 
mechanism, involving the stimulation of adenylyl cyclase to generate cAMP and subsequent 
effectors activation. Eventually, 12(S)-HETrE was found to inhibit platelet reactivity through a 
G-protein coupled receptor (GPCR), prostacyclin (IP), using both pharmacological and genetic 
approaches to repress or ablate IP 594. Importantly, these studies provided further understanding 
of the antithrombotic effects of DGLA as well as the rationale for the development of analogs 
derived from 12(S)-HETrE as a new approach for antithrombotic therapeutics.  
 
Figure 10.1 The pro- and anti-thrombotic oxylipins of 12-LOX.  
Investigating the mechanisms of 12-LOX regulation in platelet activation 
The work presented in chapters 5-8 primarily focused on the enzymatic function of 12-LOX, 
establishing the importance of selective oxylipin production in the regulation of platelet function; 
however, the underlying signaling mechanism by which 12-LOX and or its predominant AA-
derived oxylipin, 12(S)-HETE, participates in platelet activation still remains to be fully 
elucidated. My results presented in chapter 7, by which 12-LOX could possibly regulate the 
ITAM pathway, especially the early activation of PLCγ2 activation, suggest that other upstream 
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effectors, LAT or BTK, may be regulated by 12-LOX independent of its oxylipin, 12(S)-HETE, 
activity or vice versa. In addition, other avenues regulation of or by 12-LOX in the platelets 
described below could be potential mechanisms that have yet to be explored.  
12(S)-HETE has been reported to exert its action through multiple mechanisms: a) activation of 
high affinity GPCR, 12-HETER (GPR31); b) low affinity leukotriene B4 receptor (BLT2); c) 
transcellular eicosanoid metabolism via lipoxygenase or cyclooxygenase pathways; or d) 
activation of the peroxisome proliferator-activated receptor γ (PPARγ). While these mechanisms 
of action for 12(S)-HETE have been implicated in cell lines; however, these pathways have not 
been confirmed nor assessed in platelets yet. It is much more likely that 12(S)-HETE potentiates 
platelet activation through 12-HETER, since BLT2 has not been shown to be expressed in 
platelets to date. On the other hand, PPARγ is an intercellular receptor that is involved in platelet 
inhibition rather than activation595. 12(S)-HETE derived from cancer cells expressing platelet-
type 12-LOX had been shown to enhance metastatic spread by inducing cancer cell and lymph 
endothelial cell motility (LEC). 12(S)-HETE was shown to directly enhance phosphorylation of 
myosin light chain (pMLC) and myosin phosphatase targeting subunit 1 (MYPT) in lymph 
endothelial cells, whereas cells pretreated with RHO-GTPase and ROCK inhibitors attenuated 
pMLC and MYPT596. Furthermore, 12(S)-HETE was shown to directly stimulate intracellular 
adhesion molecule-1 (ICAM-1) expression in human aortic endothelial cells through the 
RhoA/PKCα dependent activation of NF-κB. To corroborate the role of G protein-mediated 
signaling induced by 12(S)-HETE, G12 and G13 minigenes were used to competitively inhibit 
Gα12/13 signaling in endothelial cells. Based on these data, 12-HETER appear to be coupled to 
Gα12/13, which activates RhoA pathway 597. These observations have yet to be assessed in 
platelets to confirm that 12(S)-HETE potentiates platelet activation through 12-HETER. If 
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verified, GPR31 could be a potential drug target used in therapy for prevention of thrombotic 
events.  
The “shedding” of FcγRIIa and GPVI has been demonstrated as a potential mechanism for 
irreversible inactivation of both GPVI/FcRγ and FcγRIIa–mediated signaling 598. Ligands 
binding to either GPVI or FcγRIIa induce both extracellular and intracellular cleavages mediated 
by either matrix metalloproteases (MMPs), ADAM10 and ADAM17, or intracellular calcium-
dependent protease, calpain599. A key modulator of the MMPs facilitated shedding of the 
immunoglobulin receptors is the association of calmodulin with the cytoplasmic tail of GPVI and 
FcγRIIa; however, calmodulin inhibitor has been shown to induce calmodulin dissociation and 
prevent the shedding of the receptor ectodomain by MMPs. The removal of the receptors is 
thought to contribute to reduced platelet-activation600. Besides extracellular receptor shedding of 
the receptors, intracellular cysteine protease, calpain, has also been shown to remove the ITAM 
domain of the receptors. These findings suggest potential mechanisms for dampening clinical 
sequelae associated with ITAM-dependent signaling in patients with HIT. Thus, it is possible 
that the alternative non-enzymatic function 12-LOX is to prevent extracellular shedding of the 
receptors or cleavage of the ITAMs through its regulation of either calmodulin or calpain 
activity. 12-LOX may directly regulate the removal of calmodulin from the cytoplasmic tails or 
promote the recruitment and aid in the activation of calpain to remove the ITAM domains. As a 
consequence of receptors shedding or ITAM removal, ITAM-induced proximal signaling is 
attenuated concomitant with down-regulated platelet response.  
The role of platelet-type 12-LOX is also strongly implicated in the aggressive metastatic nature 
and progression of human erythroleukemia, breast cancer, colon carcinoma, glioma, and 
epidermoid carcinoma601. Dilly et al. previously showed that 12-LOX was linked to the β4 
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cytoplasmic tail of α6β4 integrin (glycoprotein that plays a major role in promoting tumor cell 
invasion and metastases) following stimulation with extracellular matrix laminins. 12-LOX was 
found to be recruited to the cytoplasmic tail and then phosphorylated by Src family kinases in 
human epidermoid A431 cells in response to integrin stimulation. Pharmacological inhibition of 
Src kinase activity by PP2 or expression of dominant-negative mutant Src kinase reduced 12-
LOX phosphorylation at Y19 and Y614 residues and 12(S)-HETE production in response to 
integrin stimulation in A431 cells602. It is possible that 12-LOX in platelets could be 
phosphorylated by specific Src kinases, and whether specific phosphorylated residues enhance 
oxylipin formation or dictate its substrate affinity has yet to be assessed. 12-LOX may also be 
regulating the cooperative integrin/ITAM pair, by which it facilitates the recruitment of proximal 
effectors Syk and assembly of SLP76/LAT/Btk/Vav and PLCγ2 with the integrin signaling 
complex in the αIIbβ3-mediated “outside-in” signaling described in chapter 1. In another 
scenario, 12-LOX could be inactivating and disrupting the constitutively bound C-terminal Src 
kinase (CSK) (an enzyme that keeps Src in inactive conformation) from β3 and Src complex to 
shift the αIIbβ3 integrin from low to high affinity in an “inside-out” dependent signaling 
process603.  
ML355 mechanism of action, selectivity, and therapeutic use 
Previous 12-LOX inhibitors had been categorized by their mechanism of action. For instance, 
baicalein, nordihydroguaiaretic acid (NDGA), 5,8,11,14-eicosatetraynoic acid (ETYA), and 
BW755C are redox inhibitors, by which they blocked the oxidation of the nonheme ferrous 
(Fe2+) state at the catalytic from transitioning to the active ferric (Fe3+) state. In addition, OPC-
29030 and L-655,238, block the translocation of 12-LOX to the peripheral membrane and 
subsequently prevented 12-HETE formation. Several of these 12-LOX inhibitors were deemed 
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non-selective, by which they directly inactivated cPLA2, as well as inhibit cyclooxygenase-1 in 
platelets. The exact mechanism by which ML355 inactivates 12-LOX activity is not known and 
is currently being investigated. Although ML355 has been shown to be a potent inhibitor of 
human platelet 12-LOX at low concentrations without affecting other lipoxygenases (15-LOX-1, 
15-LOX-2, 5-LOX, COX-1, and COX-2)604 and no bleeding diathesis in mouse models 605, other 
potential or non-selective, and non-oxygenases targets have yet to be assessed. These are critical 
parameters that are currently being investigated before ML355 can transition into the clinical 
phase for use in the prevention and intervention of thrombotic complications. 
12(S)-HETrE mechanism of action, and selectivity 
Prostacyclin analogues had been developed over the years since the endogenous prostacyclin 
(PGI2) is extremely labile with a half-life of approximately 40 seconds606. To date, only 
epoprostenol, treprostinil, and iloprost are FDA approved analogues for the treatment of 
pulmonary arterial hypertension. While epoprostenol and treprostinil are delivered through 
intravascular (IV) infusion, iloprost is administered via nebulization. Unfortunately, these 
analogues are labile and associated with side effects (hypotension, diarrhea, nausea, headache, 
jaw pain, flushing, and cough)607. Currently, their labeled use as an anti-platelet agent has not 
been approved. Previous clinical studies have shown infusions of iloprost for the treatment of 
peripheral vascular disease enhanced platelet reactivity and coagulation in some patients, which 
represented a risk for thromboembolism, especially in patients who were already in a 
prethrombotic condition608. In contrast to the clinical findings of iloprost, which were performed 
in vitro, the thrombosis mouse models we used to demonstrate the utility of 12(S)-HETrE, which 
also modulates platelet reactivity through the prostacyclin receptor (IP), does not enhance 
platelet reactivity or coagulation. 12(S)-HETrE prevented thrombus formation following injury 
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without affecting hemostasis. The side effects presented by prostacyclin analogues and other 
potential targets of 12(S)-HETrE are currently being evaluated before its transition into the 
clinics for treatment of platelet related disorders. 
Targeting 12-LOX  or its oxylipin, 12-HETE, for the treatment of HIT  
Immune mediated heparin-induced thrombocytopenia (HIT) is an atypical immune disorder that 
afflicts 1 in 5000 hospitalized patients. HIT is characterized by low platelet count and thrombosis 
following heparin exposure (see chapter 7). Approximately 50% of these patients develop 
thromboembolic complications due to autoantibodies recognizing the complexes of heparin and 
platelet factor 4 (PF4). Risks for HIT includes the type of heparin (unfractionated or 
fractionated), and duration of heparin exposure. Besides heparin exposure, history of surgical 
interventions can lead to enhanced platelet reactivity with circulating PF4.  Ultimately, these 
autoantibodies trigger platelet activation through the platelet FcγRIIa and consequently results in 
thrombocytopenia and thrombus formation. The only treatment for HIT is argatroban, a direct 
thrombin inhibitor (DTI); however, DTIs are associated with high bleeding risk. Previous studies 
had demonstrated the utility of regulating Syk (see section 1.4) to inhibit FcγRIIa-mediated 
platelet activation and thrombosis. Syk is not only expressed in platelets, but also in a variety of 
tissues, primarily in hematopoietic cells. Thereby, inhibiting Syk can adversely prevent critical 
lymphocytic function609, lymphatic development610, and increase the risk for tumorigenesis611. I 
had proposed in chapter 7 that targeting platelet 12-LOX with ML355 could be a potential 
therapy for immune-mediated thrombosis disorder, such as HIT. ML355 is much more selective 
in inhibiting 12-LOX without targeting the lipoxygenases, 15-LOX and 5-LOX, expressed in 
other hematopoietic cells. This would be much more viable than targeting 12-HETER, since 12-
HETER may also be expressed in other myeloid cells as well as lymphatic tissues.  
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Conclusion 
Antiplatelet therapies have decreased the incidence and mortality of thrombotic complications 
associated with myocardial infarction and stroke. Although the current antiplatelet therapies 
provide additional thrombotic protection, these have come at the expense of increases in 
bleeding. The goal of my thesis was to delineate a target in platelet function that is involved in 
pathological intravascular thrombosis; however dispensable in hemostasis.  As indicated above, 
regulating the 12-LOX pathway in platelet activation serves a promising therapeutic approach for 
thrombotic related diseases, including immune-mediated thrombosis, such as HIT. The orally 
bioavailable 12-LOX inhibitor, ML355, has been demonstrated to inhibit thrombosis in vivo with 
minimal impact on hemostasis based on the presence of fibrin formation in murine models.  
Besides directly targeting 12-LOX, the action of oxylipins, derived from the oxygenase, 
also demonstrate potential therapeutic avenue in the prevention of thrombotic events. 12(S)-
HETE, the predominant oxylipin derived from 12-LOX oxidation, is deemed to be pro-
thrombotic through its action on GPR31. Although GPR31 was discovered as the high affinity 
receptor for 12(S)-HETE, its functional role in platelets has received limited attention. 
Characterizing the mechanism of GPR31 function in platelets can aid in the development of 
small molecules inhibitor for the receptor to elucidate GPR31 function and a potential 
therapeutic target for treatment of thrombosis. Additionally, the anti-thrombotic oxylipin derived 
from DGLA, 12(S)-HETrE, also aids in acceleration of potent drug design that will also inhibit 
thrombosis without prolonging bleeding.  
In general, elucidating the role of 12-LOX with selective inhibitors was essential to 
differentiate between the role of 12-LOX in pathophysiological thrombosis and hemostasis. 
These inhibitors provided insights that regulating 12-LOX activity is essential in preventing 
 
 
195 
thrombosis with minimal bleeding diathesis. In addition, these inhibitor studies established the 
activity of 12-LOX potentiated thrombosis; however, the role of its derived oxylipin, 12(S)-
HETE, in platelet signaling is still unclear. Further understanding of comprehensive molecular 
and cellular mechanism of 12(S)-HETE would help delineate its significance in platelet biology 
and facility development of novel prophylactic treatment for thrombotic related diseases. 
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 Appendix A
 
Protein Kinase Regulation of 12-Lipoxygenase-Mediated Human Platelet Activation8 
 
 
Figure A.1 Pleckstrin is a 47 kDa protein corresponding to one of the phospho-(Ser)-PKC substrate bands.  
To identify which of the phospho-(Ser) PKC substrate bands is pleckstrin, platelet samples were treated as indicated in the lane 
conditions on the right. Green represents phospho-(Ser) PKC substrate antibody staining, red represents pleckstrin antibody 
staining and the bottom panel is an overlay of the two analyzed with the 2-laser Licor imaging system. Pleckstrin staining 
correlates to a 4 7 kDa protein band in the phospho-(Ser) PKC substrate. Staining of This band in the phospho-(Ser) PKC 
substrate staining is significantly diminished in the presence of NCTT-956 or Ro 31-8220, but it rescued in the presence of 
NCTT-956 + PMA
                                                
8 This section has been published in Molecular Pharmacology. Yeung J, Apopa PL, Vesci J, Kenyon V, Rai G, Jadhav A, 
Simeonov A, Holman TR, Maloney DJ, Boutaud O, Holinstat M. Protein kinase C regulation of 12-lipoxygenase-mediated 
human platelet activation. Molecular pharmacology. 2012 Mar 1;81(3):420-30. 
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 Appendix B
 
12-Lipoxygenase Activity Plays an Important Role in PAR4 and GPVI-Mediated Platelet9 
Reactivity 
 
 
Figure B.1 12-LOX inhibitor selectivity towards 12-LOX.  
To confirm substrate selectivity for NCTT-956, platelets were stimulated in the absence or presence of 25 µM NCTT-956 and the 
levels of TxB2 and 12-HETE formation were assessed by mass spectrometry (N=2-3). While NCTT-956 did not significantly 
affect TxB2 formation, the level of 12-HETE produced in the presence of 25 µM NCTT-596 was substantially reduced. This 
figure was provided by our collaborator Dr. Theodore Holman’s group 
 
                                                
9 This section has been published in Thrombosis and Hemostasis. Yeung J, Apopa PL, Vesci J, Stolla M, Rai G, Simeonov A, 
Jadhav A, Fernandez-Perez P, Maloney DJ, Boutaud O, Holman TR. 12-lipoxygenase activity plays an important role in PAR4 
and GPVI-mediated platelet reactivity. Thrombosis and haemostasis. 2013 Sep;110(3):569. 
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Figure B.2 12-LOX inhibitors do not interfere with ATP luciferase assay.  
To confirm the positive and negative analogs for the 12-LOX inhibitors did not directly interact with the luciferase assay, washed 
platelets were incubated with chronolume for 2 minutes in the absence or presence of NCTT-956 or NCTT-694. Following 
incubation, the platelets were spiked with 2 nM ATP and the level of ATP was confirmed in the lumi-aggregometer. Neither 
NCTT-956 nor NCTT-694 significantly inhibited the interaction of the chronolume reagent with ATP, confirming the observed 
inhibition of ATP secretion in Figure 2 is not due to inhibition of the reaction due to the addition of the small molecule inhibitors. 
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Figure B.3 NCTT-956 inhibition of dense granule secretion.  
The presence of 25 µM NCTT-956 inhibits ATP secretion (dense granule secretion) following stimulation with a number of 
agonists including thrombin, PAR4-AP, collagen, and ADP. This figure was co- provided by Jennifer Yeung and Dr. Patrick 
Apopa.
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 Appendix C
 
Platelet 12-LOX is Essential for FcγRIIa-Mediated Platelet Activation10 
 
 
Table C.1 Complete blood count was performed on hFcR/ALOX12-/- (n=4) and hFcR/ALOX12+/+ (n=3) mice.   
Data represents the mean ± SEM. An unpaired, two-tailed t-test was performed and no significant differences were observed. 
This figure was generated by Dr. Benjamin Tourdot. 
                                                
10 This has been published in Blood. Yeung J, Tourdot BE, Fernandez-Perez P, Vesci J, Ren J, Smyrniotis CJ, Luci DK, Jadhav 
A, Simeonov A, Maloney DJ, Holman TR. Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation. Blood. 2014 
Oct 2;124(14):2271-9. 
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 Appendix D
 
Investigations of Human Platelet-Type 12-Lipoxygenase: Role of Lipoxygenase Products in 
Platelet Activation11 
 
 
Figure D.1 Charge remote allylic fragmentation. 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
 
Figure D.2  1D proton NMR of 13-HODE. 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
                                                
11 This section has been published in Journal of Lipids Research. Ikei KN, Yeung J, Apopa PL, Ceja J, Vesci J, Holman TR, 
Holinstat M. Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation. Journal 
of lipid research. 2012 Dec 1;53(12):2546-59. 
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Figure D.3 2D COSY NMR of 13-HODE. 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
 
Figure D.4 1D Proton NMR of 13-HODE ester with Mosher (S).  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 203 
 
Figure D.5 2D COSY NMR of 13-HODE ester with Mosher (S). 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
Figure D.6 1D Proton NMR of 13-HODE ester with Mosher (R).  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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Figure D.7 2D COSY NMR of 13-HODE ester with Mosher (R).  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
 
 
 
Figure D.8 13-HODE with labeled protons.  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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Figure D.9 Chemical Shifts of 13-HOTrE.  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
Figure D.10 1D Proton NMR of 12-HETrE.  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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Figure D.11 1D proton NMR of 12-HETrE ester with Mosher (S). 
 
Figure  D.12 2D COSY NMR of 12-HETrE ester with Mosher (S).  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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Figure  D.13 1D Proton NMR of 12-HETrE ester with Mosher (R) 
 
 
Figure D.14 2D COSY NMR of 12-HETrE ester with Mosher (R).  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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Figure D.15 12-HETrE with labeled protons. 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
 
 
 
Figure D.16 Chemical Shifts of 12-HETrE. 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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Figure D.17 1D Proton NMR of 13-HOTrE.  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
 
Figure D.18 2D COSY NMR of 13-HOTrE. 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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Figure D.19 1D Proton NMR of 13-HOTrE ester with Mosher (S). 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
Figure D.20 2D COSY NMR of 13-HOTrE ester with Mosher (S). 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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Figure  D.21 1D Proton NMR or 13-HOTrE ester with Mosher (R). 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
Figure D.22 2D COSY NMR of 13-HOTrE ester with Mosher (R). 
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
 
 212 
 
Figure D.23 13-HOTrE with labeled protons.  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
 
 
 
Figure  D.24 Chemical Shifts of 13-HOTrE.  
This figure was provided by our collaborator Dr. Theodore Holman’s group. 
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